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Triptolide, a diterpene triepoxide extracted from traditional Chinese medicinal 
plant, Leigongteng, has been shown to have strong anti-tumor activities. However, the 
molecular mechanisms of triptolide against colorectal cancer remains largely elusive 
to date. In my study, triptolide was demonstrated to interfere with ROS, actin 
cytoskeleton, cell migration, cell adhesion, protein synthesis and induce alteration of 
transcription factors in colorectal cancer cell line HCT 116. In my first project, 
protein alterations of HCT 116 cells treated with triptolide were profiled at a global 
level, by using Isobaric Tags for Relative and Absolute Quantitation (iTRAQ) 
labeling followed by MS/MS analysis. The study of networks provides some insight 
into the molecular mechanisms of triptolide against colorectal cancer. In my second 
project, direct binding targets of triptolide were identified, by using combination of 
Activity-based Protein Profiling (ABPP) and proteomic approaches. Peroxiredoxin I 
and Annexin A1 were validated to be the direct binding targets of triptolide. 
Proteomics approaches allow the study of altered proteins by triptolide and binding 
targets of triptolide at a global level, which provides some insight into the mechanism 
of action of triptolide and aid to identify potential targets for cancer therapy. 
Furthermore, construction of important protein networks might offer fruitful 
information for future research on colorectal cancer treatment. Revealing the direct 
targets of triptolide will also aid to design derivatives that might be less toxic with 
fewer side effects.  
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1.1 An overview of colorectal cancer 
1.1.1 Cancer 
Cancer is characterized by rapid and uncontrolled growth of abnormal cells with 
the capability of spreading to distant sites of the body [1]. Other terms of cancer 
include malignant tumors and neoplasms [2]. Cancers are the leading causes of death 
in the world and the burden of cancers is increasing in developed countries [1]. The 
top four cancer sites (lung, breast, colorectum and stomach) account for about 42% of 
the total cancer diagnoses in the world [3]. In Singapore, about ten thousand cases of 
cancer per year were reported with the increasing rate [4]. High risk of cancers could 
be attributed to heredity, high fat intake and genetic factors [5].  
 
The traits of cancer include sustaining proliferative signaling, promoting 
metastasis and invasion, resisting cell death and so on [6]. These characteristics are 
progressively acquired and provide driving forces in the process of cancer progression 
[7]. The growth of tumors is not only due to the uncontrolled proliferation but also 
because of the evasion of apoptosis. Apoptosis is a physiological suicide mechanism 
that controls the normal cell numbers [8]. However, cancer cells resist cell death 




1.1.2 Hallmarks of cancer 
 Cancer begins when abnormal cells start to proliferate in an uncontrolled way. In 
the normal conditions, cell proliferation, cell division, apoptosis, autophagy, etc. are 
strictly regulated by the organism [10]. However, in the case of cancers, the regulation 
is interfered and cells begin rapid and uncontrolled growth, followed by invasion, and 
metastasis. Characteristics of cancer could be classified into ten hallmarks. They are: 
1) Sustaining proliferative signaling, 2) Evading growth suppressors, 3) Resisting cell 
death, 4) Enabling replicative immortality, 5) Inducing angiogenesis, 6) Activating 
invasion and metastasis, 7) Genome instability and mutation, 8) Tumor-promoting 
inflammation, 9) Deregulating cellular energetic and 10) Avoiding immune 
destruction [6].  
 
 Cancers have the ability to sustain proliferation without external 
growth-promoting signals [11]. Through mutations, cancer cells acquire the ability to 
sustain growth signaling in alternative ways including producing transcription factors 
such as Myc and supplying growth factors [7]. At the same time, cancer cells could 
also escape from the regulation of multiple tumor suppressors. For example, 
transforming growth factor beta (TGFβ) are suppressed in the cancer cells [12]. 
 
 Apoptosis is another important mechanism that regulates the normal growth of 




the mechanism to escape from the programmed cell death. Cancer cells resist cell 
death via mutations. For example, the mutations of oncogene B-cell lymphoma 2 
(Bcl-2) leads to cell resistance to apoptosis in cancer cells [13].  
 
 Normal cells usually have limited cell cycle due to senescence and apoptosis. 
Telomeres, a special DNA polymerase, protect the ends of chromosome and are 
involved in the unlimited proliferation [14]. The lengths of telomeric DNA are 
shortened progressively with the division of cells [15]. However, cancer cells could 
escape these regulation, growing and dividing immortally. Telomeres are maintained 
via the continuous addition of telomeres by enzyme telomerase [6].  
 
 Cancer cells also induce angiogenesis [16]. In cancer cells, the supply of oxygen 
and nutrients become scarce due to the unlimited proliferation. Therefore, tumor cells 
promote the formation of new blood vessels by turning on the angiogenic switch, 
which is activated due to the changes of angiogenic inducers and inhibitors [7].  
 
 The main cause of cancer deaths is metastasis [13]. Besides the capability of 
unlimited proliferation, evasion of growth suppression, as well as resistance to cell 
death, the ability of invasion and metastasis allows abnormal cells spread to 
surrounding tissues. It begins by initiating the escape of cancer cells form from their 
original sites to nearby blood and lymphatic vessels during intravasation [6]. Next, in 




activation of invasion is triggered by proteins involved in cell motility, adhesion, and 
cell migration [18].  
 
 In addition, instability of genome leads to random mutations and contributes to 
genetic alteration. The genome instability is the basis for the genetic alteration that 
lead cancer cells to the above hallmarks [7]. Therefore, genome instability is one of 
the main enabling characteristics of cancer cells. Another enabling characteristic is 
tumor-promoting inflammation. It provides bioactive molecules to the tumor 
microenvironment, supporting the other cancer characteristics above [13].  
 
 Another two hallmarks include reprogramming energy metabolism to support 
rapid cell growth and proliferation, and evading immune destruction, which prevents 
cancer cells from attacking by immune system. These two capabilities are considered 
as emerging hallmarks of cancer according to Hanahan and Weinberg [6].  
1.1.3 Colorectal Cancer 
Colorectal cancer (CRC) is the second most common cancer with the third 
leading mortality rate in developed countries [1]. In Singapore, colorectal cancer is 
the most common cancer in Singaporean males and second most common cancer 
amongst Singaporean females [19, 20]. In addition, colorectal cancer leads to death 
within 5 years after diagnosis among half of the patients. Besides heredity, high fat 




important roles as risk factors of colorectal cancer. For example, mutations in the 
tumor suppressor genes such as Adenomatous polyposis coli (APC), p53, and 
SMAD4 cause the cells growing and spreading uncontrollably.  
 
The multi-step molecular mechanism of colorectal cancer development has been 
well-elucidated by Fearon and Vogelstein [21]. Colorectal cancer begins from 
colorectal polyps. Abnormal cells start to divide in an uncontrolled way. The mutation 
of APC, which is involved in the Wnt pathway, is involved in the development of 
cancerous traits. Abnormal cells escape from the normal checks and balances that 
control cell growth. As polyps grow, additional genetic mutations occurred, leading to 
transition from normal cells to adenoma then to carcinoma. Three stages of adenoma 
formation are described in Figure 1.1. Genetic alterations such as mutations of KRAS, 
DCC and p53 occur during the development of colorectal cancer. When these 
precancerous tumors invade other layers of the large intestine (such as the muscular 







Figure 1.1 A genetic model of colorectal cancer development. Multi-step 
development of colorectal cancer from normal epithelium to carcinoma. Several 
genetic factors such as APC, p53, KRAS are involved in the progression of colon 
cancer. This model was proposed by Fearon and Vogelstein [21].  
 
Several therapeutic approaches like surgery and radiotherapy have shown some 
anti-cancer effects. However, each of them has side effects. For example, besides the 
difficulty for the early diagnosis of colorectal cancer for surgery [22], cancers often 
recur after surgery [23]. Among the organism sites, liver and lung are commonly 
subjected to recurrence. Thus, resection of liver and lung metastasis is needed to 
protect patients from recurrence [24]. Other side effects include susceptibility to 
infection, abdominal cramps, excoriation of perianal skin and anemia, neutropenia 
and hair loss. Due to above limitations, an increasing attention has been paid on the 




1.2 Triptolide as a therapeutic agent against cancers 
1.2.1 Chemotherapy  
Chemotherapy for treating against cancers was introduced into the clinical 
application since more the 50 years ago [25]. Chemotherapeutic drugs have been 
successfully applied to treat some tumors, such as leukemia, breast, colorectal and 
lung cancer [26][27]. Among the chemotherapies, novel natural anti-cancer 
compounds have drawn the attention of scientists all over the world, especially those 
in East Asia. Natural products have been studied as cancer chemotherapy for the past 
40 years [28][29]. Several plants, such as etoposide, Podophyllum peltatum, 
Catharanthus roseus were shown to effectively treat small-cell lung caner [30], acute 
lymphocytic leukemia [31] and so on. The folk medicine’s significant contribution 
results in the exploration the large-scale screening of native plants for cancers [28]. 
One of such chemotherapy is triptolide, a natural plant-derived compound.  
1.2.2 Derivation and history of triptolide 
Triptolide, a diterpene triepoxide, was purified from traditional Chinese medicine 
herb Tripterygium wilfordii hook F, commonly known as thunder god vine or 
Leigongteng in Chinese. Leigongteng was used to treat inflammatory disease such as 
rheumatoid arthritis in China [32]. Its clinical therapeutic effects stimulated the 
isolation of triptolide in 1972 [33]. Right after its isolation, triptolide was revealed to 




other antitumor properties. Owing to numerous studies, triptolide has been 
demonstrated to induce apoptosis of hepatocellular carcinoma, promyelocytic 
leukemia, cervical adenocarcinoma, lung cancer, pancreatic carcinoma and oral 
cancer cells [34-38].  
1.2.3 The structure of triptolide 
 Compounds derived from natural products, especially those originating from 
plants, have played important roles in disease treatment in the drug discovery history 
[39]. Diterpenoids from plant exert an extensive range of important physiological 
functions and give hope for the development of new therapeutic agents against cancer, 
inflammation and cardiovascular disease as secondary metabolites [40-42]. Recently, 
p50, a crucial regulator of NF-κB signaling, was identified as the cellular target of 
Eriocalyxin B (EriB), an ent-kaurene diterpenoid isolated from Isodon eriocalyx var. 
Laxiflora [43]. EriB was shown to induce cancer cell apoptosis via binding Cysteine 
62 of p50, which was the same binding site for another diterpenoid, andrographolide 
[44, 45]. However, the diterpenoids form several structurally diverse types and have a 
wide spectrum of activities, leaving open the exploration of their biological functions 
and binding targets.  
 
As shown in Figure 1.2, triptolide contains natural reactive electrophile and three 
epoxide groups. The Structure Activity Relationship (SAR) of triptolide was 




conducted in the previous studies, focusing on the C-14-hydroxyl group, the C5, 




























Figure 1.2 Chemical structure of triptolide. Chemical structure of triptolide was 
depicted with the software Chemdraw.  
1.2.3.1 C-14-hydroxyl group 
According to Structure Activity Relationship (SAR) of triptolide, the position 
C-14β-OH was demonstrated to be associated with cytotoxicity of triptolide. Previous 
studies indicated that hydrogen-bonded C-14 of triptolide may account for its 
antitumor effect [46]. This position is also related to the water solubility. Due to the 
poor water-solubility of native triptolide, for a long time, the modification’s aim was 
to improve the triptolide’s water solubility by carboxylation of C-14β-OH to introduce 
water-solubility-enhancing moieties [47]. In addition, most of these derivatives were 
enzymatically converted into triptolide when they were utilized in vivo, retaining most 
of triptolide’s effects [48]. Another study found that replacing the C-14-hydroxyl 
group with fluoride or with a chiral epoxy group, containing α oxygen configuration 




C-14-spirotriptolide derivatives (Figure 1.3A and 1.3B) were designed not to form 
intramolecular hydrogen bonds. After evaluation, the novel derivative (Figure 1.3A) 
has strong anti-tumor activity and potential low systemic toxicity, making it a 
candidate of promising anticancer drug. These above achievements challenge the 
traditional understanding that C-14β-OH cannot be altered for retaining of toxic 
activity by triptolide analogues [46]. Therefore, C-14β-OH group was demonstrated to 
be one of the sites that could be modified without changing the property of native 
triptolide. 
1.2.3.2 α, β-unsaturated-5-membered-lactone ring 
The five-membered unsaturated lactone ring was identified as the most important 
group for the function of triptolide. Some studies synthesized triptolide analogues 
with furan ring instead of the five-membered unsaturated lactone ring (Figure 1.3D) 
or with the lactone ring opened [50]. Although these analogues showed enhanced 
efficiency of uptake due to the improved water solubility, triptolide analogues with a 
transbutenolide (Figure 1.3C) was shown to be slightly toxic. Another analogue 
(Figure 1.3D) with the furan ring completely lost toxic activity. These investigations 
suggest that the five-membered unsaturated lactone is necessary and critical for the 
anti-tumor activity of triptolide and the C18 carbonyl group might play significant 




1.2.3.3 C-5, 6 functional group 
For a long time, there is little research focusing on C-5, 6 modification because of 
the lack of modification sites. In 2005, Fu’s group reported that 
(5R)-5-hydroxytriptolide (Figure 1.3E) possessed strong anti-inflammatory and 
immunosuppressive activities [51]. In addition, the introduction of the hydroxyl group 
at C-5 led to a significant elimination in side effects. Therefore, modification in C-5,6 
function group did not change the property of triptolide. 
1.2.3.4 Epoxy groups 
According to the analysis of SAR of triptolide, three epoxy groups of triptolide 
were demonstrated to play critical roles in determining therapeutic activities of 
triptolide. Among them, the C-12, 13-epoxide group is the most important 
modification site due to its small steric impact. Therefore, the C-12, 13-epoxide group 
is sensitive to nucleophilic attack, which may cause ring-opening [52]. By comparison, 
the C-7, 8-β-epoxide group is not as sensitive as the C-12, 13-epoxide group towards 
nucleophilic attack. The inhibitory activity of triptolide derivatives with ring-opening 
at the C7 was significantly decreased in vitro [53]. Moreover, three analogues 
modified in the position of C9, 11-β-epoxide were synthesized by Zhou at al. Their 
further work demonstrated that C-9, 11-olenfin analogues were effective against 
SKOV-3 and prostate cancer PC-3 cell lines [54]. These results indicated that 




triptolide’s activity. On the other hand, the C-9, 11-β-epoxide group could be 




Figure 1.3 Chemical structures of different analogues of triptolide. Different 
analogues of triptolide were synthesized to examine the influence of different 
modification sites on its anti-cancer property. (A, B) Derivatives with modification on 
C 14 have strong anti-tumor activity, making C 14 as a promising modifiable site. (C, 
D) The properties of compounds with the modification on five-membered unsaturated 
lactone ring change greatly, making the unsaturated lactone ring necessary for the 
anti-tumor activity of native triptolide. (E) (5R)-5-hydroxytriptolide, which has 
modification on C-5, 6, possesses strong anti-inflammatory and immunosuppressive 
activities, making it as a suitable site for modification. (F) Omtriptolide 
(PG-490-88Na, F60008) which has the modification on C 14, has entered clinical 
trials as a pro-drug to treat advanced solid tumors, verifying that C 14 is suitable for 






1.2.4 Literature review of triptolide’s properties 
1.2.4.1 Inflammatory and immunosuppressive activities 
For more than two centuries, leigongteng was used to treat against a variety of 
inflammatory and autoimmune diseases in ancient China [55]. Its main functional 
component, triptolide, has been revealed responsible for those activities in patients 
with rheumatoid arthritis. Triptolide was also shown to be the main component for 
treatment against autoimmune and inflammatory diseases in various animal models 
[56]. Hoyle’s group identified that triptolide inhibits lung inflammation in the NIH 
Clinical Collection, using acute lung injury model [57].  
 
Moreover, triptolide was shown to impair the function of T-cell in vivo and in 
vitro [58]. Triptolide was also demonstrated to inhibit the T-cell proliferative 





-independent pathways [59]. As for numerous 
pro-inflammatory mediators, triptolide suppresses the production of TNF-α, IL-4, 
IL-6, IL-8, cyclooxygenase (COX)-2 and interferon (IFN)-α [59-61]. In addition, 
triptolide inhibits B-cell proliferation and immunoglobulin production, suggesting that 
it interferes with humoral immunity [58].  
1.2.4.2 Antitumor activity 




inhibit proliferation as well as to induce apoptosis in various cancer cell lines with 
IC50 (half-maximal inhibitory concentration) values in nano-molar range [62].  
 
The mechanisms of anti-proliferation and pro-apoptosis activity of triptolide have 
been studied in the past forty years. Triptolide was demonstrated to inhibit expression 
of numerous transcription factors like NF-κB [59], TFIIH subunit XPB [63], heat 
shock transcription factor 1 (HSF1) [64], and so on via the inhibition of RNA 
polymerase II [62]. Triptolide’s inhibitory effect on RNA polymerase affects the 
transcription machinery indirectly, causing a rapid depletion of short-lived mRNA of 
transcription factors. The global transcriptional inhibition could provide the 
explanation for the finding that triptolide decreased diverse proteins involved in 
various biological functions.  
 
1). Triptolide decreases expression level of proteins involved in apoptosis such as 
anti-apoptotic proteins Bcl-2 [65], Mcl-1, the IAP family members cIAP2 and XIAP 
[66]. Triptolide was also shown to induce caspase-dependent apoptosis mediated by 
mitochondria-mediated pathways [34]. In gastric cancers, triptolide was shown to 
induce tumor suppressor p53, p21, Bcl2-associated X protein (Bax) and increase the 
activity of caspases [65, 67]. 
 
2) Triptolide exerted inhibitory effects on oncogenic proteins, such as Myc, Src 




roles in balancing cell stress, survival and cell death mechanisms. The inhibitory 
effect of triptolide on the heat shock response makes cancer cells sensitive to 
stress-induced cell death. Triptolide also decreased mRNA and protein levels of 
HSP70 in MiaPaCa-2 and PANC-1 cell lines [64].  
 
3) Triptolide was shown to exert epigenetics effects on cancer cells. In the 
previous study, triptolide was demonstrated to decrease methylation of histone H3K9 
and H3K27 through inhibiting histone methyltransferases EZH2 and SUV39H1, 
respectively. Meanwhile, triptolide also increased the histone H3 and H4 acetylation 
through reducing histone deacetylase 8 (HDAC8) [69]. These regulated molecules 
were reported to be responsible for epigenetic effects and anti-myeloma mechanism of 
triptolide.  
 
4) Triptolide was reported to suppress proteins involved in anti-tumor related 
signal pathways. Besides NF-κB signal pathway, triptolide also suppresses the 
expression of mitogen-activated protein kinase phosphatase-1 (MKP-1), which 
inactivates ERK-1/2, MAPK and c-Jun N-terminal kinase-1/2 (JNK-1/2). MKP-1 
plays critical roles in suppressing the proliferative and metastatic abilities of 
non-small cell lung cancer (NSCLC) [70]. Triptolide also decreases PI3K activity in 
human fibrosarcoma HT-1080, which causes the augmentation of JNK1 





5) Triptolide induces chemotherapeutic agents-induced apoptosis. It is reported 
that triptolide could inhibit the growth of colon carcinoma and human KB oral cancer 
cells. In addition, the anti-tumor activity is much stronger when introducing the 
co-treatment of triptolide and 5-FU. The growth of these cells was significantly 
inhibited and the activity is much stronger, compared to using the agents individually, 
especially when used at low dose [72]. The proposed explanation is that triptolide 
inhibits NF-κB activity and sensitized colon cancer cell lines to 5-FU by activating 
expression of caspase 3 and Bax as well as by inhibiting Bcl-2. In addition, in 
pancreatic cancer model, combination of triptolide with ionizing radiation (IR) 
reduces cell survival to 21% and induces tumor cell apoptosis [73]. Triptolide also 
enhances the cytotoxicity induced by cisplatin in gastric cancer cells in vitro and in 
vivo [74].  
1.2.4.3 Clinical applications of triptolide and its derivatives  
Since 1960s, Leigongteng has been evaluated in the clinic, mainly focused on 
autoimmune and inflammatory diseases [75], including graft-versus-host diseases, 
systemic lupus erythematosus, rheumatoid arthritis, nephropathies, Behcet’s disease, 
Crohn’s disease, ankylosing spondylitis and autosomal dominant polycystic kidney 
disease [76, 77].  
 
1) Triptolide has entered clinical trials to treat leukemia and rheumatoid arthritis 




therapeutic effects and caused no obvious side effects. However, when at 40 μg kg-1, 
triptolide caused severely toxic effects, such as phlebitis and gastrointestinal 
abnormalities, leading to the suspension of the regimen [78]. Ten years later, its 
clinical anti-leukemia effects were evaluated again. 30-40μg kg-1 daily was used as 
regimen on 45 patients. Among them, 18 patients has complete remission and 6 
patients have partial remission [79].  
 
The clinical influence of triptolide for treatment against rheumatoid arthritis was 
evaluated at 0.5-0.75 mg day
-1
 in 15 patients. However, it showed serious toxicities, 
including leucopenia, urinary abnormalities, liver and myocardial damage although it 
displayed significant improvement for rheumatoid arthritis. The high toxicities make 
47% withdrawal in the treatment group [75] [80]. 
 
Therefore, triptolide has shown severe toxicities at higher concentrations. In 
addition, triptolide has a very poor water solubility. These properties restrict its 
clinical application. Thus, modification of the molecular structure of triptolide with 
the goal of producing safer and water-soluble analogues while retaining or improving 
anti-tumor efficacy of triptolide is very important [81]. Several derivatives of 
triptolide were developed. So far, there are two derivatives shown to have strong 
anti-tumor activities with less toxicity and greater water solubility. In addition, they 
have entered the clinical trials. For the treatment against relapsing acute leukemia as 




Phase I clinical trials of Omtriptolide on refractory or relapsing acute leukemia and 
advanced solid tumors was completed [52] [79]. In addition, Omtriptolide has also 
entered the Phase I clinical trials for its treatment against prostate cancer [79]. 
Moreover, (5R)-5-hydroxytriptolide (LLDT-8) also has entered Phase II for its 
treatment against rheumatoid arthritis [82].  
 
2) Omtriptolide (PG-490-88Na, F60008) is one of the derivatives of triptolide 
(Figure 1.3F). It is designed to be highly water soluble. In addition, it could be 
converted into triptolide in the serum [83]. Omtriptolide has shown to inhibit 
proliferation of tumors in mice bearing COLO 205 (colorectal cancer) and HT-29 
(colorectal cancer) xenografts. It also eradicated tumors in mice bearing H23 
(non-small cell lung cancer) and COLO 205 xenografts [84]. In the phase I clinical 
trial on patients with refractory or relapsing acute leukemia, patients were given 









, larger than which the 
cerebellar toxicity would occur [78]. In the phase I clinical trial on patients with 
advanced solid tumors, 20 patients were given 9 dose between 0.5 mg m
-2
 and 18 mg 
m
-2
. The dose tolerance was demonstrated to be 18 mg m
-2
. By far, the phase I studies 
of omtriptolide on patients with advanced solid tumors and relapsing acute leukemia 
were completed. In addition, omtriptolide has entered Phase I for treatment against 
human prostatic epithelial cells [79]. There studies make Omtriptolide a promising 





3) (5R)-5-hydroxytriptolide displayed promising anti-inflammatory activity in 
clinical trials [85]. In the Phase II clinical trials, its oral administration (0.125, 0.25, 
and 0.5 mg/kg) consistently attenuated the severity of collagen-induced arthritis (CIA). 
More importantly, compared to triptolide, (5R)-5-hydroxytriptolide displayed a much 
lower toxicity both in vitro and in vivo. Its CC50 value is 256.6 ± 73.8 nmol/L, while 
the CC50 value of triptolide is 2.1 ± 0.3 nmol/L in murine splenocytes. Its higher 
safety property makes it more suitable as a promising anti-tumor drug candidate. It is 
now ready to enter the Phase II clinical trials on patients with rheumatoid arthritis [82, 
86, 87]. The safety and side effects of it need to be further elucidated.  
 
 
Table 1.1 Clinical evaluation of triptolide and its derivatives. Analogues of 
triptolide that entered the clinical trials were listed. The disease model, regimen, 
response, toxicity and phase status were demonstrated.  
 
Compound Disease Regimen Response Toxicity Status Ref 
Triptolide Leukemia 5-40 μg kg
-1




















































































 Triptolide’s derivatives had entered clinic trials and showed inhibition effects on 
tumors. In addition, one of the promising pro-drugs, Omtriptolide, exerts its function 
via converted to native triptolide in vivo. Therefore, the knowledge of triptolide’s 
mechanisms becomes very important. Previous studies have explored triptolide’s 
possible mechanisms; however, as tumor grows in a complex and multi-step way, the 
detailed mechanisms of its anti-tumor activity remain unclear. With the development 
of proteomics, a global picture of the regulated molecular proteins will definitely 
provide some insights on the mechanisms of its anti-tumor functions.  
 
1.3 Drug target identification of triptolide using proteomics approaches 
1.3.1 Introduction of proteomics  
With the investigation of the Human Genome Project (HGP) and whole genome 
sequences of various organisms, genomics have established a firm foundation for 
modern biological investigation to unravel the blueprint of life [89]. Massively 
parallel measurement strategies aim to understand the complicated biochemical 
circuitry which is responsible for disease processes and physiologic homeostasis [90]. 
The large-scale “omics” studies, including proteomics, aim to accelerate the study of 
cellular and metabolic functions of molecules responsible for controlling normal 
development. In the last decade, many attentions turned towards proteomics research 




many cases, there is not a direct correlation between gene expression and protein 
expression patterns. Some post-translational modifications on the proteins, such as 
phosphorylation and glycosylation play important roles during the life process. 
 
 Proteome, as the name suggests, refers to as the entire proteins expressed in cells, 
tissues and organisms [91]. Proteomics can be defined as the large scale study of the 
protein properties, including expression level, post-translational modification, 
interaction [92]. This kind of study is extremely important for us to obtain an 
integrated view of cellular processes, disease processes, and network of proteins at the 
global level [92], therefore unveiling the mechanism of biological perturbations such 
as disease and drug treatment, accelerating the development of diagnostic techniques 
and therapeutic approaches [93]. 
1.3.2 Mass Spectrometry  
With the development of Mass spectrometry (MS), the study of proteomics 
advances further. Initially, the conventional proteomics was only to identify and 
characterize proteins. Protein was identified most frequently by Edman degradation of 
isolated peptide fragments [94]. When correlating sequences obtained from 
experiment in which peptides were analyzed with the sequence database, even the 
short and imperfect sequences could be utilized for identification of proteins due to 
the growth of database. Subsequently, the sequence information required for mapping 




spectrometry. Mass spectrometry identifies a molecule by measuring the 
mass-to-charge (m/z) ratio. A classical mass spectrometer consists of three parts: 
ionizer, mass analyzer and detector.  
1.3.2.1 Ionization techniques 
The ionization methods include Matrix-Assisted Laser Desorption Ionization 
(MALDI) and Electrospray Ionization (ESI). MALDI matrix absorbs laser energy and 
transfers the energy to the acidified analyte. The rapid laser heating leads [M + H]
+
 
ions of analyte into the gas phase, generating singly charged ions [95].  
 
Unlike MALDI, ESI generates ions from solution at atmospheric pressure when 
passing through a small capillary. Electrostatic spraying of a sample solution 
generated an aerosol of multi-charged droplets [94]. Then, ions become free of 
solvent and make their way to the analyzer [95]. Multiple charging allows mass 
spectrometers with limited m/z ranges to analyze molecules with higher molecular 
weight.  
1.3.2.2 Mass analyzers 
 The basic types of mass analyzer include time-of-flight (TOF), quadrupole (Q), 
Fourier transform-ion cyclotron resonance (FT-ICR), ion traps and OrbiTrap. They 
have different properties to identify a molecule according to their m/z value. For 




same charge could obtain the same kinetic energy after acceleration. The lower m/z 
ions have higher speed [51]. Therefore, by measuring the time it takes to reach the 
detector, its m/z value could be determined. These mass analyzers can be used alone 
or combined in hybrid analyzers.   
1.3.2.3 Tandem mass spectrometry 
 MS/MS includes two stages of MS. In the first MS, ions of certain m/z are 
isolated from other ions emanating from the ion source. These isolated ions are called 
parent ions or precursor ions. The ions are then further fragmented, commonly using 
the method, Collision Induced Dissociation (CID). The resulting ions are called 
product ions or daughter ions, which are then analyzed by the second stage of 
MS/MS. 
 
On top of the mass spectrometry analysis, quantitative and comparative studies 
become available due to the advancement in chromatography and isotope labeling 
methods. The quantitative studies enable the wider application, such as biomarker 
discovery, drug treatment, drug efficacy and toxicity, and disease mechanism studies. 
1.3.3 The methods of separation and comparison of whole proteome  
 Separation is critical for the mass spectrometry analysis. A variety of separation 




of proteomics approaches. The widely used approaches for proteome profiling include 
gel-based proteomics and LCMS-based proteomics.  
1.3.3.1 Gel-based proteomics and two-dimensional gel electrophoresis (2-DE)  
In two-dimensional polyacrylamide gel electrophoresis (2-D PAGE), the set of 
proteins were firstly separated by isoelectric focusing (IEF), corresponding to their 
isoelectric points (pI) in the first dimension, followed by SDS-PAGE according to 
their molecular weight in the second dimension (rotate 90 °C). Subsequently, the 
resultant regulated proteins spots were excised and identified using mass 
spectrometry.  
  
However, this method has some limitations. The fraction created by 2-D PAGE is 
quite limited for the total number of proteins [93]. There are several reasons for that: 1) 
many low-abundance proteins might not be detectable by staining in 2D-PAGE 
technique, 2) missing polypeptides might not enter the gel because they could not be 
resolved by the limited range of pH or molecular weight, etc. In addition, the staining 
process might also result in the variation from gel to gel, making it hard to 
differentiate the real expression changes, although the staining methods for sensitivity 
and limited dynamic range are optimized [96]. In addition, the fatal limitation for the 
2D-PAGE is the poor reproducibility due to different amount of proteins transferred 




1.3.3.2 Difference Gel Electrophoresis (DIGE)   
 In the method of DIGE, control and treatment samples were labeled with 
size-matched and charge-matched fluorescent dyes such as Cyanine2, Cyanine3 and 
Cyanine5 prior to 2-D Electrophoresis. The labeled proteins were then mixed and 
separated by running gel [97]. Then, the gel was scanned with different excitation 
wavelengths of individual fluorescent dyes [98]. This technology minimizes the 
variations among gels [99]. This technique allows up to three samples directly 
compared in a single gel. In the experiments which comprise several gels, an internal 
standard in each gel could be introduced to improve the accuracy of protein 
quantification of samples [100].  
 
However, these gel-based techniques were challenged with the achievement of 
LC-based approaches. Non-gel- and LC-based technologies produce good 
reproducibility and aid to identify the low-abundant proteins with the high-throughput 
screening. 
1.3.3.3 Liquid Chromatography (LC) - Mass Spectrometry (MS) 
LC-MS is commonly used proteomic method to analyze solution-based sample 
[101]. LC allows combination of stationary and mobile phases for separating peptides 
[24]. The two or more multimodal separation improve the resolution and provide 




separated firstly by SCX, followed by C18 reversed phased chromatography [102]. 
Several tagging strategies based on LC-MS, such as SILAC, ICAT, as well as iTRAQ 
could be utilized to label different samples to study the quantification of proteins.  
1.3.3.4 Stable Isotope Labeling with Amino acids in Cell culture (SILAC) 
 SILAC is a simple and in vivo metabolic labeling method for quantitative 
proteomics. It depends on “light” and “heavy” forms of amino acids in proteins in pair 
samples. One group of cells were cultured with natural amino acids, in the “light” 
form. The other group of cells were cultured with amino acids modified with 
13
C 




N-labeled L-lysine, in the “heavy” form. The proteins 
with abundance changes can be identified by mass spectrometry. Since there is an 
early introduction of isotope, SILAC could increase efficiency and reproducibility. It 
becomes popular also because of a relatively accurate comparison of expression level 
of proteins and post-transcription modifications [96].  
 
However, there were some limitations and challenges of this technique. 1) SILAC 
was only applied to cells but not tissues and in vivo. 2) The continuous usage of 
labeled amino acids induces a high budget for the biological experiment.  
1.3.3.5 Isotope Coded Affinity Tag (ICAT) 
The core of ICAT is the usage of tags that could attach to cysteine residues. The 




the quantitative proteomics field, control and treated samples could be labeled with 
the heavy and light ICAT reagents respectively, followed by combination and 
identification by MS/MS. However, ICAT could not identify proteins without 
cysteine residues. In addition, only two samples could be compared using ICAT, 
making it limited for application.  
1.3.3.6 Isobaric Tag for Relative and Absolute Quantitation (iTRAQ) 
The biological system is usually complex. In some cases, groups with different 
conditions need to be compared with multiple groups. However, neither SILAC nor 
ICAT is powerful enough to compare eight samples simultaneously like iTRAQ.  
 
ITRAQ is a non-gel-based technique used in proteomics to study quantitative 
changes of up to eight samples simultaneously. ITRAQ reagents were designed as 
isobaric tags which consist of reporter groups (ranging from 113-119, and 121 for 
8-plex iTRAQ reagents), their mass balance group and the peptide reactive group 
(PRG) [103]. The mass at 120 is ruled out to avoid contamination from phenylalanine 
immonium ion whose m/z is 120.08. The peptides labeled with different isobaric tags 
are mixed and separated by Liquid Chromatography (LC) and identified by tandem 
mass spectrometry (MS/MS), to be identified as a single MS peak (identical m/z). The 
quantification of the peptide abundance can be calculated by the relative areas of the 
reporter peaks. After performing iTRAQ labeling and LC-MS/MS, bioinformatics 




provide clues for exploring the signaling pathway [104]. The proteins found to be 
differentially altered and/or associated with the biological process/disease of interest 
will be chosen for functional validation and exploration for successive downstream 
signaling pathways. The workflow of iTRAQ labeling and protein identification will 
be discussed in the Chapter 3.  
 
1.4 Identifying cellular direct targets of triptolide using chemical proteomics 
approaches 
1.4.1 The development of chemical proteomics  
Numerous proteomics methods have be developed in the identification of drug 
therapeutic targets, screening of enzyme inhibitors, as well as discovery of tumor 
biomarkers [105, 106]. Although studies on drug-induced downstream signaling 
pathways have provided some insights, studies of protein targets are required because 
target-identification and mechanism-of-action studies play vital roles in drug 
discovery [88]. However, the traditional proteomics approaches only focus on 
measuring quantitative alterations in protein abundance, which do not necessarily 
correlate with protein activities [47], neither do they provide functional interpretation 
of proteins in the physiologically relevant environment [47]. Thus, additional 
combinatory and interdisciplinary techniques could be utilized in the application of 




interaction, protein – ligand interaction.  
 
The emerging multidisciplinary methods, chemical proteomics provides an 
opportunity to reveal the protein activity as well as the interaction between protein 
and small molecules. Chemical proteomics utilizes the synthetic small molecules, 
which could covalently bind to the catalytic residues in an enzyme active site. Thus, 
proteins could be tagged, enriched and detected. This kind of probes could monitor 
different properties of proteins, such as protein activity, protein location, 
protein-protein interaction and post-transcriptional modification.  
1.4.2 Activity Based Protein Profiling (ABPP)  
Many drugs exert pharmacological functions by binding their targets and may 
inhibit their activities, the study of function or activity of their binding targets is 
extremely important. In addition, hydrolytic and proteolytic enzymes have been 
shown up-regulated in many tumor cells [47]. As enzymes regulated essential cellular 
processes, they have become vital therapeutic targets for many human diseases 
including cancers [107]. However, it is difficult to investigate the functional roles of 
enzymes in cancers by traditional proteomics because those strategies do not provide 
functional understanding of proteins in the physiologically relevant environment in 
vivo [47]. Moreover, proteins’ abundance does not truly reflect their activities because 
most enzymes are expressed as inactive zymogens or reside in complexes with their 





To circumvent these limitations, Activity-based protein profiling (ABPP) could 
be utilized to unravel the enzyme activities and to identify the targets of small 
molecules [46]. The main advantage of ABPP over the traditional proteomics 
approaches is that it could profile the active sites of enzymes. Activity-based protein 
profiling (ABPP) combined with bio-orthogonal click chemistry is a novel functional 
proteomics technology to directly examine the functional state of enzymes both in 
vitro and in vivo [46, 47, 53, 108]. The ABPP method can mainly detect the 
functionally active form of the targets because most of the regulatory mechanisms for 
enzyme activities involve changes of the proteins’ active sites.  
  
The core of ABPP technology is a small molecule called activity-based probe 
(ABP). ABP was designed to contain three basic elements: 1) A reactive group, which 
could target and covalently bind to the active sites of the enzyme, 2) a reporter tag and 
3) a linker, which connect the reporter tag, as well as the reactive group (Figure 1.4). 
The reactive group was designed to contain the electrophile and could interact with 
active-site residues of target proteins, forming a stable covalent bond. The reporter tag 
could be 1) fluorophore for visualization, 2) biotin for enrichment and purification, 





Figure 1.4 Components of activity-based probe (ABP). ABP contains a reactive 
group, a tag that could be a fluorophore such as cyanine 3 for fluorescence detecting, 
or a biotin for enrichment, and a linker.  
1.4.3 Tagging strategies for chemical proteomics 
 The core of chemical proteomics is the integration of synthetic chemical 
molecular into the proteins of interest. The design of synthetic molecules depends on 
different purposes, such as protein enrichment, visualization, purification, etc. The 
commonly used probe contains isotope tags, fluorophores, affinity tags or tandem 
bio-orthogonal tagging.  
1.4.3.1 Isotope tags 




I, could be integrated into probes. Tritium 
can replace hydrogen in probes without changing the structure of small probes. 
Therefore, radioactive probes could be used to monitor alterations in enzyme activity. 
Some studies utilized the isotope-labeled drugs to study and identify the targets of 
drugs [109].  
 




iodine or hydrogen does not affect the whole structure of the small molecule, retaining 
the original permeability and function of the native molecule. Secondly, the 
radioactive isotopes could provide sensitive signal for detection, easier to be identified 
compared with fluorophores. However, some big challenges exist, including 1) 
difficulty to enrich its targets from proteomes, and 2) restricted handling and dealing 
with the radioactive reagents.  
1.4.3.2 Fluorophores 
 There are diverse types of fluorophores with a relatively broad range of 
absorbance and emission spectra for chemical proteomics strategies, providing 
efficient ways for most imaging applications. Nowadays, with large amount of 
commercially available fluorophores, the scope of chemical proteomics increases 
dramatically. Among the various types of fluorophores, cyanine dyes display high 
absorption coefficients, narrow absorption and high quantum yields, making them 
appropriate for majorities of biological applications. In addition, Cy-dyes are 
hydrophobic, making them freely penetrate cell membranes for protein localization.  
  
 Fluorophores allow the early detection of the tagged proteins, which could 
efficiently facilitate the further exploration such as identification and purification of 
the proteins of interest. They could also directly provide visualization of the location, 
the expression level of proteins from the whole proteome. Fluorescent tags could be 




dynamic range. What is more, when using diverse fluorophores with different 
excitation/emission spectra, the results in a single gel could be obtained.  
1.4.3.3 Affinity tags 
 The usage of affinity tags enables the enrichment of the proteins of interest. 
Especially in the chemical proteomics field, affinity tags were commonly and widely 
used for purification of labeled proteins, because purification and enrichment of 
probe-bound proteins are quite important for the identification of probe’s targets. 
Among various affinity tags, biotin is the most commonly used affinity tag. Its 
binding to streptavidin is one of the strongest non-covalent interactions, making it 
feasible for the binding of low-abundant biotinylated proteins.  
  
 However, there are some limitations of this kind of tags. First, because 
biotin-labeled or biotinylated proteins are usually binding to an avidin resin, the 
bound proteins need to be eluted by using detergents or denaturants, resulting in 
eluting nonspecific-binding and endogenously biotinylated proteins. This might 
increase the possibility of the negative candidates for drug target screening. Another 
challenge of using biotin for protein enrichment is the size of biotin. Biotin is too 
large to permeate the cell membrane, making it hard to be used to pull down the 
proteins of interest in vivo and in situ. Recently a tandem biorthogonal labeling 
method was quickly developed to address these problems. It enables 




Another strategy to exclude the nonspecific-binding or endogenously biotinylated 
proteins is the introduction of iTRAQ. The detail of these mechanisms will be 
discussed in the following sections. 
1.4.3.4 Tandem biorthogonal tagging 
 The important part of tandem biorthogonal strategy is the usage of the small 
chemical functionalities. This kind of tags have minimal alteration of parent 
compound and cell permeability. The great advantage is that the tags could be later 
used for chemical modification with various reporter tags.  
  
 The most commonly used strategy is called “click chemistry” (Figure 1.5). In this 
strategy, an alkyne and an azide functional group are catalyzed by Cu (I) to form a 
triazole conjugate through cycloaddition. This reaction is highly biocompatible with 
chemical functionality in biomolecules such as proteins and metabolites. The reaction 
could also proceed in aqueous environment even containing strong denaturants. 
Therefore, this strategy was largely used in the chemical proteomics fields [47, 53, 
108, 110]. Briefly, the alkyne-labeled probe is small enough to permeate the cell 
membrane. After binding its potential targets in the proteome, the probe-target 
compound as well as the whole proteome were then react with the azide-modified 







Figure 1.5 Click chemistry catalyzed by Copper (I). The drug probe was designed 
to contain alkyne, which could react with azide to form a triazole conjugate through 
cycloaddition. The tag could be a fluorophore or biotin. In our experiments, 
Cy3-azide or biotin-azide were used in click chemistry for fluorescence labeling or 
enrichment, respectively. 
 
1.4.4 Previous studies of direct targets and their limitations 
So far, only five proteins were identified as cellular targets of triptolide, as listed 
in Table 1.2. The first binding target of triptolide, Polycystin-2 (PC2), was identified 
by Crews’ group in 2007, using tritium-labeled triptolide [109]. They found the 
specific [
3
H] triptolide-binding activity through chromatographic purification, and 
identified PC2 as a putative target of triptolide. Although usage of tritium-labeled 
probes maintains the activity or property of the native triptolide, the tritiation could 
never be enriched and it needs more safety regulation matters.  
 
After that, this group also identified dCTP Pyrophosphatase 1 (dCTPP1) as the 
direct binding target of triptolide [111], using a biotinylated photoaffinity derivative 
of triptolide as the probe. This improved strategy allows the candidate targets to be 
enriched. However, this biotin-conjugated triptolide probe contains a quite long linker 




probe is 168 μM, extremely higher than the IC50 of native triptolide. As a result, 
dCTPP1 might not be a physiologically associated target of triptolide.  
 
In the same year, Liu’s lab identified XPB as a target of triptolide, and recently in 
2015, identified its binding site, Cysteine 342 [112, 113]. They utilized the “top-down” 
approach. Their research and previous literature [114] found that RNA Polymerase II 
(RNAPII) was inhibited by triptolide. Then their group analyzed the protein clusters 
that compose RNAPII. Among them, TFIIH was indicated to be inhibited by triptolide. 
Subsequently by screening the individual proteins in TFIIH, XPB was found to 
interact with triptolide directly. This method is a repeat of screening process from the 
complex to the individual proteins. However, the candidates need to be validated 
further, and this method might generate a large amount of negative results if applied 
to target screening in large scale. Therefore, this method’s efficiency needs to be 
improved.   
 
In addition, Yan Lu, et al identified TAB1 as the target of triptolide in 
macrophages. They utilized triptolide succinate (mTP) as the hapten derivative, 
followed by co-immunoprecipitation (coIP) with anti-TP. As a result, the specific 
band of candidate was excised and identified by mass spectrometry. Although their 
finding did not focus on binding targets of triptolide in cancers, it provided some 





Recently Yang’s lab identified the triptolide’s binding target – Peroxiredoxin I. 
Yang’s lab utilized two chemical proteomics probes, fluorophore-conjugated probe 
and biotin-conjugated probe. However, both probes were bulky and not ideal to enter 
the cells. Actually, they extracted the proteins and incubated the proteins with the 
probes in vitro. Therefore, the application of these two probes was limited. In addition, 
the pull-down candidates might contain non-physiologically relevant targets.  
 
Table 1.2 Direct binding targets of triptolide currently found. So far, there are 
only five proteins identified as the direct binding targets of triptolide.  
 
 
Some studies have shown that drugs exert their functions through interacting with 
multiple targets. One of the methods to study the multiple targets is chemical 
proteomics [115-117]. For example, multiple proteins ranging from anti-inflammatory 
to anticancer properties were identified as Artemisinin’s binding target, by using 
proteomics approaches [118]. Therefore, the attempts to identify binding targets of 
triptolide indicated that triptolide’s molecular targets have not been fully 
characterized and there are more possible binding targets with low affinity or low 
abundance remains unexplored. Considering the above limitations, and with the aim 




to utilize the chemical proteomics approaches to profile the direct binding targets of 
triptolide in vivo. Profiling the targets of triptolide and exploring the signaling 
pathways are mutually promotional to unravel the mechanisms of triptolide against 
colorectal cancer. In addition, revealing the direct targets of triptolide might aid to 
design derivatives that have fewer side effects and less toxicity.  
 
1.5 Aims of my projects 
 Compounds derived from natural products, especially those originating from 
plants, have played invaluable roles in drug discovery process regarding to all disease 
types [39]. Diterpenoids from plant exert an extensive range of important 
physiological functions and give hope for the development of new therapeutic agents 
against cancer, inflammation and cardiovascular diseases [40-42].  
 
Triptolide, a diterpene triepoxide extracted from natural plant, exerts strong 
anti-tumor activities. Previously numerous studies have demonstrated that triptolide 
has anti-proliferative and pro-apoptotic activity in various tumor models in vitro and 
in vivo. However, the detailed molecular mechanisms of triptolide against colorectal 
cancer remains largely elusive to date. Fortunately, the current achievement in the 
fields of proteomics and bioinformatics provide the opportunity to study protein 
changes at a global level, facilitating the exploration of the cellular signaling pathway 




quantitation (iTRAQ) is a non-gel-based technique used in proteomics to study 
quantitative changes in up to eight samples simultaneously. Until now, only a few 
limited studies in the area of colorectal cancer treatment have exploited this 
high-throughput technique. The previous works focused on individual proteins, which 
might not provide an overall picture of the regulated proteins at a global level.  
 
On the other hand, identification of the binding targets of a drug is very important 
in exploring its mechanism as well as refining the drug in the clinic trials with 
minimal side effects. However, only five proteins so far have been identified as direct 
binding targets of triptolide, using methods with some limitations described above. 
Therefore, in our study, the chemical proteomics method will be utilized, which could 
profile the target candidates with high confidence at a global level.  
 
Therefore, the aims of my projects include two parts: 1) to profile the protein 
alterations with triptolide’s treatment at a global level, revealing the signaling 
pathways of the regulated proteins 2) to identify the direct binding targets of triptolide. 
These studies might shed some lights on the mechanism of triptolide against 
colorectal cancer cells. An understanding of the direct binding targets of triptolide and 
the signaling pathways will aid to unravel its mechanism.  
 
For my first objective, the regulated proteins in colorectal cancer cell line HCT 




using bioinformatics approaches. These approaches could generate an overall picture 
of protein level changes, which provides some insights into the mechanism of 
triptolide against colorectal cancer. For my second objective, the specific targets of 
triptolide will be identified using Activity-based Protein Profiling (ABPP) combined 
with bio-orthogonal “click chemistry”. The mechanism of the drug’s binding activity 
with targets will also be evaluated. These methods will provide us with a profile of 









































2.1 Cell Culture 
Human colorectal cancer cell line HCT 116 was obtained from American type 
culture collection (ATCC) and cultured in McCoy’s 5A Medium supplemented with 
10% fetal bovine serum (FBS) and 1% antibiotic-antimycotic at 37℃ in 5% CO2 
mixed with air.  
 
2.2 Cell Proliferation Assay 
HCT 116 cells were seeded at a density of 8,000 cells per well of a 96-well plate 
and allowed to adhere overnight. Cells were treated with 1% DMSO as control or 
triptolide at different concentrations ranging from 2 nM to 50 nM, in 6 replicates. 
After 48 hrs of incubation, the medium was removed and cells from each condition 
were fixed, stained and rinsed thoroughly. A staining solution contained 20% 
methanol and 0.5% crystal violet. After air-drying, 100 μl of 1% SDS in PBS was 
added to each well to solubilize the dye completely. The absorbance value was read at 
590 nm. In another experiment to study time-effects, cells were treated with selected 
concentrations (10 nM and 25 nM) of triptolide for 24, 48 and 72 hrs.  
 
2.3 Cell Cycle Analysis 
HCT 116 cells were synchronized with serum-free medium overnight and then 
treated with 1% DMSO or 25 nM of triptolide for 6, 12 or 48 hrs, in three biological 
replicates. To harvest, a number of 1×10
6




without wash. 70% ice-cold absolute ethanol was added into cell pallets by gentle 
pipetting. After being fixed overnight at -20℃, cells were then spun down and stained 
with 1 ml propidium iodide (50 μg/ml; Sigma-Aldrich) containing RNase A (50 μg/ml; 
Sigma-Aldrich) for 3 hrs at room temperature in tinfoil-covered tubes. Next, analysis 
of DNA content was carried out on a FACScan flow cytometer.  
 
2.4 Proteomics Sample Preparation 
Samples were prepared by sonicating the harvested cells with a lysis buffer 
containing 0.5 M triethylammonium bicarbonate (TEAB) and 1% SDS, pH 8.5. The 
lysates were then centrifuged at 12,500 g for 30 min to remove cell debris. Protein 
quantitation was performed using RCDC Protein Assay Kit (Bio-Rad); 100 μg of each 
sample was used for iTRAQ labeling.  
 
2.5 ITRAQ labeling 
ITRAQ labeling was carried out using commercial reagents (iTRAQ
TM
 Reagent 
8-Plex kit, Applied Biosystem) based on the manufacturer’s protocol. Cell lysates 
were reduced with tris-(2-carboxyethyl) phosphine (TCEP), alkylated with methyl 
methane-thiosulfonate (MMTS), and diluted 20 times before digesting overnight by 
trypsin (w/CaCl2; Promega; 1:10 (w/w)) at 37°C. Equal amount of digested peptides 
was reconstituted with 0.5 M TEAB. A pair of whole cell lysates of HCT 116 cells 




iTRAQ labeling reagents, respectively. Another pair of its biological replicates of the 
same samples was labeled with 117 and 118 iTRAQ labeling reagents, respectively. 
For another comparison, a pair of whole cell lysates of HCT 116 cells treated with 
DMSO and 25 nM of triptolide for 48 hrs was labeled with 115 and 116 iTRAQ 
reagents, respectively. Another pair of its biological replicates of the same samples 
was labeled with 119 and 121 iTRAQ reagents, respectively. Once the peptides were 
added with respective isobaric tags, they were incubated at room temperature for 2 hrs 
before mixing (Figure 2.1).  
 
Figure 2.1 Schematic representation of workflow of iTRAQ labeling showing 
biological replicates. In our experiment, proteome from HCT 116 cells treated with 
DMSO either with 25 nM of triptolide for 6 or 48 hrs were reduced and digested. 
Subsequently, the digested peptides from each sample were labeled with respective 
isobaric tags and mixed. Strong Cation Exchange (SCX) chromatography followed by 
desalting was applied to facilitate the identification and quantification of the 
respective samples by 2D LC-MS/MS. 
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2.6 Strong Cation Exchange (SCX) Chromatography and Desalting 
SCX was carried out to remove interfering substances such as dissolution buffer, 
organic solvent, reducing agent and excess iTRAQ reagents. Cation exchange system 
provided in the iTRAQ Method Development Kit (AB SCIEX) was utilized. The 
labeled peptide mixture was diluted 10 times with Cation Exchange Buffer-Load. The 
pH was checked and brought down in the range of 2.5 to 3.3. The cation-exchange 
cartridge was conditioned by injecting 1 ml of the Cation Exchange Buffer-Clean and 
2 ml of Cation Exchange Buffer-Load. Then the diluted sample mixture was injected 
slowly into the cartridge. The cartridge was washed with 1 ml Cation Exchange 
Buffer-Load and finally the peptides were eluted with 500 μl of Cation Exchange 
Buffer-Elute and collected in a new tube. This fraction was then desalted using 
Sep-Pak C18 cartridges (Waters, Milford, MA). Subsequently the sample was 
lyophilized and dried. The desalted and dried sample was reconstituted with 98% H2O, 
2% acetonitrile and 0.05% formic acid for 2D LC-MS/MS analysis.  
 
2.7 2D LC Analysis and Tandem Mass Spectrometry (MS/MS) 
Peptide separation was performed on Ultimate 3000 LC system 
(Dionex-LC-Packing, Sunnyvale, CA) connected to SCX NanoEase trap column 
(PolyLC inc, PolySULFOETHYLA
TM
) for the first dimension. Peptides were 
separated using step gradients of mobile A (10 mM K2HPO4, 25% ACN, pH=3) and 




mobile B for 10 min, 0-36% for next 80 min, 36-70% for the next 30 min, and 100% 
for last 5 min and 0% for another 15 min, at a flow rate of 0.5 ml/min. Then twenty 
eluting fractions were desalted with Sep-Pak C18 cartridges (Waters, Milford, MA) 
for second-dimension reverse phase (RP) chromatography. The MS analysis was 
performed using a 5600 TripleTOF analyzer (AB SCIEX, Foster City, CA).   
 
2.8 Peptide and Protein Identification and Bioinformatics Analysis 
ProteinPilot Software 2.0.1 (AB SCIEX) was exploited for protein identification 
and relative iTRAQ quantification. A strict unused score cutoff > 1.3 was used as the 
qualification criteria, which corresponds to a protein confidence level of > 95%. Four 
sets of fold change of treatment to control for both early and late time points were 
averaged. Gene Ontology (GO) studies classified the significantly altered proteins as 
per their molecular function, cellular component and the biological process. To better 
analyze the data generated, protein list of these proteins was uploaded into Ingenuity 
Pathway Analysis (IPA) software. The top biological processes, molecular functions 
as well as networks including the significantly altered proteins were established.  
 
2.9 Validation of Proteomics Data using Western Blot 
SDS-PAGE was performed to run equal amount of whole proteins extracted from 
harvested cells. The proteins were then transferred onto PVDF (Polyvinylidene 




0.1% Tween 20 (PBST). The membranes were incubated with rabbit anti-BRD4 mAb 
(Santa Cruz Biotechnology), rabbit anti-GAPDH mAb (Santa Cruz Biotechnology), 
rabbit anti-Cyclin D1 mAb (Santa Cruz Biotechnology) and rabbit anti-CDK4 mAb 
(Santa Cruz Biotechnology) overnight. HRP-conjugated anti-mouse IgG (1:5000) 
from GE Healthcare, or HRP-conjugated anti-rabbit IgM (1:5000) from Pierce 
Biotechnology were used as secondary antibodies. Subsequent visualization was 
performed using ECL substrate (Santa Cruz Biotechnology, Inc.) with GAPDH as the 
loading control. 
 
2.10 Immunocytochemistry Staining 
HCT 116 cells were seeded on 6-well plate covered with autoclaved coverslips 
and grown until 50%. Full medium was then changed to medium with 1% DMSO or 
difference concentrations of triptolide (25 nM, 50 nM and 100 nM). After incubating 
for 48 hrs, cells were then fixed with 4% paraformaldehyde in PBS (pH 7.4) for 10 
min at room temperature. The coverslips were then washed with cold PBS and 
permeabilized for 10 min with PBS containing 0.25% Triton X-100. Subsequently, 
coverslips were washed and blocked with 1% BSA for 1 hr and incubated with rabbit 
monoclonal anti-BRD4 antibody (Santa Cruz Biotechnology; diluted 1:500) overnight 
at 4 degrees. Cells were then incubated with Alexa Fluor-555 conjugated donkey 




mounting solution (Santa Cruz Biotechnology). The immunofluorescence was 
analyzed under Leica DMI6000 B.  
 
2.11 In situ fluorescence labeling using triptolide probe 
HCT 116 cells were seeded into 6-well plates and allowed to adhere overnight at 
37°C. Then cells were treated with medium containing 1% DMSO or increasing 
concentrations (5-500 μM) of triptolide-probe for 12 hrs. Cells were harvested and 
suspended in 150 μL of PBS containing 0.16% SDS and proteinase inhibitor. After 
cell lysis by sonication, the lysate was centrifuged at 12,500×g for 30 min. 
Concentration of proteins in supernatant was calculated by using Bradford assay. 
Equal amount of sample was incubated with Cy3-azide (20 μM), Tris (2-carboxyethyl) 
phosphine (TCEP) (1 mM, 100×fresh stock in water), Tris [(1-benzyl-1H-1, 2, 
3-triazol-4-yl) methyl] amine (TBTA ligand) (100 μM, 100×stock in DMSO), and 
CuSO4 (1 mM, 100×stock in water) at 37 °C for 4 hrs. Subsequently, the clicked 
proteins were precipitated by cold acetone and air-dried. Proteins were dissolved with 
1×SDS loading buffer and separated by SDS gel electrophoresis on 12% 
polyacrylamide gel. After SDS-PAGE, gel was visualized using Typhoon 9410 laser 
scanner (GE, healthcare; Buckinghamshire, UK).  
 
2.12 Proteome labeling with triptolide probe 




followed by treatment with 1% DMSO or 100 μM triptolide-probe for 12 hrs, in two 
biological replicates. Cells were then suspended in 5mL of 800 μM PBS containing 
1.2% SDS, followed by sonication. Next, samples were centrifuged at 12,500×g for 
30 min and the supernatant was applied to protein quantitation. Equal amount of 
proteins was incubated with Biotin-azide (20 μM), TCEP (1 mM, 100×fresh stock in 
water), TBTA ligand (100 μM, 100×stock in DMSO), and CuSO4 (1 mM, 100×stock 
in water) at 37 °C for 4 hrs. Subsequently, the clicked proteins were precipitated by 
cold acetone and stored at -80°C until further use. After the proteins were fully 
precipitated, samples were centrifuged; Acetone in the supernatant was completely 
removed.  
 
2.13 Pull down and MS analysis of triptolide-bound proteins 
 The precipitated proteins were dissolved in 1 mL of PBS containing 0.1% SDS 
and incubated with 70 μl of avidin beads (Sigma-Aldrich) with gentle mixing 
overnight at 4°C. The beads were washed with 1% SDS in PBS thrice, with 6 M urea 
thrice, and with PBS thrice. Each of these steps started with gentle centrifugation (800 
rpm, 3 min), followed by removal of supernatant, and addition of 12 mL of 
above-mentioned washing solution with gentle shaking for 10 min. A small amount of 
enriched bead-bound proteins were separated by SDS-PAGE and visualized by silver 
staining. By comparison of the enriched target bands with control samples, the bands 




identification by LC-MS/MS. 
 
2.14 Immunofluorescence staining using triptolide probe 
HCT 116 cells were seeded on Corning Disposable Sterile Suspension Culture 
Dishes (Corning Glass Works, N. Y.) and grown until 70% confluence. Full medium 
was then changed to medium containing 1% DMSO or 100 μM of triptolide probe. 
After incubation for 12 hrs, medium was removed and cells were then fixed with 4% 
paraformaldehyde in PBS (pH 7.4) for 10 min at room temperature. Next, cells were 
washed with cold PBS and permeabilized with PBS containing 0.25% Triton X-100. 
Next, cells were clicked with Cy3 alkyne. Briefly, cells were incubated with 
fresh-made click chemistry reaction solution containing 20 μM Cy3-azide, 1 mM 
TCEP, 100 μM TBTA and 1 mM CuSO4 at room temperature for 2 hrs. The 
immunofluorescence was visualized using Leica DMI6000 B.   
 
2.15 Protein synthesis evaluation 
HCT 116 cells were cultured in L-methionine-free medium for 30 min to remove 
the previous methionine reserves. Then cells were labeled with 50 μM AHA with 
DMSO or 100 nM triptolide. After 12 hrs’ incubation, cells were harvested and the 
amount of AHA incorporated into the protein could be detected using the click 






2.16 Preparation of recombinant PRDX I 
 Human gene of PRDX I (GenBank Accession No. NP_859048.1) was subcloned 
into pET28a to generate a 6×His-tagged fusion protein. After confirming DNA 
sequence with 100 % identities, the construct was transformed into E.coli strain BL21 
for protein purification. Briefly, BL21 containing the desired plasmid was cultured in 
LB medium containing 100 μg/mL kanamycin at 37 °C until OD600 of 0.7 was 
reached. Then protein expression was induced by incubating with 0.4 mM Isopropyl 
β-D-1-thiogalactopyranoside (IPTG) at 37 °C for 2 hrs and then at 16 °C overnight. 
Subsequently, cells were harvested by centrifugation (4,500 rpm, 15-20 min) and 
suspended in lysis buffer (B-PER Reagent PI) by rotating for 20 min. Cell pellets 
were removed by centrifugation at 15,000g for 15-20 min. The protein in the 
supernatant was then bound to the beads (Ni
+
 (His-Pr)) with rotation at 4 °C for 1 hr 
and then washed three times with wash buffer (50 mM Tris, pH 8.0). Next, protein 
was eluted with elution buffer (50 mM Tris, pH 8.0, 100 mM NaCl, 250 mM 
Imidazole and 10% Glycerol).  
 
2.17 In vitro Labeling of PRDX I 
The recombinant PRDX I was reconstituted with PBS. Equal amount of proteins 
(1 μg) was incubated with 1 μl triptolide probe with a final concentration of 0, 10, 25, 




with 10×triptolide for 4 hrs and then incubated with triptolide probe. After incubation, 
PRDX I-probe complex was precipitated by acetone, and then applied to click 
chemistry reaction, SDS-PAGE and fluorescence scanning.   
 
2.18 Binding sites mapping by MS/MS 
The recombinant PRDX I was reconstituted with PBS. Equal amount of proteins 
(50 μg) were incubated with 1 μl of 10 mM triptolide or 1% DMSO in 100 μL of PBS 
at 37 °C for 4 hrs. Subsequently, samples were exchanged against 50 mM NH4HCO3 
for removing salt and unbound drug by using PD-10 Desalting Columns (GE 
Healthcare). Then protein was reduced and cysteine blocked, followed by trypsin 
digestion. The digested sample was applied to LC-MS/MS. For identification of 
triptolide-modified sites, the mass spectra were converted into Mascot generic format 
(MGF). Triptolide-modified residue mass difference 360.2 amu was specified as a 
parameter for modification searching. The same method was also utilized to study the 
binding sites mapping of Annexin A1.  
 
2.19 Docking simulation of target-triptolide compound 
The dimeric PRDX II (PDB: 1QMV) was used for docking simulation, using 
Autodock version 4.2 (http://autodock.scripps.edu/) with the Lamarckian Genetic 
algorithm (LGA). Water was moved and polar hydrogen atoms were added. Next, the 




triptolide was manually docked into PRDX II as a flexible ligand. Each docking 
simulation was repeated 10 times and the molecular modeling with minimum energy 
was adopted. The interaction of PRDX II-triptolide compound was analyzed using 
Pymol. The same method was also used for the study of Annexin A1-triptolide 
complex. The full-length Annexin A1 (PDB: 1MCX) was utilized.  
 
2.20 Peroxiredoxin function study 
Peroxiredoxin I function was tested by using Peroxidase Activity Assay Kit 
purchased from Sigma-Aldrich based on the manufacturer’s protocol. Briefly, 20 μg 
of PRDX I was incubated with 0, 100, 500 μM and 1 mM of triptolide at room 
temperature for 1 hr. Next, fluorescent peroxidase substrate and 12.5 mM H2O2 
substrate was added. Samples were then transferred into 96-well black plate with clear 
bottoms and incubated at 37 °C. The fluorescence intensity was measured 
(λex=535/λem=585 nm) for every 2 min (after 30 min, interval becomes 5 min until 60 
min). The amount of H2O2 reduced by PRDX I was calculated according to the H2O2 
standard curve. Peroxidase activity of a sample was determined by the following 
equation:  
Peroxidase Activity = Amount of H2O2 reduced/ (Reaction Time) ×V.  
Peroxidase activity reported as nmole/min/mL = milliunit/mL, where one unit of 
peroxidase is defined as the amount of enzyme that reduces 1.0 mmole of H2O2 per 





2.21 Evaluation of Reactive Oxygen Species (ROS) level  
 HCT 116 cells were treated with 100 nM triptolide or DMSO for 12 hrs, followed 
by incubation with CM-H2DCFDA, an indicator for ROS. The ideal Ex/Em for it is 
about 495/525 nm. The fluorescence intensity was finally analyzed by flow 
cytometry.  
 
2.22 Wound healing assay 
HCT 116 cells were seeded in 6-well plate in 3 biological replicates, and cultured 
until 100% confluency. Subsequently a wound was produced by gently scraping the 
cells with a yellow pipette tip. After removing the scraped cells with PBS twice, 
medium with DMSO as the control or triptolide were added into the well. The 
wounded cell cultures were then incubated at 37 °C in the humidified and equilibrated 
(5% v/v CO2) incubation. After 12 hours of treatment, the cells of the control and 
treatment were then photographed under microscope. The distances of migration 




























Chapter 3 Studies of global alteration of 
proteins in HCT116 with triptolide 













Triptolide, an extract from traditional Chinese medicine, has been investigated for 
many of its potential therapeutic uses, including the reduction of tumor progression 
and solid tumor masses. It has entered clinical trials based on its potent anti-tumor 
effects on prostate cancer and acute myeloid leukemia [79, 119]. Extensive scrutiny of 
its mechanism of action in the past few decades has yielded important insights. So far, 
triptolide has been demonstrated to directly induce apoptosis of human hepatocellular 
carcinoma, promyelocytic leukemia, cervical adenocarcinoma, pancreatic carcinoma, 
T cell lymphoma, lung caner and oral cancer cells [34, 36-38, 120].  
 
As described above, triptolide was demonstrated to have anti-proliferative and 
pro-apoptosic activity in various types of cancers. It was shown to induce apoptosis 
via activation of cysteine protease caspases 3, 8 and 9, and subsequent cleavage of 
DNA repair enzyme (ADP-ribose) polymerase in multiple myeloma cells [121]. 
Triptolide was also shown to decrease histone H3K9 and H3K27 methylations via 
down-regulating histone methyltransferase, which may be a potential anti-myeloma 
mechanism [122]. Vispe et al. concluded that triptolide was an original 
pharmacologic inhibitor of RNA Polymerase activity, indirectly affecting the 
transcription machinery, resulting in a rapid depletion of short-lived mRNA of 





However, as a tumor grows in a complicated way, the whole mechanism of the 
anti-tumor function of triptolide remain unclear. With the development of proteomics 
and bioinformatics methods, we have the opportunity to study protein changes in a 
whole picture, facilitating the study of the cellular signaling pathways. Therefore, in 
our study, the regulated proteins in colorectal cancer cell line HCT 116 treated with 
triptolide were profiled at whole proteins level by iTRAQ labeling followed by 
MS/MS. An eight-plex iTRAQ workflow followed by 2D LC-MS/MS was adopted to 
identify differentially expressed proteins. These approaches will aid to discover 
therapeutic targets of triptolide.  
 
3.2 Results 
3.2.1 Anti-tumor properties of triptolide 
3.2.1.1 Proliferation assay and cell morphology analysis 
To explore anti-proliferative activity of triptolide, the proliferation assay was 
performed. HCT 116 and CCD 841 cells were treated with DMSO as the control or 
increasing concentrations of triptolide for 48 hrs, in six biological replicates. IC50 
(concentration at which growth inhibition of 50 % of the cell population was achieved) 
of triptolide against HCT 116 cells was determined to be 10 nM, suggesting that 
triptolide has a strong inhibitory effect on HCT 116 cells proliferation with IC50 in 





By comparison, the proliferation of non-cancerous CCD 841 cells was not altered 
with triptolide’s treatment in low concentrations. IC50 of triptolide on CCD 841 was 
demonstrated to be more than 500 nM. The CCD 841 is one of the colorectal 
epithelial cell lines. They are adherent and stretched cells, and grow as a disorganized 
and flattened layer. Comparison of colorectal normal cells with the colorectal cancer 
cells is essentially important. It could definitely provide some insights on the 
mechanism of triptolide against colorectal cancer cells.   
 
Different concentrations of triptolide were chosen to study the effect of triptolide. 
In another independent cell proliferation assay, cells were treated with 10 nM and 25 
nM of triptolide for 24, 48 and 72 hrs. From the result, the percentage of viable cells 
decreased exponentially with increasing dosage level and treatment duration of 
triptolide (Figure 3.1B), which indicates that triptolide has a potent anti-proliferative 








Figure 3.1 Triptolide showed strong anti-proliferative effects on colorectal cancer 
cell line HCT 116 but did not interfere with the proliferation of colorectal 
epithelial cell line CCD 841. (A) HCT 116 cells and CCD 841 were treated with 
increasing concentrations of triptolide. The IC50 of triptolide was determined to be 10 
nM against HCT 116. The IC50 of triptolide against CCD 841 was more than 500 nM. 
(B) Cells were treated with 10 nM or 25 nM of triptolide for 24, 48 and 72 hrs, 
followed by the proliferation assay. Triptolide was shown to significantly attenuate 




To explore whether triptolide could alter cell morphology of HCT 116 cells, cells 
were treated with DMSO or 25 nM of triptolide for 48 hrs. The cell morphology was 
then observed under the microscope (Figure 3.2). Cell morphology image 
demonstrated that more than 20% of the total cells were detached with treatment. It 
suggested the presence of cell death with triptolide’s treatment at the low 
concentration. The detached cells also lost characteristic of the ordinary HCT 116 




Figure 3.2 Triptolide induced cell morphology change of colorectal cancer cell 
line HCT 116. The image of cell morphologies of HCT 116 cells treated with 1 % 
DMSO (A) or 25 nM of triptolide (B) for 48 hrs were observed and compared under 




3.2.1.2 Cell cycle and apoptotic analysis by flow cytometry 
To explore the function of triptolide on cell cycle of HCT 116 cells, flow 
cytometry analysis was then carried out. Cell distribution in three cell cycle phases 
were carefully calculated using software Flowing Software version 2.5.1. As shown in 
Figure 3.3A and 3.3B, Cell numbers in G0 phase were increased with 6, 12 and 48 hrs 
of treatment, from 51.7% to 60.8%, 33.6% to 38.8, 58.9% to 66.5%, respectively. 
Flow cytometry assay indicated that triptolide induced G0 phase cell cycle arrest and 
slowed down cell cycle shift from G0 to S phase (Figure 3.3A). 
 
In addition, to examine whether triptolide possesses pro-apoptotic activity on 
HCT 116 cells, the apoptotic analysis was then conducted by flow cytometry. 
Synchronized cells treated with DMSO or triptolide for 48 hrs were applied to the 
flow cytometric analysis in three biological replicates. Cell distributions in three cell 
cycle phases were also calculated using Flowing Software. As shown in Figure 3.3C, 
triptolide induced an obvious accumulation of cells in the sub G0/G1 region with 48 
hrs of treatment (in red color), verifying that triptolide exerted the apoptotic activity 










Figure 3.3 Effects of triptolide on cell cycle phases and apoptosis. The percentage 
of cells in phase G0, S and G2/M was showed (A) and summarized in (B), using 




phase arrest with 6, 12 and 48 hrs of treatment. (C) Cell apoptosis was evaluated 
using Flow Cytometry analysis. Cell cycle of HCT 116 cells were synchronized. Then 
cells incubated with 25 nM of triptolide for 48 hrs. Cell cycle analysis was performed 
by Propidium Iodide staining, followed by flow cytometry analysis. Accumulation of 
cells in sub G0/G1 region (labeled with red area) represented that triptolide induced 
apoptosis with 48 hrs of treatment.  
3.2.2 ITRAQ results 
To better understand the short-term and long-term effects of triptolide on 
colorectal cancer cells, proteins extracts from HCT 116 cells with 6 and 48 hrs of drug 
treatment were analyzed using 8-plex iTRAQ labeling followed by Strong Cation 
Exchange (SCX) and LC-MS/MS. The brief workflow of iTRAQ is describe in Figure 
3.4. A strict cutoff of unused protein score was utilized, which corresponds to a 5% 




Figure 3.4 Workflow of iTRAQ. Proteins extracted from HCT 116 cells treated with 




treatment for 6 hrs were labeled with 113 and 117 iTRAQ reagents, in two biological 
replicates. Peptides with triptolide treatment for 6 hrs were labeled with 114 and 118 
iTRAQ reagents, in two biological replicates. Similarly, peptides with DMSO 
treatment for 48 hrs were labeled with 115 and 119 iTRAQ reagents. Peptides with 
triptolide treatment for 48 hrs were labeled with 116 and 121 iTRAQ reagents. After 
mixing, SCX and desalting were performed. The peptides were finally identified by 
2D LC-MS/MS.  
 
 
Under this criterion, there were 2382 proteins identified. Subsequently, the final 
cutoff ratio for significantly up- or down-regulated proteins were determined using 
the method described in the previous literature [123]. The biological variation caused 
by random biological effects were then measured. 
 
The biological effect caused the most likely source of variation compared to 
technical or experimental replicates [123]. This increased the need for fixing a cutoff 
with certainty that the protein alteration is real and thereby eliminated the need for 
other types of replicates [124]. The detailed method to determine cutoff value was 
described in the previous literature [123]. The proteins of the iTRAQ results were 
categorized into groups of variation ranging from 5% to 70% (Figure 3.5). Briefly, all 
peptide ratios were converted into log2 space. The average ratios of log2 values were 
then calculated, followed by being converted into linear space. Peptide ratios were 
then normalized and the normalized peptide ratios determine the variance. For 
example, at ±5% variation, 36.8% of the expression values from the 6 hrs of treatment 
and 19.2% of the expression values from the 48 hrs of treatment, respectively, fall 




quantified with criteria that variation of expression is less than 5%, respectively. 
Applying this cutoff method to our whole dataset, 17.3% and 22.1% variation 
corresponded to 88% coverage of protein for 6 and 48 hrs of treatment, respectively. 
Hence, the cutoff was determined to be 1.173 fold (±17.3% variation) for 6 hrs of 
treatment and 1.221 fold (±22.1% variation) for 48 hrs of treatment. With this 
criterion, 105 proteins were found to be significantly altered with 6 hrs of treatment 



































Figure 3.5 The percentage at different geometric standard deviation levels of 
total 2382 proteins. The X-axis represent percentage of geometric standard variation 
among four sets of iTRAQ ratios resulting from the comparisons between two 
controls and two treatments. Y-axis represents the corresponding percentage coverage. 
In our data, more than 88% of proteins had less than about 20% of variation. The 
cutoff thresholds for protein alteration were determined to be 1.173 fold (±17.3%) for 




3.2.3 GO analysis of significantly altered proteins 
The list of significantly altered proteins was analyzed via Gene Ontology analysis. 
It classified the significantly changed proteins as per their cellular component, as well 
as biological process (Figure 3.6). The wide distribution of cellular location indicated 
the proteins were fully extracted and triptolide significantly interfered with proteins in 






Figure 3.6 Cellular localization (Upper) and biological process (Bottom) of 
differentially regulated proteins. Two lists of significantly altered proteins from 6 
and 48 hrs of treatment were uploaded to the software STRAP 1.5. The cellular 
components and biological processes were presented, providing an overview 




3.2.4 IPA analysis 
The list of significantly changed proteins was then analyzed via Ingenuity 
Pathway Analysis (IPA) approach. IPA also ranked the molecular and cellular 
functions and top networks of significantly altered proteins (Table 3.1). The top 
functions of altered proteins were determined to be cellular maintenance, cell 
morphology and molecular transport. In addition, the associated top networks of 
these proteins were cell death and survival, gene expression and protein synthesis, 
and cell cycle. These data demonstrated that cell maintenance and morphology were 
interfered with triptolide. Cell death and survival ranked the top network of the altered 
proteins, which is consistent with our previous findings. Triptolide was also shown to 
alter the expression of proteins, which constitute the networks associated with cell 
death and cell cycle.  
 
Table 3.1 Functions and top networks of differentiated proteins. IPA analysis 








Next, the functions of the proteins altered by short-term and long-term treatments 
were analyzed separately, which were illustrated in Figure 3.7. The top-ranked 
function of proteins in 6 hrs of treatment was Cellular Assembly and Organization. 
This finding indicated that as early as 6 hrs, triptolide had interfered with cells 
morphology and cell adhesion, which were enhanced by longer treatment. With 48 hrs 
of treatment, the top functions of the altered proteins were determined to be Cellular 
Growth and Proliferation, concordant with our previous proliferation assay. This 
comparison between short-term and long-term treatment periods demonstrated that 
triptolide exerts its anticancer activities such as interfering with cell adhesion as early 
as 6 hrs but with longer treatment, triptolide has strong anti-proliferative and 







Figure 3.7 Functions of significantly altered proteins by IPA analysis. The list of 
significantly altered proteins were uploaded into IPA. These proteins were classified 
based on their functions and networks associated with cancer growth. The top 
functions of short-term treatment are Cellular assembly and top functions of 
long-term treatment is Cellular Growth and Proliferation.  
 
Associated networks including Cellular Assembly and Organization, as well as 
Metabolic Disease of proteins with 6 hrs of treatment were illustrated in Figure 3.8A 
and Figure 3.8B, respectively. The top networks of 48 hrs of treatment, Cell Death 
and Survival and Cell Morphology were depicted in Figure 3.8C and Figure 3.8D, 
respectively. The red nodes in the network represent significantly up-regulated 
proteins from iTRAQ results and the green ones represent significantly 









Figure 3.8 Networks of significantly altered proteins using Ingenuity Pathway 
Analysis (IPA) method. (A, B) In the 6 hrs of treatment, the top networks of Cellular 
Assembly and Organization, as well as Metabolic Disease were depicted, respectively. 
(C, D) In the 48 hrs of treatment, the top networks of Cell Death and Survival and 
Cell Morphology were depicted, respectively. The red nodes represent up-regulated 
proteins and green nodes represent down-regulated proteins based on our iTRAQ 
results. Lines with arrows represent the downstream signaling and lines alone 





The top canonical pathway was determined to be Remodeling of Epithelial 
Adherens Junctions. This network might be related to cell adhesion and cell 
movement. Previous observation has demonstrated that 20% of cells were detached 
with triptolide treatment, which is in line with our canonical pathway analysis. To 
examine whether triptolide could also inhibit cell migration, the Wound Healing assay 
was then carried out. HCT 116 cells were treated with DMSO or triptolide until 100% 
cell confluency, followed by the creation of wounds with scratching. Cells were 
photographed at time 0 and 12 hrs. The initial edges of cells were labeled and the new 
edges of cells after treatment for 12 hrs were marked. The migration distances were 
measured and compared. As shown in Figure 3.9, the migration distances of cells 
treated with triptolide were much less than those of control samples. This suggests 
that triptolide also inhibits cell migration. 
 
 
Figure 3.9 Wound Healing Assay. HCT 116 cells were cultured until 100% 
confluency and wounds were created by scratching. Then the cells were treated with 
DMSO and triptolide for 12 hrs. The distances of migration were calculated at time 0 
and 12 hrs. The migration of HCT 116 cells treated with triptolide was less compared 





3.2.5 Validation of significantly altered proteins 
3.2.5.1 Bromodomain-containing protein 4 (BRD4) 
Bromodomain-containing protein 4 (BRD4) was first described as an unusual 
chromatin binding factor that remained bound to chromosomes throughout mitosis 
[125]. It belongs to the Bromo and Extra Terminal (BET) family of nuclear proteins 
that play important roles in numerous functions including transcription regulation, 
genome structure, chromatin boundary maintenance as well as cell cycle regulation 
[126]. In mammals, once bound to the hyperacetylated histones at the promoter, 
BRD4 recruits Positive Transcription Elongation Factor b (p-TEFb) to the 5’-end of 
genes to release paused RNA Polymerase II (RNAPII) into productive elongation 
[127]. BRD4 was also demonstrated to have a kinase activity capable of directly 
phosphorylating Ser2 of the RNAPII C-terminal domain (CTD), suggesting a direct 
role in transcription elongation [128].  
 
In addition, RNA polymerase II was also decreased with triptolide treatment in 
our iTRAQ result, which is in line with a previous study [114]. RNA polymerase II 
(RNAPII) played important roles for promoter escape and the recruitment of the 
mRNA processing machinery during transcription. Its inhibition was demonstrated to 





BRD4 was demonstrated to be the upstream regulator of RNAPII. This 
fundamental role of BRD4 in the transcriptional regulation puts it to the center of 
numerous biological activities in cells, especially in tumor cells, which require 
extraordinary levels of transcription. As a matter of fact, BRD4 had been identified as 
a therapeutic target for acute myeloid leukemia, multiple myeloma and other cancers. 
[129, 130] 
 
Therefore, our result suggested that triptolide interferes with transcription factors’ 
expression through decreasing BRD4. BRD4 might be one of the potential targets of 
triptolide to exert its anti-tumor activity. It was selected for further validation by 
western blot analysis (Figure 3.10). 
 
 
Figure 3.10 Triptolide inhibited expression of BRD4 with 48 hrs of treatment. (A) 
ITRAQ data was validated by Western blot. With 25 nM triptolide treatment, BRD4 
was significantly decreased, which was in conformity with iTRAQ results. (B) HCT 
116 cells were treated with DMSO or 25 nM, 50 nM and 100 nM of triptolide for 48 





To further validate the quantitative expression of BRD4 in colorectal cancer cells 
treated with triptolide or control, immunocytochemistry analysis was carried out. 
Intracellular levels of protein BRD4 in control and treated HCT 116 cells were shown 
in Figure 3.11. The level of protein BRD4 was decreased with the concentration of 
triptolide increased. Under the microscope, the cells treated with triptolide also 
showed alterations in cell morphologies. Cells were then analyzed by the quantitative 
analysis based on fluorescence intensity. Experiment was carried out twice to get the 
same trends of protein level change. This observation was also consistent with our 
western blot result and iTRAQ result, which indicates that BRD4 could be one of the 







Figure 3.11 Quantitative immunocytochemistry analysis for expression of BRD4 
in HCT 116 treated with DMSO or different concentrations of triptolide. 
Fluorescent image validated down-regulation of BRD4 in HCT 116 cells treated with 
triptolide for 48 hrs. Red channel represents BRD4 staining and blue channel 
represents DAPI. 
3.2.5.2 β-catenin 
β-catenin is known to regulate the coordination of cell-cell adhesion and gene 
transcription. β-catenin was firstly discovered for its roles in the cell adhesion [131] 
[132]. Cell-cell adhesion determines the cell morphology and regulates several 
cellular processes such as motility and survival [133]. Disruption of normal cell-cell 




metastasis [133].  
 
As a component of Cell-cell adherens junctions (AJs), β-catenin improves cell 
adhesion by binding to cadherin, and by mediating the interaction of adherens 
junction molecules with actin cytoskeleton. β-catenin also acts as an intracellular 
signal transducer in the Wnt signaling pathway, activating the transcription of several 
genes responsible for cellular proliferation and differentiation. Both roles of β-catenin 
indicate that it is important in the cell proliferation and survival.  
 
What is more, the functions of β-catenin are deregulated in human malignancies. 
It was reported that mutations that activate the Wnt-β-catenin pathway enhance the 
stability of β-catenin and therefore activate gene transcription and alter cell migration 
[134] [135]. Due to its involvement in cancer development, inhibition of β-catenin 
receives the researchers’ attention. Several works focus on targeting the upstream 
components of Wnt pathway or ARM domain of β-catenin, therefore influencing the 
β-catenin level.  
 
In our experiment, β-catenin was shown to be down-regulated by triptolide, 
especially with 48 hours of treatment, as shown in Figure 3.12. The inhibition of 
β-catenin by triptolide suggested that triptolide might interfere with the Wnt-β-catenin 
pathway, inhibiting gene transcription. The down-regulated β-catenin suggested that 






Figure 3.12 Validation of key proteins altered by triptolide treatment using 
Western blot analysis. Cells were treated with 25 nM of triptolide or DMSO for 6 or 
48 hrs. Equal amount of proteins were loaded into SDS gel. Antibodies of BRD4 and 
β-catenin were utilized in each blot. BRD4 and β-catenin were showed to be 
significantly regulated with 48 hrs of treatment. GAPDH was used as the loading 
control.  
3.2.6 Proteins specifically regulated by triptolide in cancer cells  
As shown in the proliferation assay, viable cells of CCD 841 treated with up to 
500 nM of triptolide is still 80 % of total cells. Therefore, the IC50 of triptolide 
towards CCD 841 is much greater than 500 nM. By contrast, the proliferation of HCT 
116 cells was greatly affected by the inference of triptolide. With 10 nM triptolide’s 
treatment, the viable cells of HCT 116 went down to 50 % of total cells. This big 
difference might be because triptolide binds and interferes with highly expressed or 
specifically expressed proteins in tumor cells. Therefore, to figure out the possible 
proteins that triptolide specifically targets or inhibits is quite important and might 




cells. In addition, these specific proteins might be the potential therapeutic targets of 
triptolide when it is applied in the clinical application.  
 
Thus, to study whether triptolide interfere with the key proteins which play 
important roles in the tumor development, the significantly regulated proteins in the 
colorectal cancer cell line HCT 116 were then analyzed in normal colorectal cell line 
CCD 841 compared with HCT 116. As shown in the Figure 3.13, expression levels of 
BRD4 and β-catenin of CCD 841 cells were not changed, even with triptolide’s 
treatment. These differences demonstrated that triptolide might specifically target and 
inhibit several key proteins expressed in colorectal cancer cell lines but not normal 




Figure 3.13 Comparison of BRD4 and β-catenin in normal and cancer cell lines 
CCD 841 and HCT 116. Triptolide was shown to down-regulate BRD4 and 
β-catenin in HCT 116 but it had no obvious effect on these proteins in CCD 841, 






Colorectal cancer (CRC) is the 2
nd
 most common cancer with the 3
rd
 leading 
mortality rate in developed countries [136]. Surgery may be the most common 
treatment for CRC when it has not spread. However, the early stage of colorectal 
cancer does not have symptoms. Therefore, chemotherapy becomes vitally important 
for CRC treatment when the cancer has penetrated the bowel wall and spread. 
 
A number of natural compounds exhibit multi-targeted effects and have made a 
tremendous impact in drug discovery [137] [138]. One of the effective anti-cancer 
drugs, triptolide, was purified from traditional Chinese medicine herb, Leigongteng. 
Triptolide shows strong anti-proliferative activity, inhibiting the proliferation of all 60 
US National Cancer Institute cancer cell lines with half-maximal inhibitory 
concentration (IC50) values in the low nanomolar range (average IC50 = 12 nM).  
 
Triptolide’s derivates have entered clinical trials based on its potent anti-tumor 
effects on prostate cancer and leukemia models [79, 119]. It induces apoptosis in a 
number of cancer cell lines. So far, triptolide was demonstrated to directly induce 
apoptosis of human hepatocellular carcinoma, promyelocytic leukemia, cervical 
adenocarcinoma, pancreatic carcinoma, T cell lymphoma, lung cancer and oral cancer 
cells [34, 36-38, 120]. Extensive scrutiny of its mechanism of action in the past few 




against cancer cells remains unclear. Therefore, our study provided protein profiling 
of colorectal cancer cell HCT 116 upon triptolide treatment at a global level, by using 
proteomics approaches. In our study, triptolide was demonstrated to induce efficient 
apoptosis and inhibit cell growth of CRC cell line HCT 116. IC50 of triptolide on HCT 
116 cells was found to be 10 nM with 48 hrs of treatment, which is close to the 
average level of those 60 cancer cell lines (12 nM). Its effective anti-proliferative 
activity on colorectal cancer cell also indicated that its derivatives might potentially 
enter clinic trials against colorectal cancer.  
 
Our study evaluated significant altered proteins in HCT 116 treated with/without 
triptolide in the global protein landscape using quantitative labeling approach, iTRAQ. 
The high-throughput quantitative proteomics approach was able to identify 
significantly altered proteins at a global level. As expected, some significantly 
regulated proteins in our results, such as RNA Polymerase II and TAB1 were in line 
with earlier published reports [114, 139], demonstrating the reliability of our 
proteomics data.  
 
At the molecular level, it is clear that RNA Poly transcription regulators play vital 
roles in malignant transformation. Previous study has revealed that triptolide exerted 
anti-tumor effects through inhibiting transcription machinery RNAPII [140][141]. 
Regulation of transcription by restricting the release of paused RNAPII appears to be 




RNAPII, BRD4 promotes transcription by directly phosphorylating the C Terminal 
Domain of RNA Polymerase II. In our study, with triptolide’s treatment, BRD4 was 
found to be down-regulated, whose alternation was further validated using Western 
blot analysis. Its down-regulation could be responsible for the inhibition of RNAPII 
and subsequent inhibition of transcriptional factors.  
 
On the other hand, triptolide showed no effect on the proliferation of the 
epithelial colorectal cell line CCD 841, which suggested that triptolide might target 
some specifically or highly expressed proteins in HCT 116 cells. Then BRD4 and 
β-catenin levels of normal cell CCD 841 and cancer cell HCT 116 were compared. 
The levels of these two proteins did not change in the normal cells. As BRD4 has 
never be reported before, our study provides a novel insight into the mechanisms of 






















Chapter 4 Identifying direct binding 
targets of triptolide using combination 














Although studies on triptolide-induced downstream signaling pathways have 
provided some insights, studies of protein targets are critically important because 
target-identification and mechanism-of-action studies play vital roles in drug 
discovery [88]. So far, there were only five proteins identified as binding targets of 
triptolide. Polycystin-2 (PC2) was firstly identified by Crews’ group in 2007 [109]. 
After that, their group also identified dCTP Pyrophosphatase 1 (dCTPP1) [111]. In the 
same year, Liu’s lab identified XPB, later identified its binding site, Cysteine342 [112, 
113]. Yan Lu, et al. identified TAB1 as the target of triptolide in macrophages. 
Recently, Yang’s group identified Peroxiredoxin I as the binding target of three 
natural terpenoids: triptolide, celastrol and withaferin A [143]. However, the methods 
they utilized have their limitations. Triptolide’s targets could not be easily enriched or 
could not be pulled down with in vivo studies However, identification of targets in 
vivo is vitally important. It could reflect the active conditions of the target candidates. 
Therefore, methods for identification of binding targets will be improved, which 
allows us to focus on the active proteins in the physiologically relevant environment.  
 
Natural compounds commonly have multiple targets [138]. Numerous proteomic 
methods have been developed in identification of drug therapeutic targets, screening 
of enzyme inhibitors, as well as discovery of tumor biomarkers [105, 106]. However, 




protein abundance, which does not necessarily correlate with protein activity [47], 
neither do they provide functional understanding of native proteins in the 
physiologically relevant environment [47]. This limitation could be overcome by 
coupling Activity-Based Protein Profiling (ABPP) which uses probes to covalently 
bind to catalytic site of target enzymes in vivo with proteomic approaches [47, 53]. 
This chemical proteomics method could be utilized to identify targets of covalent 
drugs at a global level [46]. Moreover, ABPP combined with bio-orthogonal “click 
chemistry” is a widely used functional proteomics technology to determine the 
functional state of enzymes [53, 107, 108].  
 
The core of the activity-based proteomics technology is a small molecule known 
as activity-based probe (ABP) that interacts with targeted proteins, forming stable 
covalent bonds. The position of triptolide to be modified cannot be pharmacopoeic, 
nor close to the binding sites, since disruption of major active sites will impede even 
abolish interaction with targets. The linker is supposed to be sufficiently flexible to 
ensure biotin or fluorescent dye cyanine 3 (Cy3) immobilized to streptavidin/avidin 
beads. Therefore, triptolide probe was designed to contain an alkyne tag in C14 


















Figure 4.1 Chemical structure of triptolide probe. Triptolide was designed to 
contain an alkyne in the position of C14, which is not critical for the toxicity of 
triptolide according to SAR. 
 
However, the results from traditional chemical proteomics method may contain 
some non-specific protein targets. The non-specific targets can be ruled out by 
comparison of the protein profiles of probe-treated sample with the control sample. In 
my study, to discriminate specific protein targets from non-specific and endogenously 
biotinylated proteins, combination of ABPP and iTRAQ will be applied. The detailed 
workflow will be described in the result sections.  
 
4.2 Results 
4.2.1 Proliferation inhibition activity of triptolide probe 
For evaluating the property of triptolide probe, proliferation assay was performed. 
HCT 116 cells were treated with different concentrations of triptolide probe in 4 




2.2 μM, which is greater than the IC50 of native triptolide. The difference of IC50 of 
native triptolide and triptolide probe may be due to the introduction of longer moiety, 
influencing the interaction of probe with its targets. However, previous study that 
successfully identified the binding target, dCTPP1, utilized a probe with the IC50 of 
168 μM [111], which is much greater than the IC50 of our probe. To explore and 
validate the binding activity of triptolide probe, the in situ proteome profiling assay 




Figure 4.2 Triptolide probe showed inhibitory activity against cell proliferation 
with 48 hrs of treatment. HCT 116 cells were grown in 96-well plate and treated 
with increasing concentrations of triptolide probe for 48 hrs. The living cells were 
then washed by PBS and stained with crystal violet. After incubation for 10 min, 
crystal violet was completely removed and PBS containing SDS was added to 




4.2.2 In situ proteome profiling of triptolide targets 
For visualizing the cellular targets of triptolide, in situ proteome fluorescence 
labeling was performed. The probe-labeled proteomes of HCT 116 cells were applied 
to click chemistry and then visualized by fluorescence scanning. As shown in Figure 
4.3, the fluorescence signals were enhanced with the concentration of triptolide probe 
increased. All samples were equally loaded, as verified by Coomassie blue staining 
(Figure 4.3). Therefore, the enhanced fluorescence signal bands represent the native 
cellular targets of triptolide. This data also demonstrated that our probe was suitable 




Figure 4.3 In situ proteome labeling of HCT 116 cells using triptolide probe. HCT 
116 cells were treated with increasing concentrations of triptolide probe for 12 hrs. 




proteins were loaded into SDS-PAGE and their fluorescence signals were visualized 
by fluorescence scanning. The same SDS gel was then stained by Coomassie blue 
after fluorescence scanning. The intensity of triptolide targets was enhanced with the 
concentration of triptolide probe increased, using 12% SDS-PAGE gel.  
4.2.3 Pull down and iTRAQ labeling 
The targets of triptolide were enriched by pull down approach. However, the 
non-specific binding proteins or endogenously biotinylated proteins may also be 
pulled down by this approach. To deal with this problem, iTRAQ could be introduced 
for ruling out non-specific targets by comparing the protein profile of probe-treated 
samples with that of the control sample. The workflow of the cell-based proteome 
profiling approach followed by iTRAQ labeling and LC-MS/MS for identification of 





Figure 4.4 The workflow of identification of triptolide targets by combination of ABPP and iTRAQ approaches. HCT 116 cells treated 
with triptolide probe were subjected to click chemistry and pull down approaches. Proteins from cell treated with DMSO were also pulled down 
by beads. Then the control samples were labeled with iTRAQ 117 and 118, in two biological replicates. Samples treated with probe were labeled 




Thus, a total of 1585 proteins were successfully identified. The comparison 
between four sets of protein lists (119:117, 121:117, 119:118, and 121:118) was 
evaluated. Then proteins with a ratio more than 1.3 or less than 0.77 of two replicates 
(either 118:117 or 121:119 more than 1.3 or less than 0.77) were removed. To get the 
targets with high confidence, a highly strict ratio of 2.25 was chosen as the cut-off 
value for discriminating the specific from non-specific binding targets. As a result, 
237 proteins were identified as reliable target candidates of triptolide.  
4.2.4 GO analysis 
The list of binding targets of triptolide was analyzed via Gene Ontology (GO) 
studies. It classified these proteins as per their molecular function and cellular 
component (Figure 4.5). In the cellular component analysis, the detailed distribution 
of cellular location indicated targets ubiquitously presented in the whole cell, with the 
cytoplasm (23%) having the largest population. In the molecular function analysis, 






Figure 4.5 Molecular function (Upper) and cellular localization (Bottom) of 
binding targets of triptolide. The list of triptolide’s targets were classified by GO 
analysis based on molecular function and cellular component. The majority of targets 
were mainly in the cytoplasm and nucleus; most of targets exert catalytic activity and 





4.2.5 Cellular immunofluorescence image 
To examine the cellular distribution of triptolide targets, fluorescence cell images 
were obtained. HCT 116 cells were treated with 1% DMSO or 100 μM of triptolide 
probe for 12 hrs. Cellular binding targets of triptolide were incubated with click 
chemistry reagents with fluorophore and then detected by fluorescence scanning and 
photographed under 100-times microscope. As shown in Figure 4.6, there were no 
fluorescence signals in control sample but obvious signals in cells with triptolide 
probe’s treatment. The fluorescence signals represent the targets of triptolide, 
suggesting that targets were ubiquitously distributed within the cells, which is in line 
with our GO analysis. 
 
 
Figure 4.6 Quantitative cellular immunofluorescence images of triptolide targets. 
HCT 116 cells were treated with DMSO or 100 μM of triptolide probe for 12 hrs. 
Cells were washed, fixed and permeabilized. Triptolide cellular binding targets were 
labeled with click chemistry reagents with fluorophore and visualized by fluorescence 




4.2.6 Network analysis by IPA 
 The list of triptolide’s binding targets was then uploaded into IPA for network 
analysis. The functions and canonical pathways of these targets were summarized in 
Figure 4.7. The top functions of these proteins were determined to be Cell Death and 
Survival, followed by Protein Synthesis and Cellular Growth and Proliferation. These 
data demonstrated that the majority of triptolide’s targets play important roles in the 
cell death and proliferation process, which is consistent with our previous findings. In 
addition, triptolide’s targets were also shown to interfere with the protein synthesis.  
 
 The canonical pathways of triptolide’s binding targets also demonstrated the 
importance of targets on the protein synthesis (Protein Ubiquitination Pathway, EIF2 






Figure 4.7 Functions (Upper) and canonical pathways (Bottom) analysis of 
triptolide’s binding targets. The list of triptolide’s binding targets was analyzed 
using IPA. The functions and canonical pathways were listed in the horizontal bar 
chart format.  
 
Therefore, the rate of protein synthesis was measure based on 
L-azidohomoalanine (AHA) labeling method. The method was fully described in the 
previous study [144]. In the IPA network analysis, proteins synthesis ranked high and 
it plays critical roles in the development of cancers. The inhibitory activity of 
triptolide on protein synthesis was shown in Figure 4.8.  
 




proteins during protein synthesis process. In addition, AHA contains an azide moiety 
so that click reaction could be applied to. Therefore, protein degradation and protein 
synthesis could be evaluated using fluorescence labeling. As shown in Figure 4.8, the 
fluorescence signals were significantly decreased with triptolide’s treatment, which 
indicated that triptolide inhibited protein synthesis. This finding is consistent with our 
network analysis.  
 
Figure 4.8 Triptolide was shown to interfere with protein synthesis. HCT 116 
cells were labeled with 50 μM AHA with or without triptolide for 12 hrs. Then the 
cells were harvested for click reaction. The fluorescence intensity was analyzed by 
flow cytometry.  
 
The top networks constituted with the identified targets were then depicted in 
Figure 4.9. It described the first and the second top networks, Cell Death and Survival 
and Gene Expression and Protein Synthesis, respectively. The green nodes in the 







Figure 4.9 The top networks of binding targets were analyzed by Ingenuity 
Pathway Analysis (IPA). The list of binding targets of triptolide was uploaded into 
IPA for analysis. The networks “Cell Death and Survival” (A) and “Gene Expression 




4.2.7 Identification of binding targets via in-gel digestion and MS/MS 
To narrow down the target list as well as to further validate our ABPP results, the 
pulled down proteins were loaded into SDS gel and visualized by silver staining 
(Figure 4.10A). By comparing the protein bands of treatment samples with control, 
five distinct bands were excised, in-gel digested and identified by MS/MS. The 
corresponding fluorescence bands, which represented the binding targets were labeled 
in Figure 4.10B and listed in Figure 4.10C. They were identified based on unused 
scores and molecular weight. Among these binding targets, Peroxiredoxin I and 
Annexin A1 attracted our attention because they were obviously absent in the control 
sample but found to be present in the treatment sample. In addition, they had 
relatively high unused scores and high percentage of coverage. Therefore, these 







Figure 4.10 Identification of target bands by MS/MS. (A) The enriched proteins 
from HCT 116 cells with control and triptolide probe’s treatment were loaded into 
SDS-PAGE gel and visualized by silver staining. By comparing the protein bands 
from probe-treated cells with control sample, five protein bands with significantly 
difference were excised and digested. The corresponding targets were labeled in the 
fluorescence labeling gel shown in (B). Subsequently, the protein bands were 
identified by MS/MS and listed in (C). (Fluo: Fluorescence, Coo: Coomassie blue)  
 
4.2.8 Validation and functional analysis of triptolide’s target – PRDX I 




conserved cysteine to reduce peroxide subtracts such as hydrogen peroxide [63, 80]. 
In mammals, PRDXs are thiol-dependent antioxidant proteins and therefore 
responsible for neutralizing reactive oxygen species (ROS) [145]. Based on the 
position or absence of peroxidatic cysteine (CP), the mammalian PRDXs are divided 
into three subfamilies: typical 2-cys (PRDXs I-IV), atypical 2-cys (PRDX V) and 
1-cys PRDX (PRDX VI). Typical 2-cys PRDXs contain an active site CP that serves 
as the site of oxidation by peroxides to cysteine sulfenic acid (Cys-SOH). A resolving 
cysteine (CR) of the other subunit then reacts with the CP sulfonic acid to form a 
disulfide (head to tail), further reduced by Thioredoxin (Trx) [146, 147]. Much 
ongoing work is elucidating the important roles of PRDXs in antioxidant protection 
and cellular signaling pathways [148]. These studies demonstrated the potential of 
2-cysteine PRDXs as therapeutic targets for major human diseases such as cancers 
and cardiovascular diseases [57-59, 145, 149, 150]. Recently, another diterpenoid 
isolated from the leaves of Isodonadenanthus, adenanthin, was shown to induce 
differentiation of leukemic cells by directly targeting PRDX I and PRDX II [147, 
151]. 
4.2.8.1 Expression and purification of recombinant PRDX I 
Human PRDX I gene was subcloned into pET28a vector. The specific primers 
used for amplifying PRDX I are:  




Reverse primer: 5’-TCACTCGAGTCACTTCTGCTTGGAGAA-3’ 
 Therefore, the construct of 6×His-tagged fusion protein was generated. DNA 
sequence of construct of PRDX I was confirmed with 100% identities. Next, the 
construct was transformed into E.coli strain BL21 for protein expression and 
purification. The protein was finally eluted and about 10 μl of the protein elution was 
then loaded into SDS gel for validation and quantitation.  
4.2.8.2 Validation of triptolide-PRDX I binding using fluorescence labeling 
 After the protein PRDX I was expressed and purified, the binding activity of 
PRDX I with triptolide was analyzed. The purified PRDX I was incubated with 
triptolide probe and the complex was then incubated with click chemistry reagents 
with fluorophore. The binding of triptolide-PRDX I was validated by fluorescence 
labeling. Figure 4.11 showed that the purified PRDX I has the property of binding to 







Figure 4.11 Validation of triptolide-PRDX I binding activity using fluorescence 
labeling. Equal amount of recombinant PRDX I was incubated with triptolide probe, 
followed by incubation with click chemistry reagents with fluorophore. Then the 
protein bands were visualized by fluorescence labeling. Coomassie blue staining 
shows the sample loading. (Fluo: Fluorescence, Coo: Coomassie blue) 
4.2.8.3 Competition assay 
As described above, PRDX I was found to be a potential cellular binding target of 
triptolide. To further validate this result, competition assay was carried out. 
Recombinant PRDX I was incubated with increasing concentrations of triptolide 
probe or pre-incubated with excess triptolide (10×triptolide). After click chemistry 
reaction, fluorescence signals were shown in Figure 4.12. The fluorescence signals 
with triptolide probe treatment verified that triptolide probe bound to PRDX I. With 




enhanced. On the other hand, competition assay by pre-incubation of PRDX I with 
10-fold of triptolide showed significantly diminished fluorescence signal, indicating 
that native triptolide might have occupied binding sites of PRDX I in the 
pre-treatment. This also confirmed that the binding between PRDX I and triptolide 




Figure 4.12 Validation of triptolide’s target PRDX I by competition assay. PRDX 
I protein was incubated with increasing concentrations of triptolide probe or 
pre-incubated with 10 times concentration of triptolide (10 × triptolide). Click 
chemistry reaction was then performed and the fluorescence labeling was visualized 
by fluorescence scanning. PRDX I was concentration-dependently labeled by 
triptolide probe, while the 10-fold excess triptolide’s pre-treatment reduced the 
fluorescence signals. Equal amount of protein loading was confirmed by Coomassie 
blue staining. (Fluo: Fluorescence, Coo: Coomassie blue) 
4.2.8.4 Identification of binding sites 
The triptolide-PRDX I complex was further validated and the exact binding sites 
of PRDX I were explored by using Mascot searching and MS/MS. PRDX I was 
incubated with DMSO or triptolide. The complex was then digested and analyzed by 
MS/MS. The mass spectra were converted into MGF for analysis. The modified 








 of PRDX 
I incubated with DMSO or triptolide were depicted in Figure 4.13. The b and y-ions 
of this spectrum were analyzed. An m/z difference of 360.16 was detected in b-ion 
and y-ion of triptolide-PRDX I complex. There was a mass shift of around 360 Da, 
which corresponds to the molecular weight of triptolide, in b5 ion and afterwards. 











Figure 4.13 Identification of binding sites of protein PRDX I by MS/MS. PRDX I was incubated with DMSO (Upper) or triptolide (Bottom) 
for 2 hrs. The complex was digested and subjected to MS/MS sequencing for analysis. Molecular weight of triptolide was used as the parameter 
for modification search. The b- and y-ion analysis detected peaks with a mass difference of 360.16 Da compared to control. C
T*





4.2.8.5 Molecular modeling 
To further explore the triptolide-PRDX I binding model, the dimeric PRDX II 
(PDB: 1QMV) was used for Autodock simulation (Figure 4.14). The reason for 
choosing PRDX II is because PRDX I and PRDX II have 78% identities of sequence. 
In addition, all of PDB format of PRDX I have mutations in cysteines, which might 
not be suitable for our model. Triptolide was manually docked into the dimerization 
pocket and the conformation was optimized with lowest energy. In the modeled 
triptolide-PRDX II complex, triptolide has the Michael acceptor at C4 forming a C-S 
bond with Cys172 (chain A) of PRDX II and the C14 hydroxyl group pointing toward 
the outside of the pocket. This result indicated that triptolide might render the enzyme 
inactive due to the disruption of both the Cys173-Cys52 disulfide bond and the 







Figure 4.14 Docking simulation of triptolide-PRDX II complex. The PRDX II 
(PDB: 1QMV) dimer structure consists of two identical chains (yellow and green). 
The ligand triptolide (purple) was manually docked into PRDX II protein. This 
modeled triptolide-PRDX II complex contained the Michael acceptor at C4 to form a 
C-S bond with Cys172 of PRDX II, as shown in the form of (A, B) Ribbon diagram 
and (C) Molecular surface diagram.  
4.2.8.6 Inactivation of PRDX I induced by triptolide 
To study whether triptolide exerted its function via inhibition of peroxidase 
activity of PRDX I, the peroxidase activity of recombinant PRDX I was measured. 
PRDX I was incubated with increasing concentrations of triptolide. It was then 
reacted with H2O2 substrate and fluorescent peroxidase substrate. The fluorescence 
intensities of PRDX I-triptolide complex was measured every 2 min (after 30 min, 
change to 5 min) until 60 min, which were shown in Figure 4.15A. Fluorescence 
intensity represented the amount of H2O2 reduced by PRDX I, proportional to their 
peroxidase activity. The amount of reduced H2O2 was determined according to the 
standard curve. Therefore, the peroxidase activities of PRDX I-DMSO, PRDX I-100 
μM triptolide, PRDX I-500 μM triptolide and PRDX I-1 mM triptolide were 
determined to be 1.13, 1.02, 1.00 and 0.56 mU/L, respectively. This assay 
demonstrated that triptolide reduced the peroxidase activity of PRDX I significantly.  
 
As PRDX I plays critical roles in ROS, the ROS level was evaluated and shown 




incubation with CM-H2DCFDA, a general oxidative stress indicator. The 
fluorescence intensity analyzed by flow cytometry suggested an increase in the ROS 
level in cells with triptolide treatment. This data demonstrated that triptolide increased 
the ROS in HCT 116 through decreasing the activity of PRDX I.  
 
Figure 4.15 Peroxidase activity assay indicated the inhibitory activity of 
triptolide against peroxidase activity of PRDX I. (A) PRDX I was incubated with 
DMSO or increasing concentrations of triptolide. Fluorescence intensity which 
represented the amount of H2O2 reduced by PRDX I was measured every 2 min and 
then changed to 5 min after 30 min until 60 min. Peroxidase activities of 
peroxiredoxin I were reduced with the concentrations of triptolide increased. (B) ROS 
levels of control and treated cells were evaluated. HCT 116 cells were treated with 
DMSO or 100 nM of triptolide for 12 hrs, followed by incubation with 
CM-H2DCFDA. The fluorescence intensity was analyzed by flow cytometry.  
4.2.9 Validation and functional analysis of triptolide target – Annexin A1 
Annexins are a family of Ca
2+




They are composed of a conserved core, which contains four repeats (six repeats in 
Annexin 6) of 70-80 amino acids folded into five α-helices [153] [154]. Annexins 
regulate the actin cytoskeleton, which plays important roles in cell morphology and 
cell migration [154] [155]. One of the subfamilies, Annexin A1 (ANXA1), shows 
tumor type-specific patterns of expression [156]. Specifically in colorectal cancer, 
ANXA1 was shown to promote progression, invasion and metastasis of colorectal 
cancer through activating the N-formyl peptide receptors (FPR) [157] [158] [159]. It 
was shown to be involved in different cell processes such as cell survival, 
proliferation, differentiation and migration [160] [161]. ANXA1 was also found to be 
over-expressed in primary tumors compared to normal colon [162]. As a result, 
Annexin A1 was regarded as a putative tumor biomarker and potential therapeutic 
target in colorectal cancers [162] [156].  
 
Human Annexin A1 full-length protein (ab92966) from Abcam was incubated 
with excess triptolide using the same method described above. The triptolide-Annexin 
A1 complex was then digested and the modification was analyzed by MS/MS and 
Mascot searching. As a result, Cys270 and Cys324 of Annexin A1 were shown to be 
modified by triptolide, with the unused score 44 and 72, respectively (Figure 4.16).  
4.2.9.1 Identification of binding sites of ANXA1 by MS/MS 




Annexin A1 was analyzed using MS/MS. Similar to the study of binding sites of 
PRDX I, Annexin A1 was incubated with DMSO or triptolide. After digestion, the 
mass spectra were converted to MGF for analysis. As shown in Figure 4.16, the 




 of Annexin A1 was 
modified with triptolide. An m/z difference of 360.16 was detected in b-ion and y-ion 
of triptolide-Annexin A1 complex that contains Cysteine 324. This shift with the mass 
difference 
~
360 Da is consistent with the molecular weight of native triptolide, 






Figure 4.16 Identification of binding sites of ANXA1 with triptolide, using MS/MS analysis. Annexin A1 was incubated with DMSO 
(Upper) and triptolide (Bottom). After digestion, the peptides spectra were then converted to MGF for analysis. By analyzing the b- and y-ions of 
the spectra, a shift of 360.16 Da has be found between the triptolide-incubated and DMSO-incubated samples, which corresponds to the 




4.2.9.2 Docking simulation model of ANXA1-triptolide complex 
To simulate the interaction between Annexin A1 and triptolide, the docking 
simulation was then carried out. Full-length Annexin A1 (PDB: 1MCX, Annexin A1 
in the presence of calcium) was chosen to be input into the AutoDockTools for 
autodock simulation. The reason to select this structure is that other structures (like 
1HM6) do not represent a typical core fold, neither to be full-length [152]. 1AIN was 
also considered. However, only the molecular surface diagram of 1AIN could be 
obtained, which cannot provide the detailed binding sites of protein-ligand compound. 
The structural alignment of protein Annexin A1 (PDB IDs: IMCX and 1AIN) was 
performed using PyMOL software. The result obtained showed that the RMS (Root 
Mean Square) Deviation is 0.475 between the two proteins which means that the 
proteins have very high structural similarity (Higher structural similarity is denoted by 
lower RMS values i.e., 100% structural similarity = 0.0 RMS value). In addition, 
1MCX has the 89% sequence similarity with native Annexin A1. Due to above 
reasons, 1MCX was chosen for docking.  
 
As shown in Figure 4.17, triptolide was manually docked into the pocket of 
Annexin A1. The conformation was optimized with lowest energy. C4 of triptolide and 
Cys270 of Annexin A1 formed a C-S bond, leading to the bond breakage in the 






Figure 4.17 Docking simulation of triptolide-ANXA1 complex. Full-length 
Annexin A1 (PDB: 1MCX) was input into the AutoDockTools software. The ligand 
triptolide (green) was manually docked into Annexin A1 (blue). This complex was 
illustrated in the form of Ribbon diagram (Left upper and bottom) and Molecular 
surface diagram format (Right). 
 
4.3 Discussion 
As drugs exert pharmacological functions by binding their targets and inhibiting 
their activities, a comprehensive identification of the specific targets of a drug is 
important for unraveling its mechanisms and functions. Hydrolytic and proteolytic 
enzymes have been demonstrated to be up-regulated in many tumor cells [47]. As 
enzymes regulated essential cellular processes, they have become vital therapeutic 
targets for many human diseases [107]. However, it is difficult to investigate the 




these technologies do not provide functional understanding of native proteins in the 
physiologically relevant environment in vivo [47]. Moreover, protein abundance does 
not truly reflect activity because most enzymes are expressed as inactive zymogens or 
reside in complex with their endogenous inhibitors [47].   
 
So far, there are only five proteins identified as the direct binding targets of 
triptolide, indicating that there may be more binding targets with low abundance. 
However, all of their methods found the targets of triptolide in vitro, which might not 
truly reflect the active proteins in vivo.  
 
Generally, chemical proteomics method have been developed to reveal 
drug-target interaction [116]. The commonly used methods involve global proteomics 
approach, affinity chromatography approach and activity-based protein profiling 
method. With global proteomics method, cells are treated with small molecules 
followed by system-wide proteome analysis [163]. However, although it maintains the 
native drug unmodified and the result is unbiased, the lack of enrichment limit its 
wide application. Another classic method to identify the drug-target interaction is the 
drug affinity chromatography method. The noncritical sites of the drug will be 
attached to affinity tag and then incubated with proteome [164][165]. However, strict 
washing required for removing nonspecific target identification decreases the 





To circumvent these limitations, a chemical proteomic method ABPP could be 
utilized to unravel the global target spectrum for covalent drugs [46]. Activity-based 
protein profiling (ABPP) combined with bio-orthogonal click chemistry is a novel 
functional proteomics technology to directly determine the functional state of 
enzymes both in vitro and in vivo [46, 47, 53, 108]. ABPP can only detect the 
functionally active form of target enzymes because most of the regulatory 
mechanisms for enzyme activity change the protein’s active site. However, the results 
from this method may contain non-specific protein targets. The non-specific targets 
can be ruled out by comparison the protein profiles of probe-treated sample with the 
control. In our study, to discriminate specific protein targets from non-specific and 
endogenously biotinylated proteins, combination of ABPP and iTRAQ was 
introduced. The peptides labeled with different isobaric tags were pooled and 
fractionated by Liquid Chromatography (LC) and analyzed by tandem mass 
spectrometry (MS/MS), to be identified as a single MS peak (identical m/z). The 
quantification of the peptide abundance can be calculated from the relative areas of 
the reporter peaks. 
 
In our study, triptolide probe was first designed to contain an alkyne and then 
subjected to ABPP. The triptolide-target complexes were visualized by fluorescence 





For designing probe to contain an alkyne without changing the property of native 
triptolide, the activity sites of triptolide are explored according to structure-activity 
relationships (SAR). Due to triptolide’s poor water solubility, medicinal chemists 
have synthesized several triptolide analogues for improving its properties for potential 
therapeutic uses. These modifications may occur on the C-14-hydroxyl group, 
epoxide groups, the lactone ring or the C5, 6-position. Many studies unravel functions 
of different sites of triptolide. Epoxy groups play different roles in determining 
biological activities. For example, modification of C-12,13-epoxide group and 
C-7,8-β-epoxide significantly affect triptolide’s activity [78], while the 
C-9,11-β-epoxide group could be recognized as a potential modification site [166]. 
The investigations on the α, β-unsaturated-5-membered-lactone ring suggested that 
the D-ring with a five-membered unsaturated lactone or lactam ring is essential for its 
anti-cancer activity and the C18 carbonyl group may exert important roles on the 
interaction between triptolide and its targets [167]. However, the studies on 
C-14-hydroxyl group complex are complicated. Previous studies on the SAR of 
triptolide indicated that hydrogen-bonded C-14 of triptolide may account for its 
anti-tumor effect [168-171]. However, recent studies showed that substituting the 
C-14-hydroxyl group with fluoride or with a chiral epoxy group containing α oxygen 
configuration at the C-14 position retains the cytotoxicity of triptolide [171]. In 




group has entered clinical trials for acute leukemia and advanced solid tumors due to 
its high water solubility [78]. These studies demonstrated that the modification of C14 
did not change the main property of triptolide and improved water solubility. 
Therefore, in our study, the C-14-hydroxyl group was determined to be the 
modification site for probe to contain an alkyne. The triptolide probe reacted as the 
activity-based probe (ABP) that covalently binds to the catalytic site of specific target 
enzymes in vivo. 
 
Next, for evaluating the property of triptolide probe, proliferation assay as well as 
fluorescence labeling were performed. The IC50 of triptolide probe was determined to 
be 2.2 μM, which is greater than the IC50 of native triptolide. However, previous study 
which successfully identified dCTPP1 as the binding targets of triptolide [111] 
utilized a probe with the IC50 of 168 μM. The proteome profiling assay also 
demonstrates that our triptolide probe is capable to profile the binding targets and it 
works well in click chemistry reaction. With the azide-modified cyanine 3 (Cy3) or 
azide-modified biotin, the binding targets of triptolide can be visualized or enriched, 
respectively.  
 
With iTRAQ comparison of probe-enriched binding targets to the control, 237 




analysis, the cellular components, molecular functions and networks were visualized. 
Most of the targets were located in cytoplasm and nucleus. The distribution of 
triptolide binding targets was also detected with cellular immunofluorescence image, 
which further illustrates that the triptolide binding targets locate ubiquitously in 
different parts of the cell. ABPs covalently bind to active enzymes, thus permitting 
assignment of imaging signals to specific enzymes [47, 110]. As expected, the 
molecular function analysis showed that most of the targets have binding and catalytic 
activity, which is probably due to the nature of ABPP approaches. Identification of 
these enzymes also demonstrate that ABPP approach can provide us with a functional 
understanding of proteins in the complex process of tumorigenesis. The IPA analysis 
ranked the top network constituted by the enriched binding targets as “Cell Death and 
Survival”, which is consistent with the anti-tumor property of native triptolide. 
 
Among these 237 binding targets, dCTPP1 was also found in the list of enriched 
proteins, which is consistent with previous study [111]. Another two direct binding 
targets were found in our pull-down list but with cutoff less than our stringent cutoff 
value, 2.25. The stringent cutoff criterions aid to narrow down target candidates for 
the further validation study. 
 




the enriched proteins from probe-treatment or control were visualized by silver 
staining after running SDS-PAGE gel. By comparing the intensity and abundance of 
bands, five bands were cut down followed by in-gel digestion and LC-MS/MS. These 
five bands were identified to be Asparagine synthetase, α-enolase, Actin, Annexin A1 
and Peroxiredoxin I. These five proteins are also found in the list of 237 binding 
targets, further confirming the results of our proteomic approaches. Among them, 
Peroxiredoxin I and Annexin A1 were found to be obviously present in probe-treated 
sample but disappeared in control with high score and coverage. These proteins thus 
drew our attention and further validation experiments were conducted. 
 
Peroxiredoxin I is a 22 kDa protein that belongs to peroxiredoxin family 
including six mammalian isoforms. All members in this family are conserved 
peroxidases due to the conserved peroxidase cysteine (CP) and known for their 
antioxidant properties. The typical 2-cys PRDXs (PRDX I-IV) contain an additional 
conserved cysteine residue like Cys173 of PRDX I and Cys172 of PRDX II, which is 
also called resolving cysteine (CR). Typical 2-cys PRDXs exert catalytic functions 
through oxidizing the CP -SH to CP-SOH, which reacts with CR of the other subunit, 
forming a transient intermolecular disulfide. For example, Cys51 of PRDX II, the 
active site of peroxide reduction, is first oxidized to cysteine sulphinic acid by 




cysteine residue [55].  
 
To determine the specific residues of PRDX I that are modified by triptolide, the 
recombinant PRDX I protein was incubated with or without triptolide, followed by 
MS/MS. Peptides containing cysteine were evaluated because triptolide probably 
interacts as a Michael acceptor due to the α, β-unsaturated-5-membered-lactone ring. 
The molecular formula was used for modification searching. MS/MS analysis of both 




 of PRDX 
I gave a partial series of b-ion fragments corresponding to the predicted sequence. 
Both MS/MS spectrums had the same mass from b1 to b4, whereas the mass shifted 
360.16 Da for modified fragment (from b5 to b22). This result indicates that triptolide 
binds to the Cys173 of PRDX I. The y-ion fragments can also reveal the shift, which 
reflects triptolide modification. Cys173 of PRDX I is located near the C terminus at a 
disordered coil region that inserts into the pocket of another PRDX I monomer which 
contains Cys52 to form a dimmer [55, 172]. As the existing crystal structures of 
PRDX I are all mutants, the dimer structure of native PRDX II (PDB code: 1QMV) 
was used for a computation study. Triptolide molecule was manually docked into the 
dimerization pocket. This molecular modeling may provide some insights on the 
triptolide-PRDX I interaction at the atomic level. Therefore, triptolide modification 




Cys172-Cys51 disulfide bond and the dimeric conformation of the enzyme.  
 
To test triptolide’s inhibitory activity against PRDX I, the peroxidase activity of 
PRDX I incubated with or without triptolide was estimated. The peroxidase activity of 
PRDX I was decreased with the concentration of triptolide increased. Especially, 
when PRDX I was incubated with 1 mM of triptolide, the peroxidase activity was 
decreased around 50%. PRDXs are the third most abundant protein found in the 
erythrocyte [173] and ubiquitous in cells. PRDXs were shown to be upregulated in 
several human cancers [145, 149] and were proposed as potential targets for 
anticancer drugs. Many studies shows that PRDXs induce cell proliferation [58] and 
protect cancer cells from apoptosis [174, 175]. The mechanism for PRDX function 
may be due to its antioxidant property. High reactive oxygen species (ROS) level, 
which was demonstrated to increase in our experiment, can damage DNA and induce 
tumorigenesis [176, 177]. Therefore, the inhibitory activity of triptolide against 
PRDXs may have a significant impact in cancer treatment.  
 
As the binding target PRDX I was reported last year, which is earlier than our 
proposed report, another protein, Annexin A1 also attracted our attention. Annexin 
A1’s upregulation was involved in tumor invasion and lymph node metastasis of 




metastasis of colorectal cancer [178]. Therefore, Annexin A1 is a potential biomarker 
for predicting colorectal cancer malignant potential. In addition, according to the 
previous work, Annexin A1 was significantly down-regulated in HCT 
116-transplanted nude mice treated with indomethacin (a kind of nonsteroidal 
anti-inflammatory drug) by the proteomics method [179], solidifying the importance 
of Annexin A1 as the potential drug target for colorectal cancers.   
 
 Similar to the study of PRDX I-triptolide complex, MS/MS analysis followed by 
Mascot modification searching as well as docking simulation of Annexin 
A1-triptolide complex were performed. In our study, Annexin A1 was found to bind 
to and interact with triptolide. Cys270 and Cys324 were identified as the binding sites 
of Annexin A1. Our study also demonstrated that triptolide might interfere with cell 
migration through inhibiting the activity of Annexin A1.  
 
Therefore, our study profiled the targets of triptolide at a global level, which 
would shed some lights on the detailed mechanism of its biological activities. The 
regulated proteins could also serve as candidate targets for the therapeutic action of 
triptolide. Furthermore, construction of important protein networks might offer 
fruitful information for future research on colorectal cancer treatment. Profiling the 




unravel its mechanism of action. Revealing the direct targets of triptolide will aid to 
design derivatives that might be less toxic with fewer side effects, but have similar 













































5.1 Discussion  
 
 
Figure 5.1 Overall proteome picture depicting activities of triptolide against 
colorectal cancer based on proteomics approaches. In our study, triptolide was 
shown to has strong anti-proliferative and pro-apoptotic activities against colorectal 
cancer cell line HCT 116 by increasing ROS level, interfering with actin cytoskeleton, 
protein synthesis and expression of transcription factors. Triptolide increases ROS 
level by blocking peroxidase activity of PRDX I. ROS is associated with ion channels 
and actin cytoskeleton, which play important roles in cancer growth. The overall 
picture includes network analysis by bioinformatics approaches and previous 
literature, molecular alteration by iTRAQ and proteomics approaches, and 
identification of binding targets of triptolide by chemical proteomics approaches. The 
up-and down-regulated proteins by triptolide were labeled with up arrow in red and 
down arrow in green, respectively. Direct binding targets of triptolide were labeled 
with blue stars.  
 
Leigongteng was used in traditional Chinese medicine for more than two 




was firstly extracted as the main component of Leigongteng and shown to have strong 
anti-tumor activities. Since then, various studies have explored its mechanism against 
tumor growth. 
 
Triptolide possesses broad-spectrum anti-cancer activities. It was shown to induce 
apoptosis through increasing caspase 3, 8, 9 [66] and induce autophagy by increasing 
LC-3II [180]. It also inhibits expression of transcript factors such as NF-κB by 
down-regulating RNAPII [140]. However, the previous extensive studies did not 
provide us with the regulated targets at a global level. As tumors grow in multi-step 
and a complicated way, the detailed mechanism of action of the drug remains unclear. 
Therefore, in my study, proteomic approaches were utilized to provide a whole picture 
of the alteration of proteins from colorectal cancer cells treated by triptolide, as well 
as to study the direct binding targets of triptolide. These studies could shed some light 
on the mechanism of triptolide against colorectal cancer.  
 
In my study, triptolide was demonstrated to induce ROS level elevation through 
directly binding to cysteines of Peroxiredoxin I (PRDX I) and inhibiting peroxidase 
activity of Peroxiredoxin I. PRDX I contains a peroxidatic cysteine (CP), which could 
be oxidized by peroxides to cysteine sulfenic acid (Cys-SOH). Many ongoing studies 
have elucidated the importance of PRDX I in antioxidant protection [148]. As a result, 




cardiovascular disease [147, 151]. ROS is toxic in cells due to the oxidative stress by 
their reaction with proteins and nucleic acids. Cellular response to ROS is essential to 
protect cells from oxidative damage [181]. The dysfunction of PRDX I by triptolide 
might induce oxidative stress and elevation of ROS level.   
 
ROS also activate ion channels [182]. Oxidative stress induces Ca
2+
 cytoplasmic 
increase through calcium influx. The calcium influx might be due to the calcium 
release from ER [183]. H2O2 activates calcium and potassium channels. Although 
Ca
2+
 channels might be elevated by ROS, some Ca
2+
 binding proteins such as 
S100-A6 and Annexin A1 were shown to directly bind to triptolide according to our 
ABPP results. S100-A6 contributes to cellular calcium signaling and plays important 
roles in reorganizing actin cytoskeleton and in cell motility [184]. In addition, 
Annexin A1 was identified as the direct binding target of triptolide with ABPP 
approaches, followed by being validated by MS/MS approach. Annexins regulate the 
actin cytoskeleton, which plays important roles in cell morphology and cell migration. 
Cell migration was also found to be inhibited by triptolide, which implies that 
triptolide might interfere with cell migration via binding cysteines of Annexin A1 and 
inhibiting its functions.  
 
Triptolide was also found to directly bind to Actin and α-actinin-1 according to 




cell adhesion and cell mobility. Our iTRAQ results showed that actin 
cytoskeleton-related proteins, such as Rho guanine nucleotide exchange factor 2 
(ARHGEF2) and Profilin -2 (PFN2) were significantly down-regulated by triptolide. 
ARHGEF2 activates Rho-GTPases by promoting the exchange of GDP for GTP. The 
activated Rho transduces various signals, including cytoskeleton reorganization, 
cellular invasion and cell proliferation. Profilin-2 binds to actin and affects the 
structure of the cytoskeleton. These results indicate that triptolide interferes with actin 
cytoskeleton, which might further affect the cell adhesion and cell migration.  
 
 Our observation under microscope as well as network analysis elucidated that 
triptolide interferes with cell adhesion. Integrin β4 was identified to be a direct 
binding target according to our ABPP results. It is a bridge for cell-cell and 
cell-extracellular matrix (ECM) interactions and plays multiple roles in cell adhesion, 
migration and tumor progression [185]. In addition, the relevant proteins, such as 
β-catenin and Ras-related protein Rab-21 were down-regulated, based on iTRAQ 
results.  
 
In addition, triptolide also decreases expression of transcription factors. 
Transcription factors are commonly deregulated in cancer cells, making them as 
targets of cancer therapy [186]. Previous literature has demonstrated that triptolide 




and XPB [151], exerting anti-proliferative activities against cancers. 
Pro-inflammatory gene, such as NF-κB, was shown to be down-regulated [121]. Next, 
the upstream regulator of NF-κB was examined. RNA Polymerase II , which regulates 
the expression of transcription factors such as NF-κB and STAT3 [140], was shown to 
be decreased in our iTRAQ result, which is consistent with the previous study [188]. 
BRD4 was demonstrated to phosphorylate CTD of RNA Polymerase II. BRD4 also 
restricts the release of paused RNAPII, serving as the rate-limiting step in the process 
of regulating transcription factors. Its high expression in cancers [189] makes it a 
biomarker for colorectal cancer. BRD4 was firstly reported to be down-regulated by 
triptolide in our study, providing a novel insight into the detailed mechanism of action 
of the drug. 
 
In our study, triptolide was shown to interfere with protein synthesis, by 
estimating the protein synthesis rate with AHA treatment. Several proteins, such as 
eIF-2-α kinase activator GCN1 and Eukaryotic translation inhibition factor 3 subunit 
F (EIF3F) were identified as binding targets of triptolide. In addition, ASNS was 
down-regulated according to our iTRAQ result. ASNS is an enzyme that generates 
asparagine from aspartate. These results suggested that triptolide inhibits protein 
synthesis via binding several proteins like GCN1 and EIF3F and further 





In my study, triptolide has shown very strong anti-proliferation activity on 
colorectal cancer cell line HCT 116 in dose- and time-dependent manners. IC50 of 
triptolide on HCT 116 was determined to be 10 nM, which demonstrated a strong 
anti-tumor property of triptolide. The flow cytometry analysis also demonstrated that 
triptolide induces apoptosis of HCT 116. Our results indicated that several pathways, 
such as actin cytoskeleton, cell adhesion, migration, transcription factor expression 
and protein synthesis, contribute to the anti-proliferative and apoptosis activity of 
triptolide. Triptolide was also demonstrated to have multiple targets and exert many 
functions against colorectal cancer. Proteomics approaches provide us with an 
opportunity to study the alteration of proteins with triptolide’s treatment at a global 
level, which aid to explore the mechanism of triptolide. The results of combination of 
ABPP and iTRAQ approaches provided a target list of triptolide, which could be a 
reference for the further study of interacting activity of triptolide and binding targets 
of triptolide.  
 
5.2 Future Work 
5.2.1 More cell models and other possible strategies  
In the future study, some aspects could be improved. In our study, HCT 116 cells 
were used as model to study the mechanism of triptolide. Therefore, in the future 




introduced for the mechanism study of triptolide. The comparison between different 
cell lines might provide insights into the identification of the targets as well as the 
signal pathways. Moreover, some in vivo colorectal cancer models with 
patient-derived primary tumor sample could also be introduced by using our 
proteomics approaches. This might provide more solid result. In addition, to further 
explore the mechanisms of triptolide on cancer cells, different functions of triptolide 
on normal and colorectal cancer cells would be studies. As shown in our experiment, 
proliferation of normal colorectal cell CCD 841 was not interfered by triptolide. To 
explore the reasons for that difference, in the future work, CCD 841 and HCT 116 
cells will be treated with triptolide. The whole proteome from two samples will be 
extracted and labeled with iTRAQ reagents followed by MS/MS analysis. Network 
constituted by the significantly regulated proteins in normal cell samples will be 
analyzed, which might have much difference with the network of cancer cell samples. 
A comparison of protein profiling of cancer and normal cells could provide some 
insight into the study of the specific targets of triptolide in cancer cells, aiding to 
explore its application in clinic trials. As shown in our experiment, expression levels 
of BRD4 and β-catenin did not change in the normal cells. There might be more 
targets that are specifically interfered by triptolide in colorectal cancer cells. 
Identification of these specifically regulated proteins in cancer cells could aid to 
identify the targets of triptolide in cancer cells as well as to study the side effects of 




and its derivatives.  
 
In addition, other strategies for mechanism for study of pathways could be 
considered for the future study. Our work focused on analyzing the networks and 
pathways by profiling regulated proteins at a global level. The study focused mainly 
on proteomics and did not attempt to address either genomics or metabolomics. To 
provide supplemental information in facilitating data analysis, mRNA level change 
with triptolide treatment using a transcriptomics approach can be applied in the future. 
An additional advantage is that transcriptomics will also serve as supplementary 
datasets for mechanism analysis. In the future, data extracted by applying the 
proteomics approach and that acquired by applying the transcriptomics approach can 
be compared to validate and provide more solid result on the regulated molecular on 
both protein and mRNA level.  
5.2.2 Function study of triptolide’s binding targets  
The future work will also include the validation of more direct binding targets 
and the study on the functional effects of triptolide on PRDX I and Annexin A1. In 
our ABPP results, Annexin A1 was identified as a direct binding target of triptolide. 
Although Annexin A1 promotes cell migration, which was interfered with triptolide’s 
treatment, there is no direct evidence elucidating that triptolide reduces migration by 




explored. The function of Annexin A1 or PRDX I could be interfered by introducing 
the mutations or siRNA of Annexin A1 or PRDX I in HCT 116 cells. By comparing 
the migration or other functions of the cells having WT Annexin A1 with those of 
cells with mutations or siRNA, we could study the functions of Annexin A1 in 
colorectal cancer. Similarly, by comparing the ROS level or other functions of the 
cells having WT PRDX I with those of cells with mutations or siRNA, the interfering 
function of triptolide on PRDX I will be established. In addition, the anti-tumor 
activity of triptolide on WT and mutation could be compared, which might provide 
some insight on the interference function of triptolide on its targets.  
 
Our study has provided with a list of target candidates by using ABPP combined 
with iTRAQ approaches. Therefore, more binding targets of triptolide could also be 
validated based on the list. These studies might provide us with more comprehensive 
information about the mechanism of action of triptolide, which can help to unveil the 
mechanism of triptolide against colorectal cancer.  
 
5.3 Conclusion 
In summary, in our study, triptolide has been demonstrated to have strong 
anti-proliferative and pro-apoptotic activities against colorectal cancer cell line HCT 




cytoskeleton, migration and the alterations of transcription factors contribute to 
triptolide’s anti-tumor functions.  
 
Triptolide has been demonstrated to induce ROS level elevation via inhibiting 
peroxidase activity of Peroxiredoxin I, which is abundant in cells and plays important 
roles in peroxidation. Several calcium-binding proteins, such as S100-A6 were shown 
to bind to triptolide directly. Actin-regulated proteins, such as α-actinin-1, integrin-β, 
and Annexin A1 were identified as direct binding targets of triptolide. They play 
important roles in actin cytoskeleton, cell migration and cell adhesion. Some relevant 
proteins, such as Rho, Profilin, β-catenin, RAB21 were also down-regulated by 
triptolide. Furthermore, triptolide has been demonstrated to inhibit protein synthesis. 
Several transcription factors, such as BRD4, RNA Polymerase II, and NF-κB 
involved in tumor proliferation were also verified to be down-regulated by triptolide. 
Among them, the down-regulation of BRD4 with triptolide treatment has never been 
reported before. These networks and expression alteration of proteins contribute to the 
anti-tumor activities of triptolide. Proteomics approaches allows the study of altered 
proteins by triptolide and binding targets of triptolide at a global level, which provides 









1. Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2016. CA: A cancer journal for 
clinicians, 2015. 
2. Coussens, L.M. and Z. Werb, Inflammation and cancer. Nature, 2002. 420(6917): p. 860-867. 
3. Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2016. CA: a cancer journal for 
clinicians, 2016. 66(1): p. 7-30. 
4. Torre, L.A., et al., Cancer statistics for Asian Americans, Native Hawaiians, and Pacific 
Islanders, 2016: Converging incidence in males and females. CA: a cancer journal for 
clinicians, 2016. 
5. Wu, S., et al., Substantial contribution of extrinsic risk factors to cancer development. Nature, 
2016. 529(7584): p. 43-47. 
6. Hanahan, D. and R.A. Weinberg, Hallmarks of cancer: the next generation. cell, 2011. 144(5): 
p. 646-674. 
7. FEI, T.X., Elucidating tumor suppressive function of Frataxin in colorectal cancer with a 
quantitative proteomics approach. 2014. 
8. Johnstone, R.W., A.A. Ruefli, and S.W. Lowe, Apoptosis: a link between cancer genetics and 
chemotherapy. Cell, 2002. 108(2): p. 153-164. 
9. Fernald, K. and M. Kurokawa, Evading apoptosis in cancer. Trends in cell biology, 2013. 
23(12): p. 620-633. 
10. Chandel, N.S., et al., Metabolic regulation of stem cell function in tissue homeostasis and 
organismal ageing. Nature Cell Biology, 2016. 
11. Pavlova, N.N. and C.B. Thompson, The emerging hallmarks of cancer metabolism. Cell 
metabolism, 2016. 23(1): p. 27-47. 
12. Strzyz, P., Cancer biology: TGF [beta] and EMT as double agents. Nature Reviews Molecular 
Cell Biology, 2016. 
13. JINGJING, W., The role of autocrine human growth hormone in colorectal cancer progression. 
2014. 
14. Malkova, A. and G. Ira, Break-induced replication: functions and molecular mechanism. 
Current opinion in genetics & development, 2013. 23(3): p. 271-279. 
15. Xie, Z., et al., Early telomerase inactivation accelerates aging independently of telomere 
length. Cell, 2015. 160(5): p. 928-939. 
16. Elinav, E., et al., Inflammation-induced cancer: crosstalk between tumours, immune cells and 
microorganisms. Nature Reviews Cancer, 2013. 13(11): p. 759-771. 
17. Chaffer, C.L. and R.A. Weinberg, A perspective on cancer cell metastasis. Science, 2011. 
331(6024): p. 1559-1564. 
18. Ridley, A.J., et al., Cell migration: integrating signals from front to back. Science, 2003. 
302(5651): p. 1704-1709. 
19. Lee, H., et al., Colorectal cancer and diet in an asian population—A case‐control study among 
Singapore Chinese. International journal of cancer, 1989. 43(6): p. 1007-1016. 




The lancet oncology, 2005. 6(11): p. 871-876. 
21. Fearon, E.R. and B. Vogelstein, A genetic model for colorectal tumorigenesis. Cell, 1990. 
61(5): p. 759-767. 
22. Ohlsson, B., et al., Follow-up after curative surgery for colorectal carcinoma. Diseases of the 
colon & rectum, 1995. 38(6): p. 619-626. 
23. Miller, K.D., et al., Cancer treatment and survivorship statistics, 2016. CA: a cancer journal 
for clinicians, 2016. 
24. GHOSH, D., Proteomics based analysis identified CacyBP as a candidate biomarker for 
colorectal cancer metastasis. 2012. 
25. Lambertini, M., et al., Ovarian suppression with triptorelin during adjuvant breast cancer 
chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a 
randomized clinical trial. JAMA, 2015. 314(24): p. 2632-2640. 
26. Lauro, S., et al., H39Genetic polymorphism can help physician choosing the best lung cancer 
chemotherapy. Annals of Oncology, 2015. 26(suppl 6): p. vi-vi. 
27. Perroud, H.A., et al., Metastatic breast cancer patients treated with low-dose metronomic 
chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of 
response. Cancer chemotherapy and pharmacology, 2016. 77(2): p. 365-374. 
28. Mann, J., Natural products in cancer chemotherapy: past, present and future. Nature Reviews 
Cancer, 2002. 2(2): p. 143-148. 
29. Chabner, B.A. and T.G. Roberts, Chemotherapy and the war on cancer. Nature Reviews 
Cancer, 2005. 5(1): p. 65-72. 
30. Lima, C.M.S.R., et al., Abstract CT151: G1T28, a cyclin dependent kinase 4/6 inhibitor, in 
combination with etoposide and carboplatin for extensive stage small cell lung cancer 
(ES-SCLC): preliminary results. Cancer Research, 2016. 76(14 Supplement): p. 
CT151-CT151. 
31. Liu, A.P., et al., Refractory acute lymphoblastic leukemia in Chinese children: bridging to 
stem cell transplantation with clofarabine, cyclophosphamide and etoposide. Annals of 
hematology, 2016. 95(3): p. 501-507. 
32. Ding, G., Important Chinese herbal remedies. Clinical therapeutics, 1986. 9(4): p. 345-357. 
33. Kupchan, S.M., et al., Tumor inhibitors. LXXIII. Maytansine, a novel antileukemic ansa 
macrolide from Maytenus ovatus. Journal of the American Chemical Society, 1972. 94(4): p. 
1354-1356. 
34. Ling, D., et al., pH-sensitive nanoformulated triptolide as a targeted therapeutic strategy for 
hepatocellular carcinoma. ACS nano, 2014. 8(8): p. 8027-8039. 
35. Chan, E.W.-C., et al., Triptolide induced cytotoxic effects on human promyelocytic leukemia, T 
cell lymphoma and human hepatocellular carcinoma cell lines. Toxicology letters, 2001. 
122(1): p. 81-87. 
36. Kim, M.J., et al., Triptolide inactivates Akt and induces caspase-dependent death in cervical 
cancer cells via the mitochondrial pathway. International journal of oncology, 2010. 37(5): p. 
1177-1185. 
37. Chen, Z., et al., Triptolide sensitizes pancreatic cancer cells to TRAIL-induced activation of 




38. Wang, G., X.S. Xu, and Y. Zhang, The role triptolide in sensitizing lung tumor cells to 
cisplatin-induced apoptosis. Cancer Research, 2014. 74(19 Supplement): p. 5110-5110. 
39. Cragg, G.M., D.J. Newman, and K.M. Snader, Natural products in drug discovery and 
development. Journal of natural products, 1997. 60(1): p. 52-60. 
40. de Oliveira, A.M., et al., Diterpenes: a therapeutic promise for cardiovascular diseases. 
Recent patents on cardiovascular drug discovery, 2008. 3(1): p. 1-8. 
41. Tirapelli, C.R., et al., Hypotensive action of naturally occurring diterpenes: a therapeutic 
promise for the treatment of hypertension. Fitoterapia, 2010. 81(7): p. 690-702. 
42. Hanson, J.R., Diterpenoids. Natural Product Reports, 1998. 15(1): p. 93-106. 
43. Kong, L.-M., et al., Identification and validation of p50 as the cellular target of eriocalyxin B. 
Oncotarget, 2014. 5(22): p. 11354. 
44. Wang, J., et al., A quantitative chemical proteomics approach to profile the specific cellular 
targets of andrographolide, a promising anticancer agent that suppresses tumor metastasis. 
Molecular & Cellular Proteomics, 2014. 13(3): p. 876-886. 
45. Nguyen, V.S., et al., Specificity and Inhibitory Mechanism of Andrographolide and Its 
Analogues as Antiasthma Agents on NF-κB p50. Journal of natural products, 2015. 78(2): p. 
208-217. 
46. Cheng, X., et al., In situ proteome profiling of C75, a covalent bioactive compound with 
potential anticancer activities. Organic letters, 2014. 16(5): p. 1414-1417. 
47. Paulick, M.G. and M. Bogyo, Application of activity-based probes to the study of enzymes 
involved in cancer progression. Current opinion in genetics & development, 2008. 18(1): p. 
97-106. 
48. Butler, M.S., Natural products to drugs: natural product derived compounds in clinical trials. 
Nat Prod Rep, 2005. 22(2): p. 162-95. 
49. Li, Z., et al., Design and synthesis of novel C14-hydroxyl substituted triptolide derivatives as 
potential selective antitumor agents. J Med Chem, 2009. 52(16): p. 5115-23. 
50. Evans, M.J. and B.F. Cravatt, Mechanism-based profiling of enzyme families. Chemical 
reviews, 2006. 106(8): p. 3279-3301. 
51. Ghosh, D., et al., iTRAQ Based Quantitative Proteomics Approach Validated the Role of 
Calcyclin Binding Protein (CacyBP) in Promoting Colorectal Cancer Metastasis*. Molecular 
& Cellular Proteomics, 2013. 12(7): p. 1865-1880. 
52. Zhou, Z.L., et al., Triptolide: structural modifications, structure-activity relationships, 
bioactivities, clinical development and mechanisms. Nat Prod Rep, 2012. 29(4): p. 457-75. 
53. Nomura, D.K., M.M. Dix, and B.F. Cravatt, Activity-based protein profiling for biochemical 
pathway discovery in cancer. Nature Reviews Cancer, 2010. 10(9): p. 630-638. 
54. Zhou, B., et al., Synthesis and biological evaluation of novel triptolide analogues for 
anticancer activity. Bioorg Med Chem Lett, 2010. 20(21): p. 6217-21. 
55. Schröder, E., et al., Crystal structure of decameric 2-Cys peroxiredoxin from human 
erythrocytes at 1.7 Å resolution. Structure, 2000. 8(6): p. 605-615. 
56. Liu, Q., Triptolide and its expanding multiple pharmacological functions. Int 
Immunopharmacol, 2011. 11(3): p. 377-83. 




neurodegeneration and a therapeutic target. Biochimica et Biophysica Acta (BBA)-Molecular 
Basis of Disease, 2006. 1762(11): p. 1051-1067. 
58. Butterfield, L.H., et al., From cytoprotection to tumor suppression: the multifactorial role of 
peroxiredoxins. Antioxidants & redox signaling, 1999. 1(4): p. 385-402. 
59. Zhao, W., et al., Protection of peroxiredoxin II on oxidative stress-induced cardiomyocyte 
death and apoptosis. Basic research in cardiology, 2009. 104(4): p. 377-389. 
60. Qiu, D., Immunosuppressant PG490 (Triptolide) Inhibits T-cell Interleukin-2 Expression at the 
Level of Purine-box/Nuclear Factor of Activated T-cells and NF-kappa B Transcriptional 
Activation. Journal of Biological Chemistry, 1999. 274(19): p. 13443-13450. 
61. Kim, J.-A., et al., Activity assay of mammalian 2-cys peroxiredoxins using yeast thioredoxin 
reductase system. Analytical biochemistry, 2005. 338(2): p. 216-223. 
62. Pan, J., RNA polymerase - an important molecular target of triptolide in cancer cells. Cancer 
Lett, 2010. 292(2): p. 149-52. 
63. Cox, A.G., et al., The thioredoxin reductase inhibitor auranofin triggers apoptosis through a 
Bax/Bak-dependent process that involves peroxiredoxin 3 oxidation. Biochemical 
pharmacology, 2008. 76(9): p. 1097-1109. 
64. Westerheide, S.D., et al., Triptolide, an inhibitor of the human heat shock response that 
enhances stress-induced cell death. J Biol Chem, 2006. 281(14): p. 9616-22. 
65. Wan, C.K., et al., Triptolide induces Bcl-2 cleavage and mitochondria dependent apoptosis in 
p53-deficient HL-60 cells. Cancer Lett, 2006. 241(1): p. 31-41. 
66. Choi, Y.-J., et al., Immunosuppressant PG490 (triptolide) induces apoptosis through the 
activation of caspase-3 and down-regulation of XIAP in U937 cells. Biochemical 
pharmacology, 2003. 66(2): p. 273-280. 
67. Chang, W.T., et al., Triptolide and chemotherapy cooperate in tumor cell apoptosis. A role for 
the p53 pathway. J Biol Chem, 2001. 276(3): p. 2221-7. 
68. Vispe, S., et al., Triptolide is an inhibitor of RNA polymerase I and II-dependent transcription 
leading predominantly to down-regulation of short-lived mRNA. Mol Cancer Ther, 2009. 8(10): 
p. 2780-90. 
69. Zhao, F., et al., Triptolide alters histone H3K9 and H3K27 methylation state and induces 
G0/G1 arrest and caspase-dependent apoptosis in multiple myeloma in vitro. Toxicology, 
2010. 267(1-3): p. 70-9. 
70. Tai, C.J., et al., The investigation of mitogen-activated protein kinase phosphatase-1 as a 
potential pharmacological target in non-small cell lung carcinomas, assisted by non-invasive 
molecular imaging. BMC Cancer, 2010. 10: p. 95. 
71. Miyata, Y., T. Sato, and A. Ito, Triptolide, a diterpenoid triepoxide, induces antitumor 
proliferation via activation of c-Jun NH2-terminal kinase 1 by decreasing phosphatidylinositol 
3-kinase activity in human tumor cells. Biochem Biophys Res Commun, 2005. 336(4): p. 
1081-6. 
72. Xu, B., et al., Triptolide simultaneously induces reactive oxygen species, inhibits NF-kappaB 
activity and sensitizes 5-fluorouracil in colorectal cancer cell lines. Cancer Lett, 2010. 291(2): 
p. 200-8. 




Clin Cancer Res, 2007. 13(16): p. 4891-9. 
74. Li, C.J., et al., Synergistic anticancer activity of triptolide combined with cisplatin enhances 
apoptosis in gastric cancer in vitro and in vivo. Cancer Lett, 2012. 319(2): p. 203-13. 
75. Lipsky, P.E. and X.-L. Tao. A potential new treatment for rheumatoid arthritis: thunder god 
vine. in Seminars in arthritis and rheumatism. 1997. Elsevier. 
76. S., D.G., Ding G S. Important Chinese herbal remedies[J]. Clinical therapeutics, 1986, 9(4): 
345-357. 1986. 9(4). 
77. Leuenroth, S.J., et al., Triptolide is a traditional Chinese medicine-derived inhibitor of 
polycystic kidney disease. Proc Natl Acad Sci U S A, 2007. 104(11): p. 4389-94. 
78. Zhou, Z.-L., et al., Triptolide: structural modifications, structure–activity relationships, 
bioactivities, clinical development and mechanisms. Natural product reports, 2012. 29(4): p. 
457-475. 
79. Kiviharju, T.M., et al., Antiproliferative and proapoptotic activities of triptolide (PG490), a 
natural product entering clinical trials, on primary cultures of human prostatic epithelial cells. 
Clinical Cancer Research, 2002. 8(8): p. 2666-2674. 
80. Hall, A., et al., Structure-based insights into the catalytic power and conformational dexterity 
of peroxiredoxins. Antioxidants & redox signaling, 2011. 15(3): p. 795-815. 
81. Ziaei, S. and R. Halaby, Immunosuppressive, anti-inflammatory and anti-cancer properties of 
triptolide: A mini review. Avicenna Journal of Phytomedicine, 2016. 6(2): p. 149. 
82. Qi, X., et al., Dephosphorylation of Tak1 at Ser412 greatly contributes to the 
spermatocyte-specific testis toxicity induced by (5R)-5-hydroxytriptolide in C57BL/6 mice. 
Toxicology Research, 2016. 5(2): p. 594-601. 
83. Krishna, G., et al., PG490-88, a derivative of triptolide, blocks bleomycin-induced lung 
fibrosis. The American journal of pathology, 2001. 158(3): p. 997-1004. 
84. Han, R., et al., Triptolide in the treatment of psoriasis and other immune‐mediated 
inflammatory diseases. British journal of clinical pharmacology, 2012. 74(3): p. 424-436. 
85. Wang, L., et al., (5R)-5-hydroxytriptolide (LLDT-8), a novel immunosuppressant in clinical 
trials, exhibits potent antitumor activity via transcription inhibition. Cancer letters, 2012. 
324(1): p. 75-82. 
86. Zhou, R., et al., Preventive effects of (5R)-5-hydroxytriptolide on concanavalin A-induced 
hepatitis. Eur J Pharmacol, 2006. 537(1-3): p. 181-9. 
87. Liu, J., et al., Derivatization of (5R)-hydroxytriptolide from benzylamine to enhance mass 
spectrometric detection: application to a Phase I pharmacokinetic study in humans. Anal 
Chim Acta, 2011. 689(1): p. 69-76. 
88. Schenone, M., et al., Target identification and mechanism of action in chemical biology and 
drug discovery. Nature chemical biology, 2013. 9(4): p. 232-240. 
89. KAI, L., Developing Chemical Proteomic Tools Connecting Proteins and Small Molecules. 
2011. 
90. Burley, S.K., et al., Structural genomics: beyond the human genome project. Nature genetics, 
1999. 23(2): p. 151-157. 
91. Daly, S.J., et al., Production and analytical applications of scFv antibody fragments. 




92. Blackstock, W.P. and M.P. Weir, Proteomics: quantitative and physical mapping of cellular 
proteins. Trends in biotechnology, 1999. 17(3): p. 121-127. 
93. JIGANG, W., Quantitative chemical proteomics investigations of targets of andrographolide 
and proteolysis of autophagy. 2013. 
94. Yates, J.R., C.I. Ruse, and A. Nakorchevsky, Proteomics by mass spectrometry: approaches, 
advances, and applications. Annual review of biomedical engineering, 2009. 11: p. 49-79. 
95. Glish, G.L. and R.W. Vachet, The basics of mass spectrometry in the twenty-first century. 
Nature Reviews Drug Discovery, 2003. 2(2): p. 140-150. 
96. HAIBIN, S., Developing High-Throughput Chemical Approaches For Proteomic Profiling Of 
Aspartic Proteases And Protein Kinases. 2011. 
97. Duncan, P.J.G.M.W. and A.L. Yergey, Quantifying Proteins by Mass Spectrometry. 
Spectroscopy, 2015. 30(10). 
98. Zhao, Z., et al., Functional proteomics of Arabidopsis thaliana guard cells uncovers new 
stomatal signaling pathways. The Plant Cell, 2008. 20(12): p. 3210-3226. 
99. Friedman, D.B., et al., Proteome analysis of human colon cancer by two‐dimensional 
difference gel electrophoresis and mass spectrometry. Proteomics, 2004. 4(3): p. 793-811. 
100. Alban, A., et al., A novel experimental design for comparative two‐dimensional gel analysis: 
Two‐dimensional difference gel electrophoresis incorporating a pooled internal standard. 
Proteomics, 2003. 3(1): p. 36-44. 
101. Issaq, H.J., et al., Multidimensional separation of peptides for effective proteomic analysis. 
Journal of Chromatography B, 2005. 817(1): p. 35-47. 
102. Shi, Y., et al., The role of liquid chromatography in proteomics. Journal of Chromatography A, 
2004. 1053(1): p. 27-36. 
103. Han, C.-L., et al., Membrane Proteomics for the Opportunity of Cancer Biomarker and Drug 
Target Discovery, in Systems Biology: Applications in Cancer-Related Research. 2012. p. 
259-286. 
104. Langley, S.R., et al., Proteomics: from single molecules to biological pathways. 
Cardiovascular research, 2013. 97(4): p. 612-622. 
105. Savino, R., et al., The proteomics big challenge for biomarkers and new drug-targets 
discovery. International journal of molecular sciences, 2012. 13(11): p. 13926-13948. 
106. Guo, S., J. Zou, and G. Wang, Advances in the proteomic discovery of novel therapeutic 
targets in cancer. Drug design, development and therapy, 2013. 7: p. 1259. 
107. Cheng, X., et al., A tuned affinity-based staurosporine probe for in situ profiling of protein 
kinases. Chem. Commun., 2014. 50(22): p. 2851-2853. 
108. Yang, P.-Y., et al., Activity-based proteome profiling of potential cellular targets of orlistat− 
an FDA-approved drug with anti-tumor activities. Journal of the American Chemical Society, 
2009. 132(2): p. 656-666. 
109. Leuenroth, S.J., et al., Triptolide is a traditional Chinese medicine-derived inhibitor of 
polycystic kidney disease. Proceedings of the National Academy of Sciences, 2007. 104(11): p. 
4389-4394. 
110. Fonovic, M. and M. Bogyo, Activity based probes for proteases: applications to biomarker 





111. Corson, T.W., et al., Triptolide directly inhibits dCTP pyrophosphatase. ChemBioChem, 2011. 
12(11): p. 1767-1773. 
112. Titov, D.V., et al., XPB, a subunit of TFIIH, is a target of the natural product triptolide. Nature 
chemical biology, 2011. 7(3): p. 182-188. 
113. He, Q.L., et al., Covalent Modification of a Cysteine Residue in the XPB Subunit of the 
General Transcription Factor TFIIH Through Single Epoxide Cleavage of the Transcription 
Inhibitor Triptolide. Angewandte Chemie International Edition, 2015. 54(6): p. 1859-1863. 
114. Vispé, S., et al., Triptolide is an inhibitor of RNA polymerase I and II–dependent transcription 
leading predominantly to down-regulation of short-lived mRNA. Molecular cancer 
therapeutics, 2009. 8(10): p. 2780-2790. 
115. Verhelst, S. and M. Bogyo, Chemical proteomics applied to target identification and drug 
discovery. Biotechniques, 2005. 38(2): p. 175-177. 
116. Rix, U. and G. Superti-Furga, Target profiling of small molecules by chemical proteomics. 
Nature chemical biology, 2009. 5(9): p. 616-624. 
117. Pawson, A.J., et al., The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven 
knowledgebase of drug targets and their ligands. Nucleic Acids Research, 2014. 42(D1): p. 
D1098-D1106. 
118. Zhou, Y., W. Li, and Y. Xiao, Profiling of Multiple Targets of Artemisinin Activated by Hemin 
in Cancer Cell Proteome. ACS chemical biology, 2016. 11(4): p. 882-888. 
119. Fidler, J.M., et al., Preclinical antileukemic activity, toxicology, toxicokinetics and formulation 
development of triptolide derivative MRx102. Cancer chemotherapy and pharmacology, 2014. 
73(5): p. 961-974. 
120. Wai-Ching Chan, E., et al., Triptolide induced cytotoxic effects on human promyelocytic 
leukemia, T cell lymphoma and human hepatocellular carcinoma cell lines. Toxicology letters, 
2001. 122(1): p. 81-87. 
121. YinJun, L., J. Jie, and W. YunGui, Triptolide inhibits transcription factor NF-kappaB and 
induces apoptosis of multiple myeloma cells. Leukemia research, 2005. 29(1): p. 99-105. 
122. Zhao, F., et al., Triptolide alters histone H3K9 and H3K27 methylation state and induces 
G0/G1 arrest and caspase-dependent apoptosis in multiple myeloma in vitro. Toxicology, 
2010. 267(1): p. 70-79. 
123. Gan, C.S., et al., Technical, experimental, and biological variations in isobaric tags for 
relative and absolute quantitation (iTRAQ). Journal of proteome research, 2007. 6(2): p. 
821-827. 
124. Ghosh, D., et al., Identification of key players for colorectal cancer metastasis by iTRAQ 
quantitative proteomics profiling of isogenic SW480 and SW620 cell lines. Journal of 
proteome research, 2011. 10(10): p. 4373-4387. 
125. Dey, A., et al., A bromodomain protein, MCAP, associates with mitotic chromosomes and 
affects G2-to-M transition. Molecular and cellular biology, 2000. 20(17): p. 6537-6549. 
126. Wu, S.-Y. and C.-M. Chiang, The double bromodomain-containing chromatin adaptor Brd4 





127. Yang, Z., et al., Recruitment of P-TEFb for stimulation of transcriptional elongation by the 
bromodomain protein Brd4. Molecular cell, 2005. 19(4): p. 535-545. 
128. Devaiah, B.N., et al., BRD4 is an atypical kinase that phosphorylates serine2 of the RNA 
polymerase II carboxy-terminal domain. Proceedings of the National Academy of Sciences, 
2012. 109(18): p. 6927-6932. 
129. Zuber, J., et al., RNAi screen identifies Brd4 as a therapeutic target in acute myeloid 
leukaemia. Nature, 2011. 478(7370): p. 524-528. 
130. Delmore, J.E., et al., BET bromodomain inhibition as a therapeutic strategy to target c-Myc. 
Cell, 2011. 146(6): p. 904-917. 
131. Kemler, R., From cadherins to catenins: cytoplasmic protein interactions and regulation of 
cell adhesion. Trends in Genetics, 1993. 9(9): p. 317-321. 
132. Bienz, M., β-Catenin: a pivot between cell adhesion and Wnt signalling. Current Biology, 
2005. 15(2): p. R64-R67. 
133. Conacci-Sorrell, M., J. Zhurinsky, and A. Ben-Ze’ev, The cadherin-catenin adhesion system in 
signaling and cancer. The Journal of clinical investigation, 2002. 109(8): p. 987-991. 
134. Munemitsu, S., et al., Regulation of intracellular beta-catenin levels by the adenomatous 
polyposis coli (APC) tumor-suppressor protein. Proceedings of the National Academy of 
Sciences, 1995. 92(7): p. 3046-3050. 
135. Brembeck, F.H., M. Rosário, and W. Birchmeier, Balancing cell adhesion and Wnt signaling, 
the key role of β-catenin. Current opinion in genetics & development, 2006. 16(1): p. 51-59. 
136. Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2015. CA: a cancer journal for 
clinicians, 2015. 65(1): p. 5-29. 
137. Martín, M.A., L. Goya, and S. Ramos, Preventive effects of cocoa and cocoa antioxidants in 
colon cancer. Diseases, 2016. 4(1): p. 6. 
138. Shanmugam, M.K., et al. Cancer prevention and therapy through the modulation of 
transcription factors by bioactive natural compounds. in Seminars in cancer biology. 2016. 
Elsevier. 
139. Lu, Y., et al., TAB1: a target of triptolide in macrophages. Chemistry & biology, 2014. 21(2): 
p. 246-256. 
140. Pan, J., RNA polymerase–an important molecular target of triptolide in cancer cells. Cancer 
letters, 2010. 292(2): p. 149-152. 
141. Bywater, M.J., et al., Dysregulation of the basal RNA polymerase transcription apparatus in 
cancer. Nature Reviews Cancer, 2013. 13(5): p. 299-314. 
142. Kellner, W.A., et al., Distinct isoforms of the Drosophila Brd4 homologue are present at 
enhancers, promoters and insulator sites. Nucleic acids research, 2013. 41(20): p. 9274-9283. 
143. Zhao, Q., et al., Natural products triptolide, celastrol, and withaferin A inhibit the chaperone 
activity of peroxiredoxin I. Chemical Science, 2015. 6(7): p. 4124-4130. 
144. Zhang, J., et al., Development of a novel method for quantification of autophagic protein 
degradation by AHA labeling. Autophagy, 2014. 10(5): p. 901-912. 
145. Lu, W., et al., Peroxiredoxin 2 is upregulated in colorectal cancer and contributes to 
colorectal cancer cells’ survival by protecting cells from oxidative stress. Molecular and 




146. Rhee, S.G., et al., Peroxiredoxin functions as a peroxidase and a regulator and sensor of local 
peroxides. Journal of Biological Chemistry, 2012. 287(7): p. 4403-4410. 
147. Muchowicz, A., et al., Adenanthin targets proteins involved in the regulation of disulphide 
bonds. Biochemical pharmacology, 2014. 89(2): p. 210-216. 
148. Winterbourn, C.C., Reconciling the chemistry and biology of reactive oxygen species. Nature 
chemical biology, 2008. 4(5): p. 278-286. 
149. Kang, S.W., et al., 2-Cys peroxiredoxin function in intracellular signal transduction: 
therapeutic implications. Trends in molecular medicine, 2005. 11(12): p. 571-578. 
150. Stresing, V., et al., Peroxiredoxin 2 specifically regulates the oxidative and metabolic stress 
response of human metastatic breast cancer cells in lungs. Oncogene, 2013. 32(6): p. 724-735. 
151. Liu, C.-X., et al., Adenanthin targets peroxiredoxin I and II to induce differentiation of 
leukemic cells. Nature chemical biology, 2012. 8(5): p. 486-493. 
152. Rosengarth, A. and H. Luecke, A calcium-driven conformational switch of the N-terminal and 
core domains of annexin A1. Journal of molecular biology, 2003. 326(5): p. 1317-1325. 
153. Benz, J. and A. Hofmann, Annexins: from structure to function. Biological chemistry, 1996. 
378(3-4): p. 177-183. 
154. Hayes, M.J., et al., Annexin–actin interactions. Traffic, 2004. 5(8): p. 571-576. 
155. Revenu, C., et al., The co-workers of actin filaments: from cell structures to signals. Nature 
reviews Molecular cell biology, 2004. 5(8): p. 635-646. 
156. Guo, C., S. Liu, and M.-Z. Sun, Potential role of Anxa1 in cancer. Future oncology, 2013. 
9(11): p. 1773-1793. 
157. Guzmán‐Aránguez, A., et al., Differentiation of human colon adenocarcinoma cells alters the 
expression and intracellular localization of annexins A1, A2, and A5. Journal of cellular 
biochemistry, 2005. 94(1): p. 178-193. 
158. Lecona, E., et al., Upregulation of annexin A1 expression by butyrate in human colon 
adenocarcinoma cells: role of p53, NF-Y, and p38 mitogen-activated protein kinase. 
Molecular and cellular biology, 2008. 28(15): p. 4665-4674. 
159. Bizzarro, V., et al., Annexin A1 induces skeletal muscle cell migration acting through formyl 
peptide receptors. PloS one, 2012. 7(10): p. e48246. 
160. Lim, L.H. and S. Pervaiz, Annexin 1: the new face of an old molecule. The FASEB Journal, 
2007. 21(4): p. 968-975. 
161. Boudhraa, Z., et al., Annexin A1 localization and its relevance to cancer. Clinical Science, 
2016. 130(4): p. 205-220. 
162. Duncan, R., et al., Characterisation and protein expression profiling of annexins in colorectal 
cancer. British journal of cancer, 2008. 98(2): p. 426-433. 
163. García, Á., et al., A global proteomics approach identifies novel phosphorylated signaling 
proteins in GPVI‐activated platelets: Involvement of G6f, a novel platelet Grb2‐binding 
membrane adapter. Proteomics, 2006. 6(19): p. 5332-5343. 
164. Lomenick, B., et al., Target identification using drug affinity responsive target stability 
(DARTS). Proceedings of the National Academy of Sciences, 2009. 106(51): p. 21984-21989. 
165. Bertucci, C., et al., Drug affinity to immobilized target bio-polymers by high-performance 




797(1): p. 111-129. 
166. Zhou, B., et al., Synthesis and biological evaluation of novel triptolide analogues for 
anticancer activity. Bioorganic & medicinal chemistry letters, 2010. 20(21): p. 6217-6221. 
167. Yuan, H., J.H. Musser, and D. Dai, Triptolide lactone ring derivatives as immunomodulators 
and anticancer agents. 2013, Google Patents. 
168. Kupchan, S.M. and R.M. Schubert, Selective alkylation: a biomimetic reaction of the 
antileukemic triptolides? Science, 1974. 185(4153): p. 791-793. 
169. Dai, D., J.M. Fidler, and J.H. Musser, Amino acid derivatives of triptolide compounds as 
immune modulators and anticancer agents. 2003, Google Patents. 
170. Butler, M.S., Natural products to drugs: natural product-derived compounds in clinical trials. 
Natural product reports, 2008. 25(3): p. 475-516. 
171. Li, Z., et al., Design and synthesis of novel C14-hydroxyl substituted triptolide derivatives as 
potential selective antitumor agents. Journal of medicinal chemistry, 2009. 52(16): p. 
5115-5123. 
172. Hirotsu, S., et al., Crystal structure of a multifunctional 2-Cys peroxiredoxin heme-binding 
protein 23 kDa/proliferation-associated gene product. Proceedings of the National Academy 
of Sciences, 1999. 96(22): p. 12333-12338. 
173. Moore, R.B., et al., Reconstitution of Ca (2+)-dependent K+ transport in erythrocyte 
membrane vesicles requires a cytoplasmic protein. Journal of Biological Chemistry, 1991. 
266(28): p. 18964-18968. 
174. Zhang, P., et al., Thioredoxin peroxidase is a novel inhibitor of apoptosis with a mechanism 
distinct from that of Bcl-2. Journal of Biological Chemistry, 1997. 272(49): p. 30615-30618. 
175. Park, S.-H., et al., Antisense of human peroxiredoxin II enhances radiation-induced cell death. 
Clinical cancer research, 2000. 6(12): p. 4915-4920. 
176. Trachootham, D., et al., Redox regulation of cell survival. Antioxidants & redox signaling, 
2008. 10(8): p. 1343-1374. 
177. Ruckenstuhl, C., et al., The Warburg effect suppresses oxidative stress induced apoptosis in a 
yeast model for cancer. PloS one, 2009. 4(2): p. e4592. 
178. He, Z.-Y., et al., Up-regulation of hnRNP A1, Ezrin, tubulin β-2C and Annexin A1 in sentinel 
lymph nodes of colorectal cancer. World J Gastroenterol, 2010. 16(37): p. 4670-4676. 
179. Wang, Y.-J., et al., Preliminary proteomic analysis of indomethacin's effect on tumor 
transplanted with colorectal cancer cell in nude mice. BMB Reports, 2006. 39(2): p. 171-177. 
180. Mujumdar, N., et al., Triptolide induces cell death in pancreatic cancer cells by apoptotic and 
autophagic pathways. Gastroenterology, 2010. 139(2): p. 598-608. 
181. Schieffer, B., et al., Role of NAD (P) H oxidase in angiotensin II–induced JAK/STAT signaling 
and cytokine induction. Circulation Research, 2000. 87(12): p. 1195-1201. 
182. Annunziato, L., et al., Modulation of ion channels by reactive oxygen and nitrogen species: a 
pathophysiological role in brain aging? Neurobiology of aging, 2002. 23(5): p. 819-834. 
183. Ramírez, A., et al., Ion Channels and Oxidative Stress as a Potential Link for the Diagnosis or 
Treatment of Liver Diseases. Oxidative medicine and cellular longevity, 2016. 2016. 
184. Duan, L., et al., S100A6 stimulates proliferation and migration of colorectal carcinoma cells 





185. Wang, L., et al., The roles of integrin β4 in vascular endothelial cells. Journal of cellular 
physiology, 2012. 227(2): p. 474-478. 
186. Havens, C.G., et al., Regulation of late G1/S phase transition and APCCdh1 by reactive 
oxygen species. Molecular and Cellular Biology, 2006. 26(12): p. 4701-4711. 
187. Chang, W.-T., et al., Triptolide and chemotherapy cooperate in tumor cell apoptosis A role for 
the p53 pathway. Journal of Biological Chemistry, 2001. 276(3): p. 2221-2227. 
188. Manzo, S.G., et al., Natural product triptolide mediates cancer cell death by triggering 
CDK7-dependent degradation of RNA polymerase II. Cancer research, 2012. 72(20): p. 
5363-5373. 
189. Venkataraman, S., et al., Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses 




Appendices I: Significantly regulated proteins by triptolide with 6 hrs of treatment 
 
N Unused Total % Cov Accession # Protein ID 
Peptides 
(95%) 114:113 118:113 114:117 118:117 
Geometric 
Mean 
1 5.88 5.94 43.5 Q8IZ73 RNA pseudouridylate synthase domain-containing protein 2  3 0.8889 0.6453 0.4161 0.3022 0.518234936 
2 
2.04 2.06 24.9 Q3ZCQ8 
Mitochondrial import inner membrane translocase subunit 
TIM50  1 0.5741 0.4644 0.6994 0.566 
0.569974537 
3 2.05 2.14 48 Q9UL25 Ras-related protein Rab-21  2 0.5654 0.5481 0.6494 0.6298 0.596667849 
4 2.17 4.51 34.5 Q9Y4I1 Unconventional myosin-Va  2 0.7163 0.7205 0.5387 0.5355 0.621167674 
5 4.21 4.81 34.9 Q8WVB6 Chromosome transmission fidelity protein 18 homolog  2 0.5547 0.8994 0.4371 0.7091 0.627082723 
6 1.49 1.71 44.4 P49720 Proteasome subunit beta type-3  1 0.5338 0.4026 0.9884 0.7458 0.630887415 
7 2 2.05 18.4 P23511 Nuclear transcription factor Y subunit alpha  1 0.6126 0.6426 0.6207 0.6513 0.631604382 
8 2 2 37.1 Q14657 EKC/KEOPS complex subunit LAGE3  1 0.474 0.5489 0.7495 0.8683 0.64147281 
9 2.02 2.16 20.7 Q969X6 Cirhin  2 0.8512 0.636 0.7146 0.5341 0.674207501 
10 2.03 7.01 45.1 P48735 Isocitrate dehydrogenase [NADP], mitochondrial  4 0.653 0.6704 0.6925 0.7113 0.681443641 
11 0.91 1.07 37.8 Q9HBL8 NmrA-like family domain-containing protein 1  1 0.8093 0.7309 0.6528 0.5898 0.690817139 
12 2.1 2.53 46.2 Q9BZL4 Protein phosphatase 1 regulatory subunit 12C  1 1.0717 0.6249 0.7863 0.445 0.695757683 
13 1.46 1.47 20.2 Q96RF0 Sorting nexin-18  1 0.7211 0.8565 0.5642 0.68 0.69769597 
14 2 2.16 34 Q96C57 Uncharacterized protein C12orf43  1 0.6217 0.6368 0.7672 0.7862 0.69904702 
15 4.03 4.47 56.6 Q9Y2Q3 Glutathione S-transferase kappa 1  2 0.4663 0.6322 0.7804 1.0586 0.702493426 
16 1.09 1.15 54.2 Q9NP97 Dynein light chain roadblock-type 1  1 0.7304 1.0546 0.4714 0.6809 0.705148134 
17 1.14 1.17 19.5 Q96N66 Lysophospholipid acyltransferase 7  1 0.5777 0.7694 0.6486 0.8642 0.706498817 
18 2.01 2.35 28.8 Q643R3 Lysophospholipid acyltransferase LPCAT4  1 0.8002 0.5424 0.9287 0.6297 0.709793212 




20 2.08 2.25 16.4 Q8N5C8 TGF-beta-activated kinase 1 and MAP3K7-binding protein 3  1 0.6535 0.7081 0.7251 0.7807 0.715410925 
21 2.1 3.35 34.5 O60343 TBC1 domain family member 4  2 0.8401 0.9744 0.5392 0.627 0.725306252 
22 1.24 1.65 26.9 Q9UI17 Dimethylglycine dehydrogenase, mitochondrial  1 0.8027 0.5612 0.95 0.6645 0.730251368 
23 2.03 2.07 45.8 Q9NS69 Mitochondrial import receptor subunit TOM22 homolog  1 0.8418 0.648 0.8606 0.6627 0.746836543 
24 2.01 2.48 35.7 Q9UBB9 Tuftelin-interacting protein 11  1 0.7696 0.7037 0.8105 0.74 0.754934612 
25 1.79 2.69 37.5 Q8TD16 Protein bicaudal D homolog 2  1 0.8568 0.8403 0.6919 0.6788 0.762561274 
26 4 4.05 27.1 O15127 Secretory carrier-associated membrane protein 2  2 0.8483 0.7125 0.8098 0.7088 0.767465664 
27 1.01 1.24 48.4 O43427 Acidic fibroblast growth factor intracellular-binding protein  1 0.9037 0.7387 0.8039 0.6574 0.770692313 
28 7.52 7.54 59 Q15287 RNA-binding protein with serine-rich domain 1  7 0.7128 0.6574 0.9266 0.8455 0.778396411 
29 2 2.15 33.7 P23786 Carnitine O-palmitoyltransferase 2, mitochondrial  2 0.8638 0.7553 0.8054 0.7045 0.780021057 
30 4 4.09 46.6 P37235 Hippocalcin-like protein 1  2 0.827 0.9724 0.6327 0.7442 0.784439565 
31 2.04 3.12 33.7 P46100 Transcriptional regulator ATRX  1 0.6299 0.7939 0.7823 0.9822 0.787322509 
32 2.01 4.86 29.7 O15357 Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2  2 0.7088 0.8396 0.7419 0.8792 0.789327615 
33 5.52 6.54 37.1 Q9UKE5 TRAF2 and NCK-interacting protein kinase  3 0.7532 0.601 1.0392 0.8295 0.790360228 
34 4.29 4.57 32.1 Q08J23 tRNA (cytosine(34)-C(5))-methyltransferase  3 0.7543 0.7995 0.7824 0.8323 0.791621951 
35 2 2.07 16.4 O95365 Zinc finger and BTB domain-containing protein 7A  1 0.6824 0.79 0.7979 0.9241 0.794023555 
36 2.08 2.55 46.8 Q9NRP2 COX assembly mitochondrial protein 2 homolog  1 0.6997 0.798 0.7937 0.9061 0.796043534 
37 1.52 1.62 47.2 Q03135 Caveolin-1  2 0.6692 0.769 0.8513 0.9787 0.809195806 
38 2.34 2.45 30.5 Q96DV4 39S ribosomal protein L38, mitochondrial  1 0.9013 0.8173 0.8042 0.7267 0.810013999 
39 2.44 2.66 32.8 Q8IY37 Probable ATP-dependent RNA helicase DHX37  1 0.8193 0.9392 0.7043 0.8081 0.813497005 
40 1.92 2.04 35.4 Q9HCC0 Methylcrotonoyl-CoA carboxylase beta chain, mitochondrial  1 0.7782 0.7943 0.8398 0.8575 0.816810754 
41 2.06 2.55 49.1 Q9NUL3 Double-stranded RNA-binding protein Staufen homolog 2  1 0.7673 0.835 0.8133 0.8855 0.824181293 
42 1.39 1.57 23.5 Q15165 Serum paraoxonase/arylesterase 2  1 0.8327 0.7952 0.8541 0.816 0.824215835 




44 2.01 2.25 20.9 Q8TDN4 CDK5 and ABL1 enzyme substrate 1  1 0.6406 0.8314 0.8477 1.1006 0.839589815 
45 0.83 0.9 22 Q6UWP7 Lysocardiolipin acyltransferase 1  2 1.1766 1.1108 1.2534 1.1838 1.180071129 
46 2.03 7.41 63.1 P12235 ADP/ATP translocase 1  9 1.2137 1.1878 1.1761 1.1509 1.181909241 
47 4.32 5.78 53.9 P53367 Arfaptin-1  4 1.1058 1.1753 1.1899 1.2641 1.182440522 
48 2.44 2.54 47.3 P49914 5-formyltetrahydrofolate cyclo-ligase  1 1.174 1.4003 1.0012 1.1948 1.184203418 
49 4.38 5.48 33.2 Q15003 Condensin complex subunit 2  3 1.1785 1.1134 1.2706 1.2009 1.189526509 
50 2.03 2.35 31.1 O95260 Arginyl-tRNA--protein transferase 1  1 1.2338 1.3227 1.066 1.1801 1.197003812 
51 1.39 3.69 53 O43583 Density-regulated protein  2 1.0967 1.1777 1.2408 1.334 1.209191354 
52 2.99 3.15 31.8 Q8TBF2 Prostamide/prostaglandin F synthase  2 1.1326 1.2111 1.2276 1.3125 1.219279265 
53 2.11 4.87 44.2 Q9H0B6 Kinesin light chain 2  2 1.4322 1.265 1.1792 1.046 1.222653337 
54 6.02 6.22 21.6 Q9BQA1 Methylosome protein 50  3 1.2756 1.3092 1.1462 1.1757 1.224811788 
55 2.07 2.77 30.4 Q92576 PHD finger protein 3  1 1.2778 1.2516 1.2085 1.1842 1.22998563 
56 0.81 1.19 30.5 Q96DN5 TBC1 domain family member 31  2 1.1767 1.552 0.9744 1.2915 1.231252964 
57 2.71 3.07 17.1 Q9BV38 WD repeat-containing protein 18  2 1.2538 1.3543 1.1342 1.218 1.2375707 
58 2.05 2.86 39.8 Q96T58 Msx2-interacting protein  1 1.1769 1.413 1.092 1.3112 1.242205151 
59 
7.61 7.89 39.1 P04844 
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 
subunit 2  7 1.3118 1.2897 1.2068 1.1772 
1.245117882 
60 2.01 2.06 70.1 Q9NYJ1 Cytochrome c oxidase assembly factor 4 homolog 1 0.9875 1.3194 1.1797 1.5769 1.247734918 
61 2 2 49.5 P07311 Acylphosphatase-1  1 1.3157 1.5866 0.9915 1.1961 1.25435693 
62 4 4.05 40.1 Q7Z6J9 tRNA-splicing endonuclease subunit Sen54  2 1.2558 1.6058 0.9855 1.2607 1.258114241 
63 2 2.08 32.1 Q14232 Translation initiation factor eIF-2B subunit alpha  1 1.272 1.1869 1.3474 1.2578 1.264743173 
64 5.78 6.96 34.9 Q5JRA6 Melanoma inhibitory activity protein 3  3 1.3028 1.5837 1.0108 1.2284 1.26514099 
65 1.36 1.48 21.7 A8CG34 Nuclear envelope pore membrane protein POM 121C  1 1.3548 1.6958 0.946 1.1846 1.266712835 




67 2 2.08 29.1 P62306 Small nuclear ribonucleoprotein F  2 1.0202 1.3411 1.2367 1.6264 1.287981283 
68 2 2.14 33.9 Q7Z7F0 UPF0469 protein KIAA0907  1 1.2582 1.2973 1.2793 1.3196 1.28840144 
69 1.51 1.69 38.8 O75521 Enoyl-CoA delta isomerase 2, mitochondrial  1 1.5508 1.331 1.1765 1.1519 1.293257898 
70 2 2.08 28 Q9Y5P4 Collagen type IV alpha-3-binding protein  1 1.4563 1.2925 1.3004 1.1546 1.296574508 
71 2.02 2.03 52.3 O60783 28S ribosomal protein S14, mitochondrial  1 1.4756 1.2886 1.324 1.1567 1.306317887 
72 2.01 5.33 27.5 O14787 Transportin-2  2 1.106 1.2895 1.3265 1.5473 1.308020539 
73 1.03 3.09 31.4 P38432 Coilin  2 1.8665 1.3157 1.301 0.9175 1.308479912 
74 4.19 4.45 28.4 Q8WTS6 Histone-lysine N-methyltransferase SETD7  2 1.1186 1.2423 1.3846 1.5383 1.311646084 
75 6.09 6.14 33 Q10713 Mitochondrial-processing peptidase subunit alpha  3 1.2982 1.3639 1.2722 1.3372 1.317403987 
76 4.51 5.12 66.5 P61289 Proteasome activator complex subunit 3  2 1.5942 1.2356 1.4124 1.0951 1.321168006 
77 0.87 1.09 39.7 Q9UL03 Integrator complex subunit 6  1 1.4899 1.2687 1.3787 1.1744 1.322666852 
78 6.7 8.15 46 O43795 Unconventional myosin-Ib 5 1.2389 1.1944 1.8665 1.1198 1.326137714 
79 2.21 2.87 29.7 Q96N67 Dedicator of cytokinesis protein 7  1 1.5934 1.496 1.1804 1.1087 1.328999794 
80 2.04 2.15 55.7 Q5HYK3 2-methoxy-6-polyprenyl-1,4-benzoquinol methylase 1 1.4744 1.1125 1.5896 1.2 1.329983063 
81 2.43 3.07 28 P35568 Insulin receptor substrate 1  4 1.3685 1.1572 1.5388 1.3017 1.334555309 
82 0.81 0.87 27.1 Q9GZT8 Putative GTP cyclohydrolase 1 type 2 NIF3L1  1 1.1291 1.3553 1.34 1.6091 1.347764211 
83 0.81 1.32 39.8 O75335 Liprin-alpha-4  1 1.5417 1.5785 1.1509 1.1788 1.347970984 
84 2 2.01 20.6 Q9BV86 N-terminal Xaa-Pro-Lys N-methyltransferase 1  1 1.668 1.5522 1.1836 1.1018 1.355541639 
85 
2.01 2.09 47.9 Q9NRN7 
L-aminoadipate-semialdehyde 
dehydrogenase-phosphopantetheinyl transferase  1 1.0395 1.3138 1.4055 1.777 
1.358995464 
86 0.83 2.34 25 Q8IYQ7 Threonine synthase-like 1  2 1.4592 1.7071 1.0914 1.2774 1.365121043 
87 2.01 2.08 31.7 P54105 Methylosome subunit pICln  1 1.4891 1.4672 1.2711 1.2529 1.365769241 
88 5.6 6.26 37.9 P22033 Methylmalonyl-CoA mutase, mitochondrial  4 1.3729 1.2018 1.6103 1.4228 1.394377732 




exchanger 1 protein  
90 5.87 6.6 23.7 P50851 Lipopolysaccharide-responsive and beige-like anchor protein  3 1.434 1.4176 1.4225 1.4068 1.420191381 
91 2 2.15 24.1 Q9HBU6 Ethanolamine kinase 1  1 1.2945 1.0813 1.878 1.5693 1.425156163 
92 2.02 2.16 29.3 Q96BN8 Ubiquitin thioesterase otulin  1 1.9127 1.6111 1.2635 1.0647 1.426898114 
93 1.27 1.77 28.7 P55196 Afadin  1 1.348 1.9482 1.0697 1.5467 1.44376955 
94 2.05 2.99 31.3 P52306 Rap1 GTPase-GDP dissociation stimulator 1  2 2.2211 1.4517 1.556 1.0174 1.503095514 
95 1.71 1.83 31.7 Q00577 Transcriptional activator protein Pur-alpha  1 1.445 1.3698 1.7347 1.6451 1.541648705 
96 2.02 2.31 19.5 P54802 Alpha-N-acetylglucosaminidase  1 1.836 2.0465 1.2172 1.3572 1.578419927 
97 2.01 2.2 19.4 Q8NE86 Calcium uniporter protein, mitochondrial  1 1.8466 0.9031 2.7659 1.3532 1.580617494 
98 2.12 2.73 40.3 O75746 Calcium-binding mitochondrial carrier protein Aralar1  1 1.3355 1.6134 1.5631 1.8892 1.588227316 
99 2.04 4.47 34.5 Q10570 Cleavage and polyadenylation specificity factor subunit 1  2 1.701 2.1374 1.194 1.5009 1.597668052 
100 1.08 1.1 61.2 O15145 Actin-related protein 2/3 complex subunit 3  1 1.5386 1.4174 1.8238 1.6808 1.607969667 
101 3.06 3.13 32.2 Q9Y639 Neuroplastin  2 1.3418 1.3315 2.2059 2.1899 1.713995848 
102 2.85 3.82 32.5 O95834 Echinoderm microtubule-associated protein-like 2  3 1.6602 2.2618 1.3354 1.8201 1.738122204 
103 6.13 15.1 40.9 P13645 Keratin, type I cytoskeletal 10  9 2.5131 0.9875 3.0897 1.216 1.747427598 
104 2.01 2.35 34.5 Q9BYM8 RanBP-type and C3HC4-type zinc finger-containing protein 1  1 1.3464 1.02 3.3829 2.5638 1.857748394 











Appendices II: Significantly regulated proteins by triptolide with 48 hrs of treatment  
 
N Unused Total 
% 
Cov Accession # Protein ID 
Peptides 
(95%) 114:113 118:113 114:117 118:117 
Geometric 
Mean 
1 1.42 1.62 28.9 Q8N806 Putative E3 ubiquitin-protein ligase UBR7  1 0.7761 0.9133 0.01 0.0117 0.095428753 
2 2.04 2.47 22.2 Q8N612 FTS and Hook-interacting protein  1 0.5258 0.7641 0.0963 0.1417 0.272108263 
3 0.79 1.1 50.3 Q8N998 Coiled-coil domain-containing protein 89  1 0.3728 1.0384 0.0862 0.2431 0.30011189 
4 2.02 2.31 19.5 P54802 Alpha-N-acetylglucosaminidase  1 0.391 0.5643 0.2791 0.4079 0.398107251 
5 2 2.15 24.1 Q9HBU6 Ethanolamine kinase 1  1 0.5504 0.9944 0.1871 0.3423 0.432693187 
6 2.01 2.01 16.1 Q9UHY7 Enolase-phosphatase E1  1 0.5985 0.5046 0.4156 0.3548 0.459375298 
7 1.4 1.4 19.9 A6NDG6 Phosphoglycolate phosphatase  1 0.3097 0.6853 0.3379 0.7572 0.482730994 
8 1 3.72 32.1 Q8WXE1 ATR-interacting protein  2 0.6479 0.4825 0.5029 0.3792 0.494127262 
9 1.49 1.75 57.9 P57076 UPF0769 protein C21orf59  1 0.2597 0.3952 0.6294 0.97 0.50031882 
10 2 4.35 23.3 Q9NQH7 Probable Xaa-Pro aminopeptidase 3  3 0.295 0.6817 0.4388 1.0272 0.548699084 
11 1.9 4.95 26.2 O60885 Bromodomain-containing protein 4  2 0.3136 0.9782 0.3862 0.7774 0.550890305 
12 2.12 2.73 40.3 O75746 Calcium-binding mitochondrial carrier protein Aralar1  1 0.4143 1.1764 0.2677 0.77 0.562992049 
13 1.24 1.65 26.9 Q9UI17 Dimethylglycine dehydrogenase, mitochondrial  1 0.768 0.7614 0.4552 0.457 0.590572386 
14 2.18 2.66 24.7 Q14202 Zinc finger MYM-type protein 3  1 0.501 0.8416 0.4119 0.7007 0.59063182 
15 2.09 2.28 46.4 Q14554 Protein disulfide-isomerase A5  2 0.6887 0.6918 0.5144 0.5207 0.597688355 
16 2.07 4.13 35.7 Q92974 Rho guanine nucleotide exchange factor 2  2 0.381 0.5412 0.694 0.9984 0.614804024 
17 0.83 0.93 25.1 Q99720 Sigma non-opioid intracellular receptor 1  1 0.4894 0.704 0.5359 0.7807 0.616170838 
18 2.11 3.21 34.5 O95425 Supervillin  1 0.548 0.9145 0.424 0.7166 0.624671558 
19 2.4 3.68 28.2 Q9UKK3 Poly [ADP-ribose] polymerase 4  2 0.3412 0.7111 0.5609 1.184 0.633569425 




21 2.02 2.04 32.7 P12955 Xaa-Pro dipeptidase  1 0.6719 0.9059 0.4742 0.6475 0.657501209 
22 5.56 5.56 57.1 P35080 Profilin-2  4 0.6412 0.8511 0.512 0.677 0.659489953 
23 2 2.07 20.4 Q86U90 YrdC domain-containing protein, mitochondrial  1 0.8028 1 0.435 0.5487 0.661618888 
24 2.11 4.87 44.2 Q9H0B6 Kinesin light chain 2  2 0.6901 0.6597 0.6585 0.6498 0.664352387 
25 2.04 4.47 34.5 Q10570 Cleavage and polyadenylation specificity factor subunit 1  2 0.3946 0.6148 0.7145 1.1277 0.664923509 
26 2.01 5.33 27.5 O14787 Transportin-2  2 0.4358 0.7847 0.5784 1.0548 0.675845336 
27 1.99 2.22 51.1 Q86Y82 Syntaxin-12  2 0.6865 0.5066 0.9201 0.6876 0.684887368 
28 1.82 2.12 30 Q15054 DNA polymerase delta subunit 3  1 0.5404 0.7378 0.6398 0.8848 0.68926438 
29 1.81 1.86 27.2 O94888 UBX domain-containing protein 7  2 0.6687 0.4834 0.9836 0.7201 0.691731137 
30 2.04 2.18 50 Q9BRT2 Ubiquinol-cytochrome-c reductase complex assembly factor 2  1 0.435 0.8123 0.5874 1.1109 0.692952801 
31 10.11 11.1 43.9 O75150 E3 ubiquitin-protein ligase BRE1B  6 0.6241 0.6992 0.6866 0.7789 0.695040763 
32 2 2 32.7 Q96C90 Protein phosphatase 1 regulatory subunit 14B  1 0.6325 0.7888 0.6135 0.7749 0.697865799 
33 3.24 4.21 44.2 Q6WCQ1 Myosin phosphatase Rho-interacting protein  2 0.5869 0.7121 0.6797 0.8352 0.697916093 
34 4.09 4.58 43.8 Q9Y5K5 Ubiquitin carboxyl-terminal hydrolase isozyme L5  3 0.5133 0.7494 0.6573 0.9718 0.704054648 
35 6.14 6.41 62.1 P63162 Small nuclear ribonucleoprotein-associated protein N  5 0.756 0.7527 0.653 0.6682 0.705896195 
36 15.47 15.47 20.8 P16070 CD44 antigen  12 0.6772 0.7051 0.7073 0.7503 0.70949864 
37 
1.38 1.62 27.6 P19388 
DNA-directed RNA polymerases I, II, and III subunit 
RPABC1  4 0.6928 0.7135 0.7041 0.7502 
0.714830896 
38 4.04 4.19 38.7 Q96A33 Coiled-coil domain-containing protein 47  2 0.7827 0.6842 0.7535 0.6659 0.719975418 
39 2.01 2.07 24.4 Q96AB3 Isochorismatase domain-containing protein 2 1 0.6836 0.7645 0.6748 0.7644 0.7205578 
40 2.9 3.2 25.4 Q06587 E3 ubiquitin-protein ligase RING1  2 0.7359 0.6674 0.7774 0.7176 0.723490767 
41 1.98 2.31 47.3 P53004 Biliverdin reductase A  1 0.8144 0.8382 0.6208 0.6471 0.72364761 





1.36 1.77 28.2 Q9Y2L9 
Leucine-rich repeat and calponin homology domain-containing 
protein 1  1 0.5285 0.6973 0.7615 1.0174 
0.730981818 
44 4.48 5.57 44.8 Q9H2G2 STE20-like serine/threonine-protein kinase  2 0.7068 1.0141 0.5246 0.7741 0.734515 
45 0.9 0.94 26.5 A6NJ78 Probable methyltransferase-like protein 15  1 0.7517 0.7237 0.7453 0.7267 0.736753743 
46 2.04 2.06 24.9 Q3ZCQ8 Mitochondrial import inner membrane translocase subunit TIM50  1 0.8048 0.7501 0.7245 0.6838 0.739509325 
47 2 2 37.1 Q14657 EKC/KEOPS complex subunit LAGE3  1 0.7086 0.8904 0.6132 0.7804 0.741270004 
48 2 2.08 32.4 Q9UNL2 Translocon-associated protein subunit gamma  1 0.5257 0.7136 0.7664 1.0537 0.741893086 
49 2.02 2.14 26.6 Q9Y2Z4 Tyrosine--tRNA ligase, mitochondrial  1 0.6182 0.7722 0.708 0.8964 0.741905304 
50 1.49 1.71 44.4 P49720 Proteasome subunit beta type-3  1 0.8182 0.6287 0.8701 0.6772 0.741988652 
51 3.63 4.48 41.8 P52756 RNA-binding protein 5  3 0.7899 0.7195 0.7814 0.7168 0.751136003 
52 21.83 22.66 36.1 P28290 Sperm-specific antigen 2  15 0.7084 0.7865 0.7158 0.805 0.752733446 
53 2.06 2.25 21.1 Q15334 Lethal(2) giant larvae protein homolog 1  1 0.6827 0.7319 0.7933 0.8613 0.764395969 
54 2.47 2.71 44.8 Q9GZT9 Egl nine homolog 1  1 0.7014 0.8026 0.7267 0.8387 0.765343997 
55 3.74 6.13 48 Q9UDT6 CAP-Gly domain-containing linker protein 2  3 0.6731 0.7108 0.8171 0.8809 0.76605016 
56 2.02 2.13 18.5 Q00613 Heat shock factor protein 1  1 0.8833 0.8056 0.7314 0.6687 0.768074756 
57 1.76 1.9 35.8 Q8TB36 Ganglioside-induced differentiation-associated protein 1  1 0.731 0.8617 0.6847 0.8175 0.770575842 
58 2 4.77 55.8 Q9NQ29 Putative RNA-binding protein Luc7-like 1  3 0.5996 0.7744 0.7633 0.9984 0.771270465 
59 16.54 16.81 45.3 P08243 Asparagine synthetase [glutamine-hydrolyzing]  11 0.7454 0.8266 0.7224 0.8116 0.77526672 
60 3.25 3.61 26 Q9UJY5 ADP-ribosylation factor-binding protein GGA1  2 0.7717 0.927 0.6458 0.7861 0.776293622 
61 20.02 20.42 60 Q9Y617 Phosphoserine aminotransferase  15 0.7914 0.7449 0.8025 0.7715 0.777264348 
62 2.02 2.2 34.8 P13051 Uracil-DNA glycosylase  1 0.7731 1.0161 0.595 0.7909 0.779745122 
63 5.8 6.35 44.3 Q12874 Splicing factor 3A subunit 3  3 0.7329 0.7826 0.7746 0.8372 0.780949263 
64 2.22 2.45 52.5 Q9BT09 Protein canopy homolog 3  1 0.6798 0.799 0.761 0.9054 0.782146798 




66 12.18 12.24 45.5 Q9UK76 Hematological and neurological expressed 1 protein  7 0.7801 0.8777 0.697 0.8025 0.78667174 
67 8.25 8.37 41.5 Q13011 Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial  5 0.7636 0.8834 0.7013 0.8161 0.788256631 
68 4.04 4.36 30.4 Q92615 La-related protein 4B  4 0.7895 0.7766 0.7982 0.8011 0.791292399 
69 0.86 0.88 24 P85037 Forkhead box protein K1  1 0.809 0.8715 0.7166 0.7819 0.792795146 
70 2 2.23 18 Q9Y2H6 Fibronectin type-III domain-containing protein 3A  1 0.7925 0.7201 0.8722 0.8027 0.795042522 
71 2 2.5 16.6 Q6AI08 HEAT repeat-containing protein 6  2 0.6783 0.7842 0.8142 0.9534 0.801611105 
72 4 4.04 32.5 Q9Y6W5 Wiskott-Aldrich syndrome protein family member 2  2 0.7107 0.8058 0.7971 0.9153 0.803984105 
73 1.3 1.9 32 O75600 2-amino-3-ketobutyrate coenzyme A ligase, mitochondrial  2 1.2238 1.2821 1.1714 1.2429 1.229400652 
74 2 4 42.9 Q71UM5 40S ribosomal protein S27-like  3 1.2556 1.1402 1.3289 1.2222 1.23485718 
75 5.2 5.44 44.1 P20962 Parathymosin  3 1.2417 1.2308 1.2359 1.2385 1.236718558 
76 2.03 4.24 38.7 P56545 C-terminal-binding protein 2  5 1.0786 1.2337 1.2445 1.4394 1.24254348 
77 4.72 5.03 31.3 P07686 Beta-hexosaminidase subunit beta  2 1.5851 1.2436 1.2591 0.9985 1.254689947 
78 6.09 6.74 19 Q09161 Nuclear cap-binding protein subunit 1  4 1.5102 1.2563 1.2592 1.0549 1.259964933 
79 2.02 2.7 37.6 P28838 Cytosol aminopeptidase  1 1.2451 1.2136 1.3323 1.3185 1.27641086 
80 5.88 6.01 60.9 O95721 Synaptosomal-associated protein 29  3 1.2468 1.2107 1.3091 1.3595 1.280254593 
81 2 2.14 18.4 Q96ER3 Protein SAAL1  1 1.7563 1.247 1.307 0.9399 1.280724147 
82 34.79 35.09 67.5 P12277 Creatine kinase B-type  34 1.3693 1.2386 1.3199 1.2034 1.281135837 
83 2.01 2.05 51.4 P41223 Protein BUD31 homolog  1 1.3812 1.2838 1.2787 1.2037 1.285316896 
84 4.05 13.68 60.1 P12236 ADP/ATP translocase 3  11 1.4428 1.2506 1.3154 1.1519 1.285876601 
85 2.02 2.16 20.7 Q969X6 Cirhin  2 0.9438 1.3318 1.247 1.7821 1.292794146 
86 3.36 5.04 30.5 Q7Z2Z2 Elongation factor Tu GTP-binding domain-containing protein 1  3 0.9331 1.2873 1.3019 1.8248 1.299721235 
87 4.23 4.53 40.2 O95817 BAG family molecular chaperone regulator 3  4 1.3442 1.3211 1.271 1.2667 1.300333425 
88 10.78 10.82 39 P35613 Basigin  12 1.5403 1.2327 1.3649 1.1039 1.300538819 




90 128.81 129.8 51.9 P21333 Filamin-A  89 1.3878 1.2428 1.3604 1.2301 1.303418234 
91 2.07 2.14 28.1 Q96K37 Solute carrier family 35 member E1  1 1.2496 0.9791 1.7286 1.3717 1.305082387 
92 11.14 11.45 79.8 Q92522 Histone H1x  7 1.3328 1.2661 1.3525 1.3002 1.312487292 
93 32.34 32.79 93.4 P60174 Triosephosphate isomerase  35 1.4853 1.3226 1.3155 1.1837 1.322494273 
94 2 2.1 27.7 Q9H3P7 Golgi resident protein GCP60  2 1.2542 1.3311 1.3249 1.4241 1.332217906 
95 26.15 26.19 82.4 P04792 Heat shock protein beta-1  29 1.3908 1.2884 1.3996 1.3027 1.344438486 
96 2 2.34 37.8 P07738 Bisphosphoglycerate mutase  1 1.3928 1.3986 1.3095 1.3318 1.357630852 
97 2.12 2.43 39.1 Q99986 Serine/threonine-protein kinase VRK1  1 1.2731 0.8303 2.1928 1.4831 1.36165396 
98 6.41 6.91 69.7 O95232 Luc7-like protein 3  4 1.5591 1.2675 1.4623 1.2022 1.365239314 
99 3.5 4.13 33 O15269 Serine palmitoyltransferase 1  2 1.3834 1.2662 1.4649 1.3579 1.366254049 
100 5.09 5.11 55.8 Q14165 Malectin  3 1.4348 1.364 1.378 1.3128 1.371713399 
101 1.25 1.3 60.9 P52298 Nuclear cap-binding protein subunit 2  1 1.4767 1.2776 1.5287 1.3395 1.401967804 
102 2.01 2.2 19.4 Q8NE86 Calcium uniporter protein, mitochondrial  1 1.2402 1.1433 1.7248 1.6104 1.408740852 
103 2.02 2.19 25.2 P61916 Epididymal secretory protein E1  1 1.7381 1.3945 1.5166 1.2223 1.455913374 
104 2.01 4.25 38.6 P11802 Cyclin-dependent kinase 4  2 1.6988 1.497 1.4152 1.263 1.460146076 
105 2.02 2.16 29.3 Q96BN8 Ubiquitin thioesterase otulin  1 1.526 1.519 1.3955 1.4068 1.460557392 
106 
1.86 1.91 21 P63151 
Serine/threonine-protein phosphatase 2A 55 kDa regulatory 
subunit B alpha isoform  1 1.652 1.3953 1.5484 1.3245 
1.474528566 
107 28.48 29.58 55.1 P04181 Ornithine aminotransferase, mitochondrial  18 1.5017 1.4897 1.4606 1.4657 1.479328403 
108 2.29 2.85 20.6 Q9UI26 Importin-11  1 1.5487 1.7944 1.2829 1.5053 1.522038389 
109 6.27 6.5 44.4 P40938 Replication factor C subunit 3  4 1.3854 1.1991 1.9559 1.6865 1.529998111 
110 2.01 2.07 56 P21291 Cysteine and glycine-rich protein 1  1 1.1669 1.3818 1.6968 2.0348 1.536058667 
111 3.51 3.82 16 Q03519 Antigen peptide transporter 2  2 1.4693 1.5015 1.6749 1.7141 1.586409176 




113 15.78 16.15 64.5 P29373 Cellular retinoic acid-binding protein 2  8 1.9344 1.479 1.8301 1.3994 1.645253362 
114 2 2.32 20.7 O43747 AP-1 complex subunit gamma-1  1 2.8456 1.3202 2.1342 1.0028 1.6838979 
115 2.06 4.18 26.5 Q14997 Proteasome activator complex subunit 4  2 3.0597 1.3841 2.7493 1.2596 1.956929927 
116 2.1 2.54 16.9 Q8IZL8 Proline-, glutamic acid- and leucine-rich protein 1  1 2.3912 1.4326 3.4722 2.0375 2.218762411 
 
Appendices III: Direct binding targets of triptolide by pull down assay  
 
N Unused Total 
% 
Cov Accession # Protein ID 
Peptides 
(95%) 119:117 121:117 119:118 121:118 
Geometric 
Mean 
1 4.69 4.69 17.2  Q15427  Splicing factor 3B subunit 4  4 2.133 2.2241 2.304 2.4021 2.263626038 
2 4.02 6.43 23.1  O75367  Core histone macro-H2A.1  3 2.689 2.153 2.4928 2.0203 2.323723944 
3 3.5 5.32 11.4  P50453  Serpin B9  3 2.452 2.4889 2.2799 2.3147 2.382235027 
4 4.04 4.31 8.5  Q9BUQ8  Probable ATP-dependent RNA helicase DDX23  3 2.378 2.1571 2.6328 2.393 2.384298767 
5 5.16 5.18 21.4  Q9Y383  Putative RNA-binding protein Luc7-like 2  3 2.552 2.1076 2.7407 2.249 2.399550828 
6 49.48 49.48 68.5  P68371  Tubulin beta-4B chain  59 2.797 2.2177 2.6436 2.0919 2.42009816 
7 7.45 7.45 15.7  P50502  Hsc70-interacting protein  4 2.691 2.1025 2.8081 2.1921 2.429297249 
8 6 6 9.9  P04040  Catalase  3 2.598 2.3182 2.5845 2.3069 2.447929119 
9 23.24 23.36 57.1  P60842  Eukaryotic initiation factor 4A-I  13 2.832 2.2444 2.676 2.1266 2.452400279 
10 6 6 28.5  P30050  60S ribosomal protein L12  4 2.907 2.3014 2.6322 2.0812 2.460466524 
11 12 12 36.1  P62241  40S ribosomal protein S8  8 3.122 2.5035 2.5077 2.0185 2.507963473 
12 6.2 6.38 24.4  P31689  DnaJ homolog subfamily A member 1  4 2.809 2.4222 2.6052 2.2472 2.512240043 
13 7.8 8.16 17.1  Q9Y5B9  FACT complex subunit SPT16  6 3.135 2.5774 2.4425 2.031 2.516175714 
14 13.37 13.37 22.6  Q07065  Cytoskeleton-associated protein 4  8 2.921 2.3627 2.677 2.1817 2.519682881 




16 9.44 9.44 50  Q71DI3  Histone H3.2  5 2.827 2.3429 2.7917 2.2971 2.552889707 
17 13.08 13.13 64.3  P63241  Eukaryotic translation initiation factor 5A-1  11 2.642 2.2452 2.8977 2.52 2.565431672 
18 2.22 12.61 52.6  P15531  Nucleoside diphosphate kinase A  7 2.449 2.2943 2.8682 2.6897 2.565890189 
19 8.34 8.41 15.2  P04843  
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 
subunit 1  6 2.895 2.2809 2.9388 2.3141 
2.588670304 
20 3.18 3.18 11.5  O60701  UDP-glucose 6-dehydrogenase  3 2.673 2.0807 3.1906 2.5312 2.588819744 
21 9.9 9.9 73.3  P13693  Translationally-controlled tumor protein  6 2.684 2.2831 2.9502 2.5058 2.594336628 
22 23.47 23.47 65.3  P63244  Guanine nucleotide-binding protein subunit beta-2-like 1  15 3.041 2.5787 2.6106 2.227 2.598480415 
23 5.21 5.31 12.4  Q9BZZ5  Apoptosis inhibitor 5  3 2.351 2.3712 2.8457 2.8819 2.600292534 
24 6.02 6.12 11.8  Q9BYT8  Neurolysin, mitochondrial  3 2.872 2.2108 3.0649 2.3708 2.60622124 
25 8.11 8.13 23.5  Q96AG4  Leucine-rich repeat-containing protein 59  4 3.06 2.4624 2.7687 2.2133 2.606748027 
26 4 4 14  P50579  Methionine aminopeptidase 2  3 3.288 2.672 2.5485 2.0702 2.609253659 
27 20.51 20.51 25.1  Q00839  Heterogeneous nuclear ribonucleoprotein U  15 3.082 2.3812 2.8614 2.2101 2.610085605 
28 2.91 2.96 37.6  P62913  60S ribosomal protein L11  3 2.465 2.3153 2.9497 2.7907 2.618055199 
29 2 20.45 35.6  P12235  ADP/ATP translocase 1  11 2.955 2.6335 2.606 2.3223 2.61966577 
30 4 4.5 11.7  Q99733  Nucleosome assembly protein 1-like 4  3 3.205 2.6178 2.6342 2.151 2.625810697 
31 5.86 5.86 13.3  P78417  Glutathione S-transferase omega-1  3 2.827 2.2645 3.0337 2.4548 2.627675428 
32 17.9 17.9 32.6  O75874  Isocitrate dehydrogenase [NADP] cytoplasmic  11 2.937 2.4812 2.784 2.3605 2.630629819 
33 8.39 8.41 23.9  Q99536  Synaptic vesicle membrane protein VAT-1 homolog  5 3.058 2.5909 2.6691 2.2849 2.636513769 
34 13.47 13.47 16.9  O43143  
Putative pre-mRNA-splicing factor ATP-dependent RNA 
helicase DHX15  10 2.901 2.5275 2.7607 2.3992 
2.639861488 
35 4 4 22.4  Q9UI30  tRNA methyltransferase 112 homolog  3 3.022 2.3929 2.9039 2.3166 2.640966727 
36 6 6.02 35  P63208  S-phase kinase-associated protein 1  4 2.844 2.5813 2.7071 2.4585 2.643842906 




38 27.7 27.94 54.7  P48643  T-complex protein 1 subunit epsilon  21 3.062 2.4469 2.8785 2.2844 2.649353735 
39 13.24 13.24 44.6  P40925  Malate dehydrogenase, cytoplasmic  9 3.015 2.336 3.0152 2.3252 2.650843864 
40 33.45 34.79 45.1  P50990  T-complex protein 1 subunit theta  20 3.045 2.3817 2.9517 2.3106 2.651965283 
41 9.7 10.43 16.8  Q09666  Neuroblast differentiation-associated protein AHNAK  7 2.982 2.366 2.9992 2.3897 2.666660928 
42 15.54 15.73 19.9  P56192  Methionine--tRNA ligase, cytoplasmic  8 3.181 2.5706 2.7593 2.2451 2.667830269 
43 65.85 66.12 62  O43707  Alpha-actinin-4  45 3.038 2.4127 2.9638 2.3531 2.673899579 
44 4.89 4.96 14.7  P62333  26S protease regulatory subunit 10B  3 2.916 2.4026 3.0075 2.4633 2.684095623 
45 39.44 56.76 58.7  P08107  Heat shock 70 kDa protein 1A/1B  38 3.203 2.5043 2.9372 2.2923 2.710891067 
46 13.77 13.77 23.3  P11387  DNA topoisomerase 1  9 3.36 2.6865 2.7761 2.2222 2.731719438 
47 6.38 6.4 13.4  O43290  U4/U6.U5 tri-snRNP-associated protein 1  3 2.855 2.228 3.3681 2.6176 2.736543711 
48 8.07 8.07 19.2  O00154  Cytosolic acyl coenzyme A thioester hydrolase  4 3.272 2.7982 2.673 2.2963 2.737977708 
49 12.25 12.74 12.2  O60763  General vesicular transport factor p115  7 3.415 2.7545 2.7189 2.199 2.738501526 
50 6 6 12.2  Q9NQW7  Xaa-Pro aminopeptidase 1  3 3.176 2.7153 2.7761 2.3568 2.740716013 
51 7.15 7.15 10.4  Q9BQ52  Zinc phosphodiesterase ELAC protein 2  4 2.981 2.6112 2.8936 2.534 2.748601663 
52 10.39 10.53 10.7  O75694  Nuclear pore complex protein Nup155  7 3.291 2.6192 2.8832 2.2967 2.748646542 
53 5.21 5.21 7.6  Q9NSE4  Isoleucine--tRNA ligase, mitochondrial  3 3.14 2.5435 2.9788 2.4261 2.756308715 
54 12 12 29.4  Q9Y3F4  Serine-threonine kinase receptor-associated protein  6 3.168 2.4754 3.0915 2.4211 2.767917456 
55 16.01 16.01 21.2  P23246  Splicing factor, proline- and glutamine-rich  12 3.328 2.6366 2.9111 2.3104 2.771679224 
56 4.16 4.85 7.6  O15067  Phosphoribosylformylglycinamidine synthase  3 2.973 2.3712 3.2465 2.5886 2.774347531 
57 33.78 33.78 46.9  P17987  T-complex protein 1 subunit alpha  19 3.475 2.7831 2.7662 2.2185 2.775598586 
58 7.79 7.79 6.8  P46013  Antigen KI-67  5 3.18 2.5138 3.0543 2.4375 2.777496623 
59 23.86 23.98 26.8  P33176  Kinesin-1 heavy chain  13 3.252 2.5249 3.0567 2.3736 2.778201666 
60 11.66 11.66 41.4  P46777  60S ribosomal protein L5  6 2.951 2.3707 3.2839 2.6108 2.782930331 




62 12.69 12.69 25.8  Q99873  Protein arginine N-methyltransferase 1  7 2.969 2.3575 3.3255 2.6189 2.794212568 
63 6.47 28.16 48.4  Q9BUF5  Tubulin beta-6 chain  29 2.914 2.2987 3.4325 2.6551 2.79521886 
64 5.16 5.17 17.9  P39748  Flap endonuclease 1  3 3.076 2.4398 3.2331 2.5604 2.807481341 
65 11.07 11.16 20.5  P02786  Transferrin receptor protein 1  6 3.46 2.7021 2.9347 2.2886 2.81499599 
66 23.12 23.12 70.4 Q06830  Peroxiredoxin-1  14 3.444 2.359 3.3592 2.3259 2.822633529 
67 8.96 8.96 58.5  P30041  Peroxiredoxin-6  5 3.41 2.7663 2.8919 2.3374 2.825806968 
68 17.38 17.38 26.6  P26639  Threonine--tRNA ligase, cytoplasmic  11 3.525 2.7821 2.8815 2.2812 2.833534215 
69 9.54 9.54 19.9  P61158  Actin-related protein 3  5 2.921 2.4467 3.2949 2.7453 2.835541983 
70 9.33 9.39 11.5  P42224  Signal transducer and activator of transcription 1-alpha/beta  4 3.279 2.5755 3.1249 2.4525 2.836364413 
71 6 6 18.9  P00918  Carbonic anhydrase 2  3 3.323 2.7554 2.9208 2.4261 2.838124079 
72 26.55 26.81 24.1  P49736  DNA replication licensing factor MCM2  15 3.686 2.859 2.8434 2.1963 2.848228165 
73 6 6.06 11.6  P43490  Nicotinamide phosphoribosyltransferase  3 3.392 2.8205 2.8861 2.4044 2.854466894 
74 14.53 14.53 31.4  P23381  Tryptophan--tRNA ligase, cytoplasmic  7 3.147 2.5862 3.151 2.5951 2.856211331 
75 37.03 37.23 48.2  O60506  Heterogeneous nuclear ribonucleoprotein Q  26 3.571 2.8128 2.9032 2.2931 2.859612345 
76 9.83 9.94 17.4  Q9Y262  Eukaryotic translation initiation factor 3 subunit L  5 3.417 2.9107 2.8216 2.3838 2.859907072 
77 25.18 27.26 32.6  P34932  Heat shock 70 kDa protein 4  17 3.271 2.6919 3.0541 2.5046 2.86477339 
78 11.26 11.39 38.7  Q8NC51  Plasminogen activator inhibitor 1 RNA-binding protein  7 3.072 2.4243 3.3884 2.681 2.867971062 
79 26.71 26.71 29.7  Q13263  Transcription intermediary factor 1-beta  17 3.321 2.6004 3.1574 2.485 2.869070749 
80 7.2 7.2 37  P46783  40S ribosomal protein S10  4 3.117 2.4755 3.3096 2.656 2.869794691 
81 16.85 17.08 29.8  P40939  Trifunctional enzyme subunit alpha, mitochondrial  9 3.321 2.6236 3.1679 2.4594 2.870395778 
82 15.75 15.88 29.6  P54577  Tyrosine--tRNA ligase, cytoplasmic  8 3.317 2.6728 3.075 2.4939 2.871501334 
83 14 14 63.9  P04792  Heat shock protein beta-1  8 3.042 2.7662 3.001 2.7128 2.876945532 
84 9.74 9.75 35  Q15417  Calponin-3  5 3.286 2.6604 3.1462 2.5003 2.879706565 




86 31.96 31.96 34  P55072  Transitional endoplasmic reticulum ATPase  21 3.288 2.5318 3.2839 2.5253 2.882478169 
87 5.31 5.38 17  P52888  Thimet oligopeptidase  4 3.323 2.6893 3.109 2.5145 2.891082526 
88 10.16 10.16 46.7  P24534  Elongation factor 1-beta  6 3.116 2.5171 3.3201 2.6865 2.892071209 
89 10.01 10.35 61.1  P06703  Protein S100-A6  6 3.111 2.5885 3.2438 2.7008 2.898168746 
90 68.26 68.26 78.1  P63261  Actin, cytoplasmic 2  93 3.154 2.7714 3.0424 2.6731 2.903675666 
91 8.47 8.47 27.3  Q16543  Hsp90 co-chaperone Cdc37  5 3.354 2.7035 3.1298 2.5142 2.906373735 
92 3.84 4.77 6.5  Q14008  Cytoskeleton-associated protein 5  3 3.407 2.6578 3.1845 2.4864 2.909890658 
93 37.36 44.36 51.8  P11021  78 kDa glucose-regulated protein  23 3.451 2.6884 3.1553 2.4575 2.912347929 
94 13.16 13.16 18.8  P33991  DNA replication licensing factor MCM4  7 3.41 2.726 3.1578 2.5051 2.928346605 
95 21.58 21.92 26.1  P06737  Glycogen phosphorylase, liver form  12 3.605 2.7906 3.0686 2.3975 2.933090335 
96 23.14 26.24 63.2  P07195  L-lactate dehydrogenase B chain  18 3.549 2.7294 3.1574 2.4298 2.936083009 
97 8.67 8.77 24.7  P00505  Aspartate aminotransferase, mitochondrial  7 3.389 2.7102 3.1935 2.5527 2.941608706 
98 26.7 26.7 42.2  P06576  ATP synthase subunit beta, mitochondrial  18 3.361 2.6447 3.288 2.5816 2.94724624 
99 10.36 10.36 50.2  P09429  High mobility group protein B1  7 3.462 2.666 3.2569 2.5114 2.947656556 
100 4.23 4.25 9.6  Q9UHB9  Signal recognition particle subunit SRP68  3 3.788 2.977 2.9273 2.3005 2.952021858 
101 16.45 16.5 21.7  P11586  C-1-tetrahydrofolate synthase, cytoplasmic  10 3.513 2.8813 3.0463 2.4874 2.959349322 
102 23.83 23.96 32.4  P49588  Alanine--tRNA ligase, cytoplasmic  17 3.503 2.8361 3.0963 2.506 2.963100926 
103 13.8 13.8 21.9  O00232  26S proteasome non-ATPase regulatory subunit 12  9 3.641 2.9236 3.0149 2.411 2.965870529 
104 17.65 38.98 40.9  P12814  Alpha-actinin-1  27 3.369 2.6949 3.2969 2.6434 2.982483718 
105 6.03 6.06 6.1  O60610  Protein diaphanous homolog 1  3 3.233 2.9946 2.9831 2.7477 2.984663762 
106 8.68 8.71 15.7  P55884  Eukaryotic translation initiation factor 3 subunit B  4 3.276 2.5182 3.5375 2.7476 2.992409448 
107 5.21 5.27 6  O14617  AP-3 complex subunit delta-1  3 3.387 3.2178 2.7918 2.6363 2.992701106 
108 6 6.06 23.4  P35270  Sepiapterin reductase  3 3.475 2.945 3.0459 2.5749 2.993153772 




110 9.01 9.01 25.5  Q14247  Src substrate cortactin  6 3.188 2.4517 3.6816 2.8109 2.998934008 
111 10.45 10.46 46.8  Q15293  Reticulocalbin-1  7 3.452 2.848 3.1603 2.6089 3.000537985 
112 39.12 39.19 62  P49368  T-complex protein 1 subunit gamma  24 3.448 2.8729 3.1326 2.6153 3.001432328 
113 16 17.06 29.5  P52292  Importin subunit alpha-1  11 3.504 2.8848 3.1398 2.5798 3.008097839 
114 33.43 33.74 25.3  P41252  Isoleucine--tRNA ligase, cytoplasmic  17 3.565 2.8378 3.1965 2.5468 3.012504589 
115 7.85 7.85 43.4  Q99497  Protein DJ-1  6 3.772 2.9655 3.0694 2.4053 3.014554141 
116 4.03 4.03 15.5  Q9UK22  F-box only protein 2  3 3.691 2.9177 3.1397 2.4594 3.019781364 
117 16.39 16.39 48.3  P31943  Heterogeneous nuclear ribonucleoprotein H  21 3.403 2.9581 3.092 2.6885 3.02451736 
118 12.08 12.17 38  P62826  GTP-binding nuclear protein Ran  6 3.122 2.7034 3.3888 2.931 3.025876798 
119 6.05 6.05 27.7  O00303  Eukaryotic translation initiation factor 3 subunit F  4 3.595 2.8637 3.203 2.5507 3.028382192 
120 11.96 12 42.3  P52907  F-actin-capping protein subunit alpha-1  7 3.716 3.1134 2.9596 2.4631 3.030445111 
121 28.5 28.56 38.1  P02545  Prelamin-A/C  20 3.319 2.6664 3.4533 2.7699 3.033246729 
122 15.46 15.65 12.3  Q04637  Eukaryotic translation initiation factor 4 gamma 1  8 3.547 2.8877 3.1788 2.6062 3.03508635 
123 10.23 10.23 23.1  Q9Y2X3  Nucleolar protein 58  5 3.428 2.9777 3.118 2.6884 3.041395772 
124 33.43 33.43 65.6  P04083  Annexin A1  19 3.619 2.9094 3.1811 2.5637 3.044101546 
125 6.12 6.12 17.7  Q8N163  Cell cycle and apoptosis regulator protein 2  4 3.771 3.0499 3.0344 2.4645 3.045341116 
126 8.3 13.33 40  P52597  Heterogeneous nuclear ribonucleoprotein F  19 3.248 3.0966 3.0031 2.8625 3.049327742 
127 44.82 44.82 64.3  P07355  Annexin A2  28 3.147 2.8988 3.223 2.947 3.050976477 
128 63.41 63.48 76.4  P10809  60 kDa heat shock protein, mitochondrial  52 3.565 2.9554 3.1557 2.609 3.05183745 
129 10 10 13.3  P47897  Glutamine--tRNA ligase  5 3.902 3.0177 3.0818 2.3967 3.053833561 
130 8 8.38 19  P14868  Aspartate--tRNA ligase, cytoplasmic  4 3.216 2.6899 3.4814 2.8971 3.056274772 
131 13.39 13.97 51.2  P21796  Voltage-dependent anion-selective channel protein 1  10 3.374 2.6707 3.5155 2.7722 3.061226481 
132 10.37 10.37 39.3  P30044  Peroxiredoxin-5, mitochondrial  6 3.5 2.7971 3.3517 2.6848 3.063643865 




134 6.22 13.44 15.9  Q92841  Probable ATP-dependent RNA helicase DDX17  7 3.261 2.8584 3.2962 2.8762 3.066031481 
135 12.58 12.59 24.8  Q7KZF4  Staphylococcal nuclease domain-containing protein 1  8 3.511 3.0334 3.1043 2.6787 3.067694224 
136 11.85 11.86 22.8  P49748  Very long-chain specific acyl-CoA dehydrogenase  6 3.454 2.8001 3.371 2.7221 3.069302377 
137 7.57 7.57 24.1  Q9NUQ9  Protein FAM49B  5 2.868 2.7081 3.4675 3.2981 3.069948099 
138 8.26 8.26 29.6  P47756  F-actin-capping protein subunit beta  4 3.405 3.2948 2.8263 2.8168 3.074185792 
139 6 7 6.8  P16144  Integrin beta-4  5 3.329 3.2164 2.9283 2.8525 3.075255949 
140 18 18 38  Q15084  Protein disulfide-isomerase A6  11 3.365 2.7519 3.4512 2.8209 3.08137024 
141 14.79 14.79 32.7  P29401  Transketolase  13 3.173 2.5794 3.7006 2.9969 3.086620889 
142 4.02 4.26 11.5  Q16401  26S proteasome non-ATPase regulatory subunit 5  3 2.972 2.4999 3.8327 3.2244 3.09550347 
143 7.89 7.93 7.5  Q6P2E9  Enhancer of mRNA-decapping protein 4  4 3.717 3.2008 3.0144 2.5739 3.099637544 
144 2.31 2.31 9.8  Q01780  Exosome component 10  3 3.48 2.8622 3.361 2.766 3.102058455 
145 8.66 8.67 40.7  P51148  Ras-related protein Rab-5C  4 3.718 2.9939 3.2835 2.5631 3.111088115 
146 7.2 7.2 45.3  O75947  ATP synthase subunit d, mitochondrial  5 3.648 2.8553 3.3999 2.6748 3.11972281 
147 7.85 8.21 10.2  Q9Y6Y8  SEC23-interacting protein  4 3.606 2.8933 3.3604 2.7021 3.119808204 
148 10.82 11.1 19.6  Q9BXJ9  N-alpha-acetyltransferase 15, NatA auxiliary subunit  9 3.543 3.079 3.1756 2.7589 3.126695931 
149 2 4.27 16.1  P31150  Rab GDP dissociation inhibitor alpha  3 3.537 3.1823 3.0832 2.7743 3.132440457 
150 4 4.02 14.2  P47985  Cytochrome b-c1 complex subunit Rieske, mitochondrial  3 3.333 2.5788 3.8058 2.9496 3.134119239 
151 7.91 8.9 16.2  P05455  Lupus La protein  5 3.941 3.1672 3.1337 2.5097 3.147677923 
152 6 6 9.5  O15371  Eukaryotic translation initiation factor 3 subunit D  4 3.953 3.1418 3.1674 2.5029 3.150017308 
153 30.13 30.13 50.8  P78371  T-complex protein 1 subunit beta  22 3.887 3.0684 3.2384 2.5545 3.15166993 
154 6.76 6.85 28.3  P13995  
Bifunctional methylenetetrahydrofolate 
dehydrogenase/cyclohydrolase, mitochondrial  3 3.944 3.2125 3.1255 2.5039 
3.15557954 
155 4.01 4.1 19.2  P30040  Endoplasmic reticulum resident protein 29  3 3.286 2.7786 3.5975 3.0416 3.161543219 




157 12.39 12.47 43  P32322  Pyrroline-5-carboxylate reductase 1, mitochondrial  8 3.938 3.0672 3.2886 2.5588 3.175165013 
158 26.2 26.37 66.4  P12277  Creatine kinase B-type  23 3.827 3.0349 3.3322 2.6306 3.176487721 
159 8.72 8.76 18.5  P30740  Leukocyte elastase inhibitor  6 3.677 3.2575 3.1227 2.7486 3.184233924 
160 6 6.01 12.4  Q53GS9  U4/U6.U5 tri-snRNP-associated protein 2  3 3.769 3.2073 3.2386 2.6267 3.184442246 
161 6 6 14.9  Q14376  UDP-glucose 4-epimerase  3 3.71 3.0127 3.3945 2.7518 3.196543502 
162 6.63 6.69 15.8  O95202  LETM1 and EF-hand domain-containing protein 1  5 3.925 3.1006 3.3009 2.6111 3.200260411 
163 3.42 3.72 19.1  P28066  Proteasome subunit alpha type-5  3 3.38 3.1571 3.2482 3.0359 3.202829468 
164 9.07 9.07 27.7  P14550  Alcohol dehydrogenase [NADP(+)]  5 3.683 3.1399 3.2711 2.7937 3.206252943 
165 8.78 8.85 18.4  Q9UNM6  26S proteasome non-ATPase regulatory subunit 13  4 3.311 2.7764 3.7594 3.0638 3.207783442 
166 5.23 5.24 18.2  Q9HC38  Glyoxalase domain-containing protein 4  3 3.968 3.137 3.2978 2.5899 3.211059647 
167 21.9 21.95 20.2  P26640  Valine--tRNA ligase  14 3.771 3.0978 3.3359 2.7374 3.213773746 
168 36.21 36.34 41.3  P12268  Inosine-5'-monophosphate dehydrogenase 2  19 3.886 3.0327 3.4166 2.6513 3.214373315 
169 4 11.12 14.3  Q13310  Polyadenylate-binding protein 4  6 3.346 2.6003 3.9732 3.1075 3.21940222 
170 11.64 12.02 45.1  Q02790  Peptidyl-prolyl cis-trans isomerase FKBP4  8 3.611 2.8935 3.5938 2.9057 3.231944641 
171 6.06 6.66 8.5  Q92922  SWI/SNF complex subunit SMARCC1  3 3.43 2.7039 3.8701 3.0495 3.234512938 
172 8.59 8.62 21.3  O00231  26S proteasome non-ATPase regulatory subunit 11  5 3.612 2.7977 3.747 2.8954 3.235826944 
173 7.86 7.86 37.1  P10599  Thioredoxin  5 3.898 3.2007 3.2947 2.7109 3.249032417 
174 4.74 5.3 28.5  Q9HB71  Calcyclin-binding protein  3 3.761 3.0024 3.5346 2.795 3.249926151 
175 4.01 4.87 6.4  Q7L2E3  Putative ATP-dependent RNA helicase DHX30  3 3.585 3.5433 3.0124 2.9419 3.257312361 
176 5.92 5.92 22.4  P43487  Ran-specific GTPase-activating protein  3 3.398 2.6647 3.984 3.125 3.258444003 
177 21.48 21.48 32.5  Q92945  Far upstream element-binding protein 2  12 3.495 3.0883 3.423 3.0541 3.259223953 
178 9.46 9.46 12.5  Q9H3U1  Protein unc-45 homolog A  5 3.84 3.062 3.47 2.7659 3.259309406 
179 4.22 4.25 21.3  Q99615  DnaJ homolog subfamily C member 7  3 3.468 3.2585 3.2843 3.0693 3.266966969 




181 11.25 11.25 15.7  O75534  Cold shock domain-containing protein E1  6 3.742 2.9174 3.6579 2.874 3.273064687 
182 5.18 5.2 32.7  P27695  DNA-(apurinic or apyrimidinic site) lyase  4 3.664 2.8597 3.7741 2.9398 3.283611608 
183 6 6.05 13.7  P16435  NADPH--cytochrome P450 reductase  3 3.372 3.2427 3.1615 3.3665 3.284479349 
184 9.78 9.78 47.8  P51149  Ras-related protein Rab-7a  6 3.817 3.0249 3.5622 2.8321 3.285224223 
185 19.19 19.23 42.8  P61978  Heterogeneous nuclear ribonucleoprotein K  13 3.563 2.7981 3.8634 3.0287 3.286444078 
186 28.35 29.12 13.1  Q92616  Translational activator GCN1  15 4.048 3.1986 3.3885 2.6868 3.295040952 
187 31.14 31.98 48.7  P30101  Protein disulfide-isomerase A3  18 3.825 2.9836 3.6516 2.8496 3.301108392 
188 6.04 6.06 17.2  P10515  
Dihydrolipoyllysine-residue acetyltransferase component of 
pyruvate dehydrogenase complex, mitochondrial  3 4.202 3.4006 3.19 2.6174 
3.304974363 
189 21.32 21.32 49.8  O60664  Perilipin-3  13 3.708 3.2643 3.3426 2.9571 3.307273055 
190 6.84 6.89 22.8  P07741  Adenine phosphoribosyltransferase  4 3.608 2.8354 3.9114 3.0152 3.314227411 
191 8.23 8.23 45.2  Q16778  Histone H2B type 2-E  12 3.86 3.0227 3.6606 2.8627 3.325275373 
192 6 6 23.1  P37802  Transgelin-2  3 4.32 3.337 3.3418 2.5865 3.341051905 
193 9.85 9.85 16.4  Q15637  Splicing factor 1  5 4.04 3.2815 3.4313 2.7786 3.353008264 
194 6.98 8.31 14.2  O60264  
SWI/SNF-related matrix-associated actin-dependent regulator of 
chromatin subfamily A member 5  5 3.988 3.2651 3.4638 2.8217 
3.358758826 
195 6.08 6.08 25.6  O95816  BAG family molecular chaperone regulator 2  3 3.765 3.3637 3.3494 3.0154 3.362974278 
196 7.43 7.46 11.3  P00367  Glutamate dehydrogenase 1, mitochondrial  4 3.675 3.2325 3.5119 3.0926 3.370275803 
197 8.88 8.89 14.9  P48147  Prolyl endopeptidase  5 4.016 3.2715 3.4927 2.8828 3.391400709 
198 1.57 1.61 21.5  O14929  Histone acetyltransferase type B catalytic subunit  4 4.214 3.2742 3.5336 2.7514 3.40324107 
199 5.46 5.46 12.5  Q9Y305  Acyl-coenzyme A thioesterase 9, mitochondrial  3 4.285 3.4256 3.4263 2.6939 3.411721585 
200 8.26 8.26 22.6  Q9NSD9  Phenylalanine--tRNA ligase beta subunit  6 3.707 3.0904 3.8141 3.1463 3.424186193 
201 16.45 16.78 24.9  Q8WUM4  Programmed cell death 6-interacting protein  9 3.832 3.0258 3.8391 3.0948 3.425957199 




203 10.29 12.43 50.5  P32119  Peroxiredoxin-2  9 3.983 3.3509 3.5226 2.9617 3.435136844 
204 9.74 9.85 49  P60660  Myosin light polypeptide 6  6 4.026 3.2748 3.6441 2.9532 3.451321561 
205 14.47 14.47 36.4  P50395  Rab GDP dissociation inhibitor beta  8 3.868 3.1055 3.8672 3.0769 3.457657752 
206 4.55 4.62 17.2  Q01105  Protein SET  4 3.756 3.1691 3.8009 3.2072 3.47071141 
207 5.12 5.12 18.6  Q9P258  Protein RCC2  4 3.822 3.7237 3.3254 3.2226 3.514219754 
208 8.84 8.84 37.9  P30048  Thioredoxin-dependent peroxide reductase  6 4.105 3.2069 3.8924 3.0374 3.532071674 
209 6.97 7.03 7.3  Q13435  Splicing factor 3B subunit 2  4 4.097 3.6418 3.4835 3.1032 3.563706336 
210 3.27 3.27 18.4  P61019  Ras-related protein Rab-2A  3 4.205 3.8733 3.3706 3.1051 3.613328827 
211 11.42 11.44 38.2  P35232  Prohibitin  6 4.252 3.7082 3.5437 3.0931 3.62578317 
212 6.22 6.22 13  P35237  Serpin B6  3 3.71 3.1641 4.1809 3.5445 3.63171883 
213 3.55 5.71 16.9  P30483  HLA class I histocompatibility antigen, B-45 alpha chain  3 4.467 3.646 3.697 3.0045 3.667444657 
214 6 6.27 6.9  Q7L576  Cytoplasmic FMR1-interacting protein 1  3 3.783 3.3916 3.9949 3.5698 3.677881154 
215 16.46 16.54 13.1  Q14980  Nuclear mitotic apparatus protein 1  9 4.06 3.2907 4.1488 3.3446 3.689948055 
216 4.88 4.88 9.9  Q9BSJ8  Extended synaptotagmin-1  3 4.566 3.8438 3.6067 3.0517 3.728096427 
217 14 14 16.4  P43243  Matrin-3  9 4.573 3.6209 3.9482 3.1193 3.778927026 
218 6.04 6.04 11  Q9Y6M1  Insulin-like growth factor 2 mRNA-binding protein 2  3 4.628 3.5807 4.0389 3.1564 3.81244955 
219 3.21 3.27 16.9  Q9BWD1  Acetyl-CoA acetyltransferase, cytosolic  3 4.698 3.6064 4.1085 3.1259 3.840708262 
220 14.71 15.65 23.2  Q9P2E9  Ribosome-binding protein 1  9 4.171 3.7477 4.0062 3.5949 3.873522762 
221 10.43 10.52 18.8  O00429  Dynamin-1-like protein  6 4.874 4.0291 3.8055 3.1474 3.916195008 
222 6.8 6.82 10.2  P23921  Ribonucleoside-diphosphate reductase large subunit  4 5.042 3.9092 3.9588 3.0604 3.931045961 
223 6 6 25.2  O75569  
Interferon-inducible double-stranded RNA-dependent protein 
kinase activator A  3 4.746 3.9091 3.9635 3.2803 
3.940934667 
224 10.54 10.58 60.2  P84077  ADP-ribosylation factor 1  6 4.564 3.5553 4.3693 3.4196 3.945956247 




226 6.07 6.07 28.7  O95571  Persulfide dioxygenase ETHE1, mitochondrial  4 4.166 4.0015 4.153 3.9409 4.064198004 
227 6.08 6.08 16.1  P49419  Alpha-aminoadipic semialdehyde dehydrogenase  3 3.822 3.6253 4.5761 4.3334 4.071362103 
228 2.72 2.76 15.3  Q9H845  Acyl-CoA dehydrogenase family member 9, mitochondrial  3 4.899 4.139 4.0396 3.4127 4.088931504 
229 15.59 15.59 48.3  Q15365  Poly(rC)-binding protein 1  12 4.979 3.8667 4.82 3.7567 4.320997743 
230 20.8 20.8 63.6  P60174  Triosephosphate isomerase  14 5.103 4.0887 4.8862 3.9127 4.469044211 
231 40.76 40.76 73.3  P05783  Keratin, type I cytoskeletal 18  31 5.286 4.5253 5.0246 4.2816 4.762889765 
232 48.03 48.83 65.6  P05787  Keratin, type II cytoskeletal 8  35 5.391 4.7759 4.9042 4.3468 4.840225518 
233 9.3 9.31 42.4  Q9H773  dCTP pyrophosphatase 1  4 4.696 4.0305 5.9068 5.0451 4.873346202 
234 8.18 8.21 10.4  P28290  Sperm-specific antigen 2  5 5.573 4.9467 4.7219 4.3495 4.877981895 
235 8.33 8.4 33.2  P30519  Heme oxygenase 2  5 6.542 5.7182 6.2086 5.4025 5.951680158 
236 22.97 22.98 23.7  O95831  Apoptosis-inducing factor 1, mitochondrial  13 6.85 5.4901 7.5722 6.1311 6.464096416 
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